```
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265


RESULT 13
AAG89176
ID   AAG89176 standard; Protein; 247 AA.
XX
AC   AAG89176;
XX
DT   11-SEP-2001  (first entry)
XX
DE   Human secreted protein, SEQ ID NO: 296.
XX
KW   Human; secreted protein; gene therapy; vaccine; treatment; diagnosis;
KW   GENSET.
XX
OS   Homo sapiens.
XX
PN   WO200142451-A2.
XX
PD   14-JUN-2001.
XX
PF   07-DEC-2000; 2000WO-IB01938.
XX
PR   08-DEC-1999;   99US-0169629.
PR   06-MAR-2000; 2000US-0187470.
XX
PA   (GEST ) GENSET.
XX
PI   Dumas Milne Edwards J,  Bougueleret L,  Jobert S;
XX
DR   WPI; 2001-367870/38.
DR   N-PSDB; AAH64779.
XX
PT   Full length GENSET human nucleic acids encoding potentially secreted
PT   proteins, useful in gene therapy and vaccination against a variety of
PT   diseases, and for diagnosis of those diseases -
XX
PS   Claim 21; Page 827-828; 921pp; English.
XX
CC   The invention relates to full length GENSET human nucleic acids encoding
CC   potentially secreted proteins. The nucleic acids and the polypeptides
CC   they encode may be used in the prevention, treatment and diagnosis of
CC   diseases associated with inappropriate GENSET gene expression. For
CC   example, they be used to treat disorders associated with decreased
CC   GENSET gene expression by rectifying mutations or deletions in a
CC   patient's genome that affect the activity of GENSET or by supplementing
CC   the patients own production of GENSET polypeptides. Conversely,
CC   antisense nucleic acid molecules may be administered to down regulate
CC   GENSET expression by binding with the cells' own genes and preventing
CC   their expression. The sense and antisense nucleic acids may also be
CC   used as DNA probes in diagnostic assays to detect and quantitate the
CC   presence of similar nucleic acid sequences in samples, and hence to
CC   determine which patients may be in need of restorative therapy.
CC   The GENSET polypeptides may be used as antigens in the production of
CC   antibodies and in assays to identify modulators (agonists and
CC   antagonists) of GENSET polypeptide expression and activity. The
CC   present sequence is a GENSET polypeptide of the invention.
XX
SQ   Sequence   247 AA;

  Query Match           81.5%;  Score 1149;  DB 22;  Length 247;
  Best Local Similarity  100.0%;  Pred. No. 1.6e-105;
  Matches  215;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGG 215
              |||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGG 215


RESULT 14
AAM24472
ID   AAM24472 standard; Protein; 232 AA.
XX
AC   AAM24472;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Human EST encoded protein SEQ ID NO: 1997.
XX
KW   Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
KW   tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
KW   diagnostics; forensic test; gene mapping; genetic disorder;
KW   biodiversity; gene therapy; nutrition.
XX
OS   Homo sapiens.
XX
PN   WO200154477-A2.
XX
PD   02-AUG-2001.
XX
PF   25-JAN-2001; 2001WO-US02687.
XX
PR   25-JAN-2000; 2000US-0491404.
PR   17-JUL-2000; 2000US-0617746.
PR   03-AUG-2000; 2000US-0631451.
PR   15-SEP-2000; 2000US-0663870.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Zhou P,  Qian XB,  Wang Z,  Chen R,  Asundi V;
PI   Cao Y,  Drmanac RA,  Zhang J,  Werhman T;
XX
DR   WPI; 2001-476164/51.
DR   N-PSDB; AAH99131.
XX
PT   Isolated polypeptide for treatment of diseases, diagnostics, raising
PT   antibodies and research use -
XX
PS   Claim 20; Page 1266; 1275pp; English.
XX
CC   The present invention provides the protein and coding sequences of novel
CC   proteins from a variety of organisms, including human, dog, cat, horse,
CC   cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
CC   urchin and tomato. These were derived from expressed sequence tags (ESTs)
CC   from the organism of interest. They can be used in diagnostics,
CC   forensics, gene mapping, identification of mutations, to assess
CC   biodiversity and for nutritional purposes. The present sequence is a
CC   protein of the invention.
XX
SQ   Sequence   232 AA;

  Query Match           51.5%;  Score 725.5;  DB 22;  Length 232;
  Best Local Similarity  64.3%;  Pred. No. 1.6e-63;
  Matches  148;  Conservative   13;  Mismatches   56;  Indels   13;  Gaps    3;

Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 5, 2004, 16:29:57 ; Search time 41 Seconds
(without alignments)
1025.916 Million cell updates/sec

Title: US-09-990-726-223
Perfect score: 265
Sequence: 1 MGLPGLFCLAVLAASSFSKA.....EFGGFRIGNGEVRGRKAAAM 265

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 1107863 seqs, 158726573 residues

Word size : 6

Total number of hits satisfying chosen parameters: 2419

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 150 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	265	100.0	265	21	AAB24063	Human PRO809 prote
2	265	100.0	265	21	AAY66691	Membrane-bound pro
3	265	100.0	265	22	AAB65214	Human PRO809 (UNQ4
4	265	100.0	265	23	AAU83666	Human PRO protein,
5	265	100.0	265	24	ABU59107	Novel human secret
6	265	100.0	265	24	ABU59254	Human secreted/tra
7	265	100.0	265	24	ABU59403	Novel human secret
8	265	100.0	265	24	ABU60538	Human secreted/tra
9	265	100.0	265	24	ABU58029	Human PRO polypept
10	265	100.0	265	24	ABU58960	Human sectreted/tr
11	265	100.0	265	24	ABU13920	Human PRO809 polyp
12	265	100.0	265	24	ABU10875	Human PRO polypept
13	215	81.1	247	22	AAG89176	Human secreted pro
14	123	46.4	232	22	AAM24472	Human EST encoded
15	123	46.4	235	24	ABJ19682	Human secreted pro
16	123	46.4	235	24	ABP99572	Human secreted pro
17	123	46.4	236	21	AAB39216	Human secreted pro
18	119	44.9	175	22	AAU21256	Human novel foetal
19	8	3.0	13	17	AAW11113	Src SH3 domain-bin
20	8	3.0	31	18	AAW25511	Random peptide rec
21	8	3.0	273	19	AAW72021	HSV-2 strain SB5 C
22	8	3.0	466	19	AAW72230	HSV-2 strain SB5 C
23	8	3.0	523	19	AAW72229	HSV-2 strain SB5 C
24	8	3.0	610	19	AAW72228	HSV-2 strain SB5 C
25	8	3.0	649	19	AAW72097	HSV-2 strain SB5 C
26	7	2.6	68	22	AAG74210	Human colon cancer
27	7	2.6	72	23	ABB53619	Lactococcus lactis
28	7	2.6	89	22	AAM85245	Human immune/haema
29	7	2.6	104	23	ABJ01104	Ovary cell-specifi
30	7	2.6	110	22	AAU31945	Novel human secret
31	7	2.6	117	22	AAU55856	Propionibacterium
32	7	2.6	117	22	AAB95436	Human protein sequ
33	7	2.6	125	20	AAY12386	Human 5' EST secre
34	7	2.6	129	21	AAG24134	Arabidopsis thalia
35	7	2.6	133	21	AAG24133	Arabidopsis thalia
36	7	2.6	140	23	ABP01270	Human ORFX protein
37	7	2.6	141	22	AAU59496	Propionibacterium
38	7	2.6	141	22	AAB63549	Human gastric canc
39	7	2.6	149	22	AAU49867	Propionibacterium
40	7	2.6	151	20	AAY35951	Extended human sec
41	7	2.6	151	20	AAY36094	Extended human sec
42	7	2.6	172	22	ABG19542	Novel human diagno
43	7	2.6	199	21	AAY76035	Murine skin cell p
44	7	2.6	199	22	AAB55974	Skin cell protein,
45	7	2.6	199	23	ABB72174	Murine protein iso
46	7	2.6	200	24	AAO16499	Argiope trifasciat
47	7	2.6	202	22	AAU36248	Pseudomonas aerugi
48	7	2.6	220	22	AAU30601	Novel human secret
49	7	2.6	230	22	AAE07065	Human gene 15 enco
50	7	2.6	230	23	ABG65063	Human albumin fusi
51	7	2.6	232	23	ABG65064	Human albumin fusi
52	7	2.6	247	22	ABG15898	Novel human diagno
53	7	2.6	253	22	AAB63461	Human breast cance
54	7	2.6	270	21	AAB43760	Human cancer assoc
55	7	2.6	277	23	ABP41891	Human ovarian anti
56	7	2.6	281	23	ABB72324	Rat protein isolat
57	7	2.6	302	21	AAG46601	Arabidopsis thalia
58	7	2.6	309	21	AAY70501	Wheat farnesyltran
59	7	2.6	316	21	AAG46600	Arabidopsis thalia
60	7	2.6	326	21	AAY70497	Corn farnesyltrans
61	7	2.6	327	21	AAG46599	Arabidopsis thalia
62	7	2.6	331	22	ABB59547	Drosophila melanog
63	7	2.6	340	24	ABP71200	S. cinnamoneus cin
64	7	2.6	345	23	AAU84271	Human endometrial
65	7	2.6	346	17	AAW14442	Human transcriptio
66	7	2.6	358	23	ABG96248	Maize peroxidase p
67	7	2.6	432	23	ABU65180	Human NOV97a prote
68	7	2.6	432	23	ABP69406	Human polypeptide
69	7	2.6	447	22	ABB61990	Drosophila melanog
70	7	2.6	453	22	AAU49630	Propionibacterium
71	7	2.6	463	21	AAB41079	Human ORFX ORF843
72	7	2.6	464	23	ABU65079	Human NOV22a prote
73	7	2.6	468	22	ABB67159	Drosophila melanog
74	7	2.6	477	24	ABP72344	Brain factor-1, in
75	7	2.6	478	22	ABB58532	Drosophila melanog
76	7	2.6	480	14	AAR44551	Brain factor-1. R
77	7	2.6	481	23	ABB57076	Mouse ischaemic co
78	7	2.6	494	21	AAY69386	Amino acid sequenc
79	7	2.6	494	21	AAY69393	Amino acid sequenc
80	7	2.6	495	22	ABB65066	Drosophila melanog
81	7	2.6	527	24	ABG70522	Human polypeptide
82	7	2.6	561	22	AAB94345	Human protein sequ

83	7	2.6	570	24	ABJ25879	Aspergillus fumiga
84	7	2.6	573	24	ABJ26479	Aspergillus fumiga
85	7	2.6	589	22	ABU53082	Cell structure and
86	7	2.6	591	21	AAY94911	Human secreted pro
87	7	2.6	591	22	AAG68176	Cell division cycl
88	7	2.6	591	22	AAB60459	Human cell cycle a
89	7	2.6	591	24	ABR41100	Human cell divisio
90	7	2.6	600	24	ABP81206	Arabidopsis thalia
91	7	2.6	611	22	ABB60736	Drosophila melanog
92	7	2.6	709	23	AAB71320	L. major LmgSP9 an
93	7	2.6	723	22	ABB59037	Drosophila melanog
94	7	2.6	723	22	ABG00501	Novel human diagno
95	7	2.6	723	22	ABG02843	Novel human diagno
96	7	2.6	732	22	AAB93312	Human protein sequ
97	7	2.6	817	23	AAO15419	Novel human kinase
98	7	2.6	903	21	AAB25110	Eucalyptus grandis
99	7	2.6	1051	20	AAY29321	Human ataxin-2 lik
100	7	2.6	1146	12	AAR15156	Abelson Related Ge
101	7	2.6	1182	12	AAR15157	Abelson Related Ge
102	7	2.6	1798	21	AAY51611	Human HSGT1 protei
103	7	2.6	2004	23	ABG95113	Human translocatio
104	7	2.6	3606	22	ABB62595	Drosophila melanog
105	6	2.3	7	21	AAB17249	SH3 antagonist pep
106	6	2.3	7	23	ABB73242	Src homology3 (SH3
107	6	2.3	8	20	AAY41626	Mammalian ion chan
108	6	2.3	9	21	AAY94206	Human HLA-A2 bindi
109	6	2.3	9	23	AAU94083	Human novel protei
110	6	2.3	9	23	AAU94686	Human novel protei
111	6	2.3	9	23	AAU95030	Human novel protei
112	6	2.3	9	23	AAU95239	Human novel protei
113	6	2.3	9	23	AAE17183	Human G250 protein
114	6	2.3	9	24	ABR28252	Human cancer-relat
115	6	2.3	10	23	AAU95118	Human novel protei
116	6	2.3	10	23	AAU95138	Human novel protei
117	6	2.3	10	23	AAU95330	Human novel protei
118	6	2.3	10	23	AAU95360	Human novel protei
119	6	2.3	10	24	ABR28347	Human cancer-relat
120	6	2.3	13	22	AAB85381	Fructose-biphospha
121	6	2.3	15	18	AAW39016	Peptide resembling
122	6	2.3	15	18	AAW38985	Peptide resembling
123	6	2.3	15	19	AAW65570	Epstein-Barr virus
124	6	2.3	15	22	AAE09161	Epstein-Barr virus
125	6	2.3	15	24	ABR38292	Human cancer-relat
126	6	2.3	15	24	ABR38293	Human cancer-relat
127	6	2.3	15	24	ABR38294	Human cancer-relat
128	6	2.3	15	24	ABR38351	Human cancer-relat
129	6	2.3	15	24	ABR38391	Human cancer-relat
130	6	2.3	15	24	ABR38392	Human cancer-relat
131	6	2.3	15	24	ABU07645	Epstein-Barr virus
132	6	2.3	16	22	AAE09089	Epstein-Barr virus
133	6	2.3	17	3	AAP20400	Secretin precursor
134	6	2.3	17	4	AAP30019	Intermediate of se
135	6	2.3	17	23	ABG63229	Human prostate spe
136	6	2.3	19	21	AAY66942	T cell antigen rec
137	6	2.3	20	18	AAW42965	Immunogenic Hepati
138	6	2.3	21	13	AAR22966	Rat sepiapterin re
139	6	2.3	21	21	AAB24156	Rat erythrocyte se
140	6	2.3	21	21	AAB24176	Rat erythrocyte se
141	6	2.3	21	22	AAB69485	Synthetic HAV P3D
142	6	2.3	23	16	AAR84151	Peptide enhancer o
143	6	2.3	23	16	AAR84145	Peptide enhancer o
144	6	2.3	23	16	AAR77059	Synthetic anti-neo
145	6	2.3	23	16	AAR77065	Synthetic anti-neo
146	6	2.3	23	16	AAR74708	Tryptic digestion
147	6	2.3	23	16	AAR74714	Tryptic digestion
148	6	2.3	23	16	AAR64787	Amphipathic peptid
149	6	2.3	23	16	AAR64793	Amphipathic peptid
150	6	2.3	23	17	AAR92389	Lytic peptide used

ALIGNMENTS

RESULT 1
AAB24063
ID AAB24063 standard; Protein; 265 AA.
XX
AC AAB24063;
XX
DT 29-JAN-2001 (first entry)
XX
DE Human PRO809 protein sequence SEQ ID NO:23.
XX
KW Human; tumour; diagnosis; neoplastic disease; neoplastic cell growth;
KW proliferation; tumourigenesis; identification; cancer; cytostatic;
KW nootropic; neuroprotective; antiinflammatory; immunosuppressive;
KW immunostimulant; antiangiogenic; leukaemia; lymphoid malignancy;
KW neuronal disorder; glial disorder; astrocytal disorder; angiogenic;
KW hypothalamic disorder; glandular disorder; macrophagal disorder;
KW epithelial disorder; stromal disorder; blastocoelic disorder;
KW inflammatory disorder; immunologic disorder.
XX
OS Homo sapiens.
XX
PN WO200053755-A2.
XX
PD 14-SEP-2000.
XX
PF 06-JAN-2000; 2000WO-US00376.
XX
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 23-JUN-1999; 99US-0141037.
PR 07-JUL-1999; 99US-0143048.
PR 26-JUL-1999; 99US-0145698.
PR 30-NOV-1999; 99WO-US28313.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hillan KJ, Roy MA;
PI Watanabe CK, Wood WI;
XX
DR WPI; 2000-572270/53.
DR N-PSDB; AAC58373.
XX
PT Thirty PRO polynucleotides encoding PRO polypeptides, useful in the
PT treatment, diagnosis and prevention of cancer -
XX
PS Claim 61; Fig 14; 286pp; English.
XX
CC The present invention describes an isolated antibody that binds to
CC one of the human PRO proteins designated PRO212, PRO290, PRO341, PRO535,
CC PRO619, PRO717, PRO809, PRO830, PRO848, PRO943, PRO1005, PRO1009,
CC PRO1025, PRO1030, PRO1097, PRO1107, PRO1111, PRO1153, PRO1182, PRO1184,
CC PRO1187, PRO1281, PRO23, PRO39, PRO834, PRO1317, PRO1710, PRO2094,
CC PRO2145 OR PRO2198. PRO antagonists can be used to inhibit tumour cell
CC growth. The PRO polypeptides and nucleotides are useful in the
CC treatment, diagnosis and prevention of cancer. The antibodies and other
CC anti-tumour compounds maybe used to treat various conditions, including
CC those characterised by overexpression and/or activation of the amplified
CC PRO genes. Exemplary conditions or disorders to be treated with such
CC antibodies and other compounds include benign or malignant tumours
CC (e.g., renal, liver, kidney, bladder, breast, gastric, ovarian,
CC colorectal, prostate, pancreatic, lung, vulva, thyroid, hepatic
CC carcinomas, sarcomas, glioblastomas, and various head and neck tumours),
CC leukaemias and lymphoid malignancies, other disorders such as neuronal,
CC glial, astrocytal, hypothalamic and other glandular, macrophagal,
CC epithelial, stromal and blastocoelic disorders, and inflammatory,
CC angiogenic and immunologic disorders. AAC58242 to AAC58366 represent PCR
CC primers and hybridisation probes used in the isolation of the human PRO
CC sequences. AAC58367 to AAC58396 and AAB24057 to AAB24089 represent human
CC PRO polynucleotide and protein sequences given in the exemplification of
CC the present invention.
XX

SQ Sequence 265 AA;

Query Match 100.0%; Score 265; DB 21; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 2
AAY66691
ID AAY66691 standard; protein; 265 AA.
XX
AC AAY66691;
XX
DT 05-APR-2000 (first entry)
XX
DE Membrane-bound protein PRO809.
XX
KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW pharmaceutical; receptor immunoadhesin; gene mapping.
XX
OS Homo sapiens.
XX
PN WO9963088-A2.
XX
PD 09-DEC-1999.
XX
PF 02-JUN-1999; 99WO-US12252.
XX
PR 02-JUN-1998; 98US-0087607.
PR 02-JUN-1998; 98US-0087609.
PR 02-JUN-1998; 98US-0087759.
PR 03-JUN-1998; 98US-0087827.
PR 04-JUN-1998; 98US-0088021.
PR 04-JUN-1998; 98US-0088025.
PR 04-JUN-1998; 98US-0088028.
PR 04-JUN-1998; 98US-0088029.
PR 04-JUN-1998; 98US-0088030.
PR 04-JUN-1998; 98US-0088033.
PR 04-JUN-1998; 98US-0088326.
PR 05-JUN-1998; 98US-0088167.
PR 05-JUN-1998; 98US-0088202.
PR 05-JUN-1998; 98US-0088212.
PR 05-JUN-1998; 98US-0088217.
PR 09-JUN-1998; 98US-0088655.
PR 10-JUN-1998; 98US-0088722.
PR 10-JUN-1998; 98US-0088730.
PR 10-JUN-1998; 98US-0088734.
PR 10-JUN-1998; 98US-0088738.
PR 10-JUN-1998; 98US-0088740.
PR 10-JUN-1998; 98US-0088741.
PR 10-JUN-1998; 98US-0088742.
PR 10-JUN-1998; 98US-0088810.
PR 10-JUN-1998; 98US-0088811.
PR 10-JUN-1998; 98US-0088824.
PR 10-JUN-1998; 98US-0088825.
PR 10-JUN-1998; 98US-0088826.
PR 11-JUN-1998; 98US-0088858.
PR 11-JUN-1998; 98US-0088861.
PR 11-JUN-1998; 98US-0088863.
PR 11-JUN-1998; 98US-0088876.
PR 12-JUN-1998; 98US-0089090.
PR 12-JUN-1998; 98US-0089105.
PR 16-JUN-1998; 98US-0089440.
PR 16-JUN-1998; 98US-0089512.
PR 16-JUN-1998; 98US-0089514.
PR 17-JUN-1998; 98US-0089532.
PR 17-JUN-1998; 98US-0089538.
PR 17-JUN-1998; 98US-0089598.
PR 17-JUN-1998; 98US-0089599.
PR 17-JUN-1998; 98US-0089600.
PR 17-JUN-1998; 98US-0089653.
PR 18-JUN-1998; 98US-0089801.
PR 18-JUN-1998; 98US-0089907.
PR 18-JUN-1998; 98US-0089908.
PR 19-JUN-1998; 98US-0089947.
PR 19-JUN-1998; 98US-0089948.
PR 19-JUN-1998; 98US-0089952.
PR 22-JUN-1998; 98US-0090246.
PR 22-JUN-1998; 98US-0090252.
PR 22-JUN-1998; 98US-0090254.
PR 23-JUN-1998; 98US-0090349.
PR 23-JUN-1998; 98US-0090355.
PR 24-JUN-1998; 98US-0090429.
PR 24-JUN-1998; 98US-0090431.
PR 24-JUN-1998; 98US-0090435.
PR 24-JUN-1998; 98US-0090444.
PR 24-JUN-1998; 98US-0090445.
PR 24-JUN-1998; 98US-0090461.
PR 24-JUN-1998; 98US-0090472.
PR 24-JUN-1998; 98US-0090535.
PR 24-JUN-1998; 98US-0090538.
PR 24-JUN-1998; 98US-0090540.
PR 24-JUN-1998; 98US-0090557.
PR 25-JUN-1998; 98US-0090676.
PR 25-JUN-1998; 98US-0090678.
PR 25-JUN-1998; 98US-0090688.
PR 25-JUN-1998; 98US-0090690.
PR 25-JUN-1998; 98US-0090691.
PR 25-JUN-1998; 98US-0090694.
PR 25-JUN-1998; 98US-0090695.
PR 25-JUN-1998; 98US-0090696.
PR 26-JUN-1998; 98US-0090862.
PR 26-JUN-1998; 98US-0090863.
PR 01-JUL-1998; 98US-0091358.
PR 01-JUL-1998; 98US-0091360.
PR 01-JUL-1998; 98US-0091544.
PR 02-JUL-1998; 98US-0091478.
PR 02-JUL-1998; 98US-0091486.
PR 02-JUL-1998; 98US-0091519.
PR 02-JUL-1998; 98US-0091626.
PR 02-JUL-1998; 98US-0091628.
PR 02-JUL-1998; 98US-0091633.
PR 02-JUL-1998; 98US-0091646.
PR 02-JUL-1998; 98US-0091673.
PR 07-JUL-1998; 98US-0091978.
PR 07-JUL-1998; 98US-0091982.
PR 09-JUL-1998; 98US-0092182.
PR 10-JUL-1998; 98US-0092472.
PR 20-JUL-1998; 98US-0093339.
PR 30-JUL-1998; 98US-0094651.
PR 04-AUG-1998; 98US-0095282.
PR 04-AUG-1998; 98US-0095285.
PR 04-AUG-1998; 98US-0095301.
PR 04-AUG-1998; 98US-0095302.
PR 04-AUG-1998; 98US-0095318.
PR 04-AUG-1998; 98US-0095321.

```
PR   04-AUG-1998;   98US-0095325.
PR   10-AUG-1998;   98US-0095916.
PR   10-AUG-1998;   98US-0095929.
PR   10-AUG-1998;   98US-0096012.
PR   11-AUG-1998;   98US-0096143.
PR   11-AUG-1998;   98US-0096146.
PR   12-AUG-1998;   98US-0096329.
PR   17-AUG-1998;   98US-0096757.
PR   17-AUG-1998;   98US-0096766.
PR   17-AUG-1998;   98US-0096768.
PR   17-AUG-1998;   98US-0096773.
PR   17-AUG-1998;   98US-0096791.
PR   17-AUG-1998;   98US-0096867.
PR   17-AUG-1998;   98US-0096891.
PR   17-AUG-1998;   98US-0096894.
PR   17-AUG-1998;   98US-0096895.
PR   17-AUG-1998;   98US-0096897.
PR   18-AUG-1998;   98US-0096949.
PR   18-AUG-1998;   98US-0096950.
PR   18-AUG-1998;   98US-0096959.
PR   18-AUG-1998;   98US-0096960.
PR   18-AUG-1998;   98US-0097022.
PR   19-AUG-1998;   98US-0097141.
PR   20-AUG-1998;   98US-0097218.
PR   24-AUG-1998;   98US-0097661.
PR   26-AUG-1998;   98US-0097951.
PR   26-AUG-1998;   98US-0097952.
PR   26-AUG-1998;   98US-0097954.
PR   26-AUG-1998;   98US-0097955.
PR   26-AUG-1998;   98US-0097971.
PR   26-AUG-1998;   98US-0097974.
PR   26-AUG-1998;   98US-0097978.
PR   26-AUG-1998;   98US-0097979.
PR   26-AUG-1998;   98US-0097986.
PR   26-AUG-1998;   98US-0098014.
PR   31-AUG-1998;   98US-0098525.
PR   16-SEP-1998;   98US-0100634.
PR   12-JAN-1999;   99US-0115565.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker K,  Chen J,  Goddard A,  Gurney AL,  Smith V,  Watanabe CK;
PI   Wood WI,  Yuan J;
XX
DR   WPI; 2000-072883/06.
DR   N-PSDB; AAZ65030.
XX
PT   Membrane-bound proteins and related nucleotide sequences  -
XX
PS   claim 12; Fig 151; 822pp; English.
XX
CC   The invention provides membrane-bound PRO polypeptides and
CC   polynucleotides encoding them. The PRO sequences of the invention were
CC   identified based on extracellular domain homology screening. The PRO
CC   sequences have homology with proteins including LDL receptors, TIE
CC   ligands and various enzymes. The membrane-bound proteins and receptor
CC   molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC   immunoadhesins, for instance, can be used as therapeutic agents to block
CC   receptor-ligand interactions. The membrane-bound proteins can also be
CC   employed for screening of potential peptide or small molecule inhibitors
CC   of the relevant receptor/ligand interaction. The PRO encoding sequences
CC   are useful as hybridization probes, in chromosome and gene mapping and in
CC   the generation of antisense RNA and DNA. PRO nucleic acid sequences
CC   will also be useful for the preparation of PRO polypeptides, especially
CC   by recombinant techniques.
XX
SQ   Sequence   265 AA;

  Query Match             100.0%;  Score 265;  DB 21;  Length 265;
  Best Local Similarity   100.0%;  Pred. No. 7.3e-257;
  Matches  265;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265


RESULT 3
AAB65214
ID   AAB65214 standard; Protein; 265 AA.
XX
AC   AAB65214;
XX
DT   02-APR-2001  (first entry)
XX
DE   Human PRO809 (UNQ464) protein sequence SEQ ID NO:223.
XX
KW   Human; secreted and transmembrane protein; PRO; cytostatic;
KW   cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
KW   diagnostic assay.
XX
OS   Homo sapiens.
XX
PN   WO200073454-A1.
XX
PD   07-DEC-2000.
XX
PF   30-MAR-2000; 2000WO-US08439.
XX
PR   02-JUN-1999;   99WO-US12252.
PR   23-JUN-1999;   99US-0141037.
PR   07-JUL-1999;   99US-0143048.
PR   20-JUL-1999;   99US-0144758.
PR   26-JUL-1999;   99US-0145698.
PR   28-JUL-1999;   99US-0146222.
PR   17-AUG-1999;   99US-0149396.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   08-OCT-1999;   99US-0158663.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   02-MAR-2000; 2000WO-US05841.
PR   15-MAR-2000; 2000WO-US06884.
PR   20-MAR-2000; 2000WO-US07377.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi CJ,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
```

PI Zhang Z;
XX
DR WPI; 2001-032160/04.
DR N-PSDB; AAF44176.
XX
PT PRO polynucleotides used to produce polypeptides used to target
PT bioactive molecules such as toxins, radiolabels or antibodies, to
PT specific cells, to cause targeted cell death -
XX
PS Claim 12; Fig 151; 935pp; English.
XX
CC The present invention describes human secreted and transmembrane PRO
CC proteins. The PRO proteins have cytostatic activity. The PRO proteins
CC can be used for targeted delivery of bioactive molecules, such as
CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
CC sequences, and their fragments, can be used as hybridisation probes, in
CC chromosomal and gene mapping, and in the generation of anti-sense RNA
CC and DNA. They may also be used to produce transgenic animals which are
CC used to develop and screen therapeutically useful reagents. The PRO
CC nucleotide and protein sequence can be used for tissue typing and in
CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein
CC sequences given in the exemplification of the present invention.
XX
SQ Sequence 265 AA;

Query Match 100.0%; Score 265; DB 22; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 4
AAU83666
ID AAU83666 standard; Protein; 265 AA.
XX
AC AAU83666;
XX
DT 08-MAY-2002 (first entry)
XX
DE Human PRO protein, Seq ID No 150.
XX
KW Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW breast cancer; prostate tumour; rectal tumour; liver tumour;
KW pericyte cell proliferation; chondrocyte cell proliferation;
KW tumour necrosis factor-alpha.
XX
OS Homo sapiens.
XX
PN WO200208288-A2.
XX
PD 31-JAN-2002.
XX
PF 29-JUN-2001; 2001WO-US21066.
XX
PR 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220585P.
PR 25-JUL-2000; 2000US-220605P.
PR 25-JUL-2000; 2000US-220607P.
PR 25-JUL-2000; 2000US-220624P.
PR 25-JUL-2000; 2000US-220638P.
PR 25-JUL-2000; 2000US-220664P.
PR 25-JUL-2000; 2000US-220666P.
PR 26-JUL-2000; 2000US-220893P.
PR 28-JUL-2000; 2000WO-US20710.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 15-SEP-2000; 2000US-000000P.
PR 10-NOV-2000; 2000WO-US30873.
PR 28-NOV-2000; 2000US-253646P.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001WO-US17092.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2002-172001/22.
DR N-PSDB; ABK33610.
XX
PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for treating a PRO related disorder and for diagnosing tumours
PT such as lung cancer, colon cancer, breast tumour, prostate tumour, rectal
PT tumour or liver tumour -
XX
PS Claim 11; Figure 150; 359pp; English.
XX
CC The invention relates to one hundred and twenty two nucleic acids
CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC agonists and antagonists are useful for treating a PRO related disorder.
CC The PRO polypeptides are useful for diagnosing tumours, especially lung
CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. The PRO polypeptides are useful for stimulating the
CC proliferation of, or gene expression, in pericyte cells, for stimulating
CC the proliferation or differentiation of chondrocyte cells, for
CC stimulating the release of tumour necrosis factor-alpha from human blood,
CC for stimulating or inhibiting the proliferation of normal human dermal
CC fibroblast cells. The PRO polypeptide may also be used as molecular
CC weight markers and for tissue typing. The PRO nucleic acids have
CC applications in molecular biology, including use as hybridisation probes,
CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
CC protein sequences of the invention.
XX
SQ Sequence 265 AA;

Query Match 100.0%; Score 265; DB 23; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 5
ABU59107
ID ABU59107 standard; Protein; 265 AA.
XX
AC ABU59107;
XX
DT 28-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO809.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2002132252-A1.
XX
PD 19-SEP-2002.
XX
PF 14-NOV-2001; 2001US-0990442.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 06-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-247083/24.
DR N-PSDB; ABX80266.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346

PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT are therapeutically useful for enhancing immune response and in cancer
PT treatments -
XX
PS Claim 12; Fig 151; 648pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and
CC are thus useful for treating sports injuries, and arthritis. This
CC is the amino acid sequence of a novel human PRO protein.
XX
SQ Sequence 265 AA;

Query Match 100.0%; Score 265; DB 24; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 6
ABU59254
ID ABU59254 standard; Protein; 265 AA.
XX
AC ABU59254;
XX
DT 22-APR-2003 (first entry)
XX
DE Human secreted/transmembrane protein, #90.
XX
KW Human; PRO; secreted; transmembrane; pharmaceutical;
KW diagnostic; biosensor; bioreactor; tumour; therapeutic;
KW gene therapy; tumour-associated antigenic target; TAT; ADEPT;
KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003027162-A1.
XX
PD 06-FEB-2003.
XX
PF 15-NOV-2001; 2001US-0997428.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.

PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 23-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 24-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091978P.
PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-093339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095929P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096329P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096768P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096791P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.
PR 17-AUG-1998; 98US-096895P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-096960P.
PR 18-AUG-1998; 98US-097022P.
PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 26-AUG-1998; 98US-098014P.
PR 31-AUG-1998; 98US-098525P.
PR 16-SEP-1998; 98US-100634P.
PR 17-SEP-1998; 98US-100858P.
PR 22-DEC-1998; 98US-113296P.
PR 12-MAR-1999; 99US-123957P.
PR 23-JUN-1999; 99US-141037P.

Query Match 100.0%; Score 265; DB 24; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 7

```
ABU59403
ID   ABU59403 standard; Protein; 265 AA.
XX
AC   ABU59403;
XX
DT   22-APR-2003  (first entry)
XX
DE   Novel human secreted or transmembrane protein PRO791.
XX
KW   Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW   cardiac insufficiency disorder; cancer; tumour; immune response;
KW   adrenal cortical capillary endothelial growth; c-fos induction;
KW   vascular endothelial growth factor inhibition; VEGF inhibition;
KW   endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW   retinal neurons cell survival; rod photoreceptor cell survival;
KW   retinal disorder; retinitis pigmentosum; kidney disorder;
KW   mammalian kidney mesangial cell proliferation; Berger disease;
KW   dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW   chondrocyte redifferentiation; sports injury; arthritis.
XX
OS   Homo sapiens.
XX
PN   US2003027985-A1.
XX
PD   06-FEB-2003.
XX
PF   14-NOV-2001; 2001US-0990562.
XX
PR   05-NOV-1997;   97WO-US20069.
PR   16-SEP-1998;   98WO-US19330.
PR   17-SEP-1998;   98WO-US19437.
PR   07-OCT-1998;   98WO-US21141.
PR   01-DEC-1998;   98WO-US25108.
PR   05-JAN-1999;   99WO-US00106.
PR   08-MAR-1999;   99WO-US05028.
PR   02-JUN-1999;   99WO-US12252.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   30-NOV-1999;   99WO-US28313.
PR   01-DEC-1999;   99WO-US28301.
PR   01-DEC-1999;   99WO-US28634.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00376.
PR   11-FEB-2000; 2000WO-US03565.
PR   18-FEB-2000; 2000WO-US04341.
PR   22-FEB-2000; 2000WO-US04414.
PR   24-FEB-2000; 2000WO-US04914.
PR   24-FEB-2000; 2000WO-US05004.
PR   02-MAR-2000; 2000WO-US05841.
PR   10-MAR-2000; 2000WO-US06319.
PR   15-MAR-2000; 2000WO-US06884.
PR   20-MAR-2000; 2000WO-US07377.
PR   30-MAR-2000; 2000WO-US08439.
PR   15-MAY-2000; 2000WO-US13358.
PR   17-MAY-2000; 2000WO-US13705.
PR   22-MAY-2000; 2000WO-US14042.
PR   30-MAY-2000; 2000WO-US14941.
PR   02-JUN-2000; 2000WO-US15264.
PR   28-JUL-2000; 2000WO-US20710.
PR   11-AUG-2000; 2000WO-US22031.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   08-NOV-2000; 2000WO-US30952.
PR   01-DEC-2000; 2000WO-US32678.
PR   28-FEB-2001; 2001WO-US06520.
PR   01-JUN-2001; 2001WO-US17800.
PR   20-JUN-2001; 2001WO-US19692.
PR   29-JUN-2001; 2001WO-US21066.
PR   09-JUL-2001; 2001WO-US21735.
PR   16-JUN-1997;   97US-049787P.
PR   17-OCT-1997;   97US-062250P.
PR   12-NOV-1997;   97US-065186P.
PR   13-NOV-1997;   97US-065311P.
PR   24-NOV-1997;   97US-066770P.
PR   25-FEB-1998;   98US-075945P.
PR   20-MAR-1998;   98US-078910P.
PR   28-APR-1998;   98US-083322P.
PR   07-MAY-1998;   98US-084600P.
PR   28-MAY-1998;   98US-087106P.
PR   02-JUN-1998;   98US-087607P.
PR   02-JUN-1998;   98US-087609P.
PR   02-JUN-1998;   98US-087759P.
PR   03-JUN-1998;   98US-087827P.
PR   04-JUN-1998;   98US-088021P.
PR   04-JUN-1998;   98US-088025P.
PR   04-JUN-1998;   98US-088026P.
PR   04-JUN-1998;   98US-088028P.
PR   04-JUN-1998;   98US-088029P.
PR   04-JUN-1998;   98US-088030P.
PR   04-JUN-1998;   98US-088033P.
PR   04-JUN-1998;   98US-088326P.
PR   05-JUN-1998;   98US-088167P.
PR   05-JUN-1998;   98US-088202P.
PR   05-JUN-1998;   98US-088212P.
PR   05-JUN-1998;   98US-088217P.
PR   09-JUN-1998;   98US-088655P.
PR   10-JUN-1998;   98US-088734P.
PR   10-JUN-1998;   98US-088738P.
PR   10-JUN-1998;   98US-088742P.
PR   10-JUN-1998;   98US-088810P.
PR   10-JUN-1998;   98US-088824P.
PR   10-JUN-1998;   98US-088826P.
PR   11-JUN-1998;   98US-088858P.
PR   11-JUN-1998;   98US-088861P.
PR   11-JUN-1998;   98US-088876P.
PR   12-JUN-1998;   98US-089105P.
PR   16-JUN-1998;   98US-089440P.
PR   16-JUN-1998;   98US-089512P.
PR   16-JUN-1998;   98US-089514P.
PR   17-JUN-1998;   98US-089532P.
PR   17-JUN-1998;   98US-089538P.
PR   17-JUN-1998;   98US-089598P.
PR   17-JUN-1998;   98US-089599P.
PR   17-JUN-1998;   98US-089600P.
PR   17-JUN-1998;   98US-089653P.
PR   18-JUN-1998;   98US-089801P.
PR   18-JUN-1998;   98US-089907P.
PR   18-JUN-1998;   98US-089908P.
PR   19-JUN-1998;   98US-089947P.
PR   19-JUN-1998;   98US-089948P.
PR   19-JUN-1998;   98US-089952P.
PR   22-JUN-1998;   98US-090246P.
PR   22-JUN-1998;   98US-090252P.
PR   22-JUN-1998;   98US-090254P.
PR   23-JUN-1998;   98US-090349P.
PR   23-JUN-1998;   98US-090355P.
PR   24-JUN-1998;   98US-090429P.
PR   24-JUN-1998;   98US-090431P.
PR   24-JUN-1998;   98US-090435P.
PR   24-JUN-1998;   98US-090444P.
PR   24-JUN-1998;   98US-090445P.
PR   24-JUN-1998;   98US-090472P.
PR   24-JUN-1998;   98US-090535P.
PR   24-JUN-1998;   98US-090540P.
PR   24-JUN-1998;   98US-090542P.
PR   24-JUN-1998;   98US-090557P.
PR   25-JUN-1998;   98US-090676P.
PR   25-JUN-1998;   98US-090678P.
PR   25-JUN-1998;   98US-090690P.
PR   25-JUN-1998;   98US-090694P.
PR   25-JUN-1998;   98US-090695P.
PR   25-JUN-1998;   98US-090696P.
PR   26-JUN-1998;   98US-090862P.
PR   26-JUN-1998;   98US-090863P.
```

PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091978P.
PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-093339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095929P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096329P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096768P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096791P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.
PR 17-AUG-1998; 98US-096895P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-096960P.
PR 18-AUG-1998; 98US-097022P.
PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 26-AUG-1998; 98US-098014P.

Query Match 100.0%; Score 265; DB 24; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 8
ABU60538
ID ABU60538 standard; Protein; 265 AA.
XX
AC ABU60538;
XX
DT 01-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane protein, #90.
XX
KW Human; PRO; secreted; transmembrane; signal peptide;
KW pharmaceutical; diagnostic; therapeutic; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002160384-A1.
XX
PD 31-OCT-2002.
XX
PF 14-NOV-2001; 2001US-0992598.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.

PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-288106/28.
DR N-PSDB; AEX90244.
XX
PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes -
XX
PS Claim 12; Fig 151; 650pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful in gene therapy, in chromosome
CC identification, as chromosome markers, or in generating probes. The PRO
CC polypeptides are useful as molecular markers for protein
CC electrophoresis, and the isolated nucleic acids may be used for
CC recombinantly expressing those markers. The PRO polypeptides and nucleic
CC acids may also be used in tissue typing. Anti-PRO antibodies are useful
CC in diagnostic assays for PRO, and in affinity purification of PRO from
CC recombinant cell culture or natural sources. The sequences presented in
CC ABU60478-ABU60624 are the PRO polynucleotides of the invention.
CC Note: The sequence data for this patent is also available in electronic
CC format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 265 AA;

Query Match 100.0%; Score 265; DB 24; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 9
ABU58029
ID ABU58029 standard; Protein; 265 AA.
XX
AC ABU58029;
XX
DT 14-APR-2003 (first entry)
XX
DE Human PRO polypeptide #61.
XX
KW Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;
KW horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;
KW antibody-dependent enzyme mediated prodrug therapy.
XX
OS Homo sapiens.
XX
PN US2003027163-A1.
XX
PD 06-FEB-2003.
XX
PF 15-NOV-2001; 2001US-0997666.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.

PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090246P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 23-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 24-JUN-1998; 98US-090429P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090435P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 24-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091978P.
PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-093339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095929P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096329P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096768P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096791P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.
PR 17-AUG-1998; 98US-096895P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.

PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-096960P.
PR 18-AUG-1998; 98US-097022P.
PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 26-AUG-1998; 98US-098014P.
PR 31-AUG-1998; 98US-098525P.
PR 16-SEP-1998; 98US-100634P.
PR 17-SEP-1998; 98US-100858P.
PR 22-DEC-1998; 98US-113296P.
PR 12-MAR-1999; 99US-123957P.
PR 23-JUN-1999; 99US-141037P.
PR 07-JUL-1999; 99US-143048P.

Query Match 100.0%; Score 265; DB 24; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 10
ABU58960
ID ABU58960 standard; Protein; 265 AA.
XX
AC ABU58960;
XX
DT 16-APR-2003 (first entry)
XX
DE Human sectreted/transmembrane protein, #90.
XX
KW Human; PRO; secreted; transmembrane; signal peptide;
KW pharmaceutical; diagnostic; biosensor; bioreactor; tumour; therapeutic;
KW colon cancer; lung cancer; breast cancer;cancer; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002142961-A1.
XX
PD 03-OCT-2002.
XX
PF 19-NOV-2001; 2001US-0989721.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.

PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-155950/15.
XX
PT New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
PT PRO361 or PRO846) useful as targets for therapeutic intervention in
PT cancers (e.g. lung or breast cancers), or for diagnosing these cancers
PT -
XX
PS Claim 12; Fig 151; 647pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful as pharmaceuticals, diagnostics,
CC biosensors or bioreactors, for detecting or treating e.g. tumours in
CC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or
CC rabbits as targets for therapeutic intervention in certain cancers (e.g.
CC colon, lung or breast cancers) and diagnostic determination of the
CC presence of these cancers. The PRO polypeptides are also useful as
CC molecular weight markers or for chromosome identification. The PRO genes
CC are useful as hybridisation probes or for screening libraries of human
CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
CC therapy, particularly for replacing a defective gene. The sequences
CC presented in ABU58900-ABU59046 are the PRO polypeptides of the invention.
XX
SQ Sequence 265 AA;

Query Match 100.0%; Score 265; DB 24; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 11
ABU13920
ID ABU13920 standard; Protein; 265 AA.
XX
AC ABU13920;
XX
DT 26-FEB-2003 (first entry)
XX
DE Human PRO809 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive.
XX
OS Homo sapiens.
XX
PN US2002103125-A1.
XX
PD 01-AUG-2002.
XX
PF 20-NOV-2001; 2001US-0989731.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 06-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.

PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH LTD.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-102117/09.
DR N-PSDB; ABX64090.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers -
XX
PS Claim 12; Fig 151; 649pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The
CC PRO polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for
CC linking bioactive molecules to cells expressing PRO polypeptides,
CC for modulating biological activities of cells expressing PRO
CC polypeptides, and for for identifying agonists or antagonists.
CC The polynucleotide sequences encoding PRO polypeptides are useful as
CC hybridisation probes, in chromosome and gene mapping, in the generation
CC of antisense RNA and DNA, in the preparation of PRO polypeptides, for
CC generating transgenic animals or knockout animals, to construct
CC hybridisation probes for mapping the gene which encodes the PRO
CC polypeptide, and for the genetic analysis of individuals with genetic
CC disorders, in gene therapy, for chromosome identification, as
CC chromosome markers, and for generating probes for PCR, Northern
CC analysis, Southern analysis and Western analysis. ABU13860-ABU14006
CC represent the human PRO polypeptides of the invention.
CC Note: The sequence data for this patent was obtained in electronic
CC format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDEntry.html.
XX
SQ Sequence 265 AA;

Query Match 100.0%; Score 265; DB 24; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 12
ABU10875
ID ABU10875 standard; Protein; 265 AA.
XX
AC ABU10875;
XX
DT 04-FEB-2003 (first entry)
XX
DE Human PRO polypeptide #61.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW toxin; radiolabel; cell death; gene mapping; chromosome mapping;
KW protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
KW antibacterial.
XX
OS Homo sapiens.
XX
PN US2002123463-A1.
XX
PD 05-SEP-2002.
XX
PF 19-NOV-2001; 2001US-0989732.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.

PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 06-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-066810/06.
DR N-PSDB; ABX17054.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers -
XX
PS Claim 12; Fig 151; 655pp; English.
XX
CC The invention relates to a secreted and transmembrane polypeptide, termed
CC PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
CC useful for detecting PRO polypeptides and for linking a bioactive
CC molecule to a cell expressing the above polypeptides, where the bioactive
CC molecule is a toxin, radiolabel or an antibody. The bioactive material
CC causes the death of the cell. The polypeptide is useful for identifying
CC agonists or antagonists of the PRO polypeptide, for preparing variants of
CC PRO, as a molecular weight marker for protein electrophoresis purposes
CC and the PRO polynucleotide is useful for recombinantly expressing those
CC markers. The polynucleotide is also useful as a hybridisation probe, in
CC chromosome and gene mapping, in generation of antisense RNA and DNA, in
CC the preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, to construct hybridisation
CC probes for mapping the gene which encodes PRO and for the genetic
CC analysis of individuals with genetic disorders, in gene therapy, for
CC chromosome identification, as a chromosome marker and for generating
CC probes for PCR, Northern analysis, Southern analysis and Western
CC analysis. This sequence represents a human PRO polypeptide of the
CC invention.
XX
SQ Sequence 265 AA;

Query Match 100.0%; Score 265; DB 24; Length 265;
Best Local Similarity 100.0%; Pred. No. 7.3e-257;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
```

```
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265


RESULT 13
AAG89176
ID   AAG89176 standard; Protein; 247 AA.
XX
AC   AAG89176;
XX
DT   11-SEP-2001  (first entry)
XX
DE   Human secreted protein, SEQ ID NO: 296.
XX
KW   Human; secreted protein; gene therapy; vaccine; treatment; diagnosis;
KW   GENSET.
XX
OS   Homo sapiens.
XX
PN   WO200142451-A2.
XX
PD   14-JUN-2001.
XX
PF   07-DEC-2000; 2000WO-IB01938.
XX
PR   08-DEC-1999;   99US-0169629.
PR   06-MAR-2000; 2000US-0187470.
XX
PA   (GEST ) GENSET.
XX
PI   Dumas Milne Edwards J,  Bougueleret L,  Jobert S;
XX
DR   WPI; 2001-367870/38.
DR   N-PSDB; AAH64779.
XX
PT   Full length GENSET human nucleic acids encoding potentially secreted
PT   proteins, useful in gene therapy and vaccination against a variety of
PT   diseases, and for diagnosis of those diseases -
XX
PS   Claim 21; Page 827-828; 921pp; English.
XX
CC   The invention relates to full length GENSET human nucleic acids encoding
CC   potentially secreted proteins. The nucleic acids and the polypeptides
CC   they encode may be used in the prevention, treatment and diagnosis of
CC   diseases associated with inappropriate GENSET gene expression. For
CC   example, they be used to treat disorders associated with decreased
CC   GENSET gene expression by rectifying mutations or deletions in a
CC   patient's genome that affect the activity of GENSET or by supplementing
CC   the patients own production of GENSET polypeptides. Conversely,
CC   antisense nucleic acid molecules may be administered to down regulate
CC   GENSET expression by binding with the cells' own genes and preventing
CC   their expression. The sense and antisense nucleic acids may also be
CC   used as DNA probes in diagnostic assays to detect and quantitate the
CC   presence of similar nucleic acid sequences in samples, and hence to
CC   determine which patients may be in need of restorative therapy.
CC   The GENSET polypeptides may be used as antigens in the production of
CC   antibodies and in assays to identify modulators (agonists and
CC   antagonists) of GENSET polypeptide expression and activity. The
CC   present sequence is a GENSET polypeptide of the invention.
XX
SQ   Sequence   247 AA;

  Query Match             81.1%;  Score 215;  DB 22;  Length 247;
  Best Local Similarity   100.0%;  Pred. No. 8.4e-207;
  Matches  215;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGG 215
              |||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGG 215


RESULT 14
AAM24472
ID   AAM24472 standard; Protein; 232 AA.
XX
AC   AAM24472;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Human EST encoded protein SEQ ID NO: 1997.
XX
KW   Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
KW   tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
KW   diagnostics; forensic test; gene mapping; genetic disorder;
KW   biodiversity; gene therapy; nutrition.
XX
OS   Homo sapiens.
XX
PN   WO200154477-A2.
XX
PD   02-AUG-2001.
XX
PF   25-JAN-2001; 2001WO-US02687.
XX
PR   25-JAN-2000; 2000US-0491404.
PR   17-JUL-2000; 2000US-0617746.
PR   03-AUG-2000; 2000US-0631451.
PR   15-SEP-2000; 2000US-0663870.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Zhou P,  Qian XB,  Wang Z,  Chen R,  Asundi V;
PI   Cao Y,  Drmanac RA,  Zhang J,  Werhman T;
XX
DR   WPI; 2001-476164/51.
DR   N-PSDB; AAH99131.
XX
PT   Isolated polypeptide for treatment of diseases, diagnostics, raising
PT   antibodies and research use -
XX
PS   Claim 20; Page 1266; 1275pp; English.
XX
CC   The present invention provides the protein and coding sequences of novel
CC   proteins from a variety of organisms, including human, dog, cat, horse,
CC   cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
CC   urchin and tomato. These were derived from expressed sequence tags (ESTs)
CC   from the organism of interest. They can be used in diagnostics,
CC   forensics, gene mapping, identification of mutations, to assess
CC   biodiversity and for nutritional purposes. The present sequence is a
CC   protein of the invention.
XX
SQ   Sequence   232 AA;

  Query Match             46.4%;  Score 123;  DB 22;  Length 232;
  Best Local Similarity   100.0%;  Pred. No. 1.2e-114;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
```

```
Qy        121 LWS 123
              |||
Db        121 LWS 123
```

RESULT 15
ABJ19682
ID ABJ19682 standard; Protein; 235 AA.
XX
AC ABJ19682;
XX
DT 03-APR-2003 (first entry)
XX
DE Human secreted protein amino acid sequence - SEQ ID No 148.
XX
KW Human; protein therapy; immediate hypersensitivity disease;
KW allergic disorder; asthmatic disorder; gene therapy; secreted protein;
KW hay fever; allergic conjunctivitis; allergic rhinitis;
KW binding partner identification; chromosome identification;
KW radiation hybrid mapping; long-range restriction mapping.
XX
OS Homo sapiens.
XX
PN WO200277188-A2.
XX
PD 03-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US09239.
XX
PR 27-MAR-2001; 2001US-278650P.
PR 12-SEP-2001; 2001US-0950082.
PR 12-SEP-2001; 2001US-0950083.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM;
XX
DR WPI; 2003-175010/17.
XX
PT Use of human secreted proteins and nucleic acids for preparing a
PT diagnostic or pharmaceutical composition for diagnosing or treating
PT allergic or asthmatic disorders, e.g. asthma, hay fever, or allergic
PT conjunctivitis or rhinitis -
XX
PS Claim 1; Page 632-633; 823pp; English..
XX
CC The invention comprises the amino acid and coding sequences of human
CC secreted proteins. The DNA and protein sequences of the invention are
CC useful for the diagnosis and treatment of allergic disorders, asthmatic
CC disorders and immediate hypersensitivity diseases (e.g. hay fever,
CC allergic conjunctivitis and allergic rhinitis). The proteins of the
CC invention are also useful for identifying a binding partner. The nucleic
CC acids of the invention are also useful for chromosome identification,
CC radiation hybrid mapping or long-range restriction mapping. The present
CC amino acid sequence represents a human secreted protein of the invention.
XX
SQ Sequence 235 AA;

```
  Query Match             46.4%;  Score 123;  DB 24;  Length 235;
  Best Local Similarity   100.0%;  Pred. No. 1.2e-114;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWS 123
              |||
Db        121 LWS 123
```

RESULT 16
ABP99572
ID ABP99572 standard; Protein; 235 AA.
XX
AC ABP99572;
XX
DT 26-MAR-2003 (first entry)
XX
DE Human secreted protein SEQ ID NO 516.
XX
KW Human; secreted protein; nootropic; neuroprotective; cytostatic;
KW virucide; dermatological; immunosuppressive; antiinflammatory; anti-HIV;
KW vulnerary; antibacterial; antiparkinsonian; antisickling; antianaemic;
KW antiarthritic; cancer; antirheumatic; hepatotropic; cerebroprotective;
KW antiinflammatory; antiallergic; antidiabetic; antiulcer; anticonvulsant;
KW antifungal; antiparasitic; cardiant; immune disorder; infection; vaccine;
KW cardiovascular disorder; neurological disease; nephrotropic;
KW gene therapy.
XX
OS Homo sapiens.
XX
PN WO200277186-A2.
XX
PD 03-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US09188.
XX
PR 27-MAR-2001; 2001US-278650P.
PR 12-SEP-2001; 2001US-0950082.
PR 12-SEP-2001; 2001US-0950083.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM;
XX
DR WPI; 2003-040583/03.
DR N-PSDB; ABZ66993.
XX
PT New human secreted proteins encoded by genes contained in cDNA clones
PT (e.g. HGCAC19), useful for preventing, treating or diagnosing e.g.
PT AIDS, multiple sclerosis, herpes virus, leukemia, tick-borne
PT encephalitis or West Nile fever -
XX
PS Claim 1; Page 1422; 2423pp; English.
XX
CC The invention relates to novel human genes (ABZ66891-ABZ68209) and the
CC encoded secreted proteins (ABP99470-ABP99872) useful for preventing,
CC treating or ameliorating medical conditions e.g. by protein or gene
CC therapy. The genes are isolated from a range of human tissues disclosed
CC in the specification. The nucleic acids, proteins, antibodies and
CC (ant)agonists are useful in the diagnosis, treatment and prevention of:
CC (a) cancer, e.g. breast and ovarian cancer and other cancers of the
CC adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,
CC lung or urogenital; (b) immune disorders e.g. Addison's disease,
CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,
CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid
CC arthritis and ulcerative colitis; (c) cardiovascular disorders such as
CC myocardial ischaemias; (d) wound healing; (e) neurological diseases e.g.
CC cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,
CC bacterial, fungal and parasitic infections.
XX
SQ Sequence 235 AA;

```
  Query Match             46.4%;  Score 123;  DB 24;  Length 235;
  Best Local Similarity   100.0%;  Pred. No. 1.2e-114;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
```

```
Qy          61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy         121 LWS 123
               |||
Db         121 LWS 123


RESULT 17
AAB39216
ID   AAB39216 standard; Protein; 236 AA.
XX
AC   AAB39216;
XX
DT   02-FEB-2001  (first entry)
XX
DE   Human secreted protein sequence encoded by gene 38 SEQ ID NO:96.
XX
KW   Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;
KW   antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
KW   nootropic; neuroprotective; antibacterial; virucide; fungicide; neoplasm;
KW   opthalmalogical; autoimmune disease; rheumatoid arthritis; angiogenesis;
KW   hyperproliferative disorder; cardiovascular disorder; infection;
KW   cerebrovascular disorder; nervous system disorder; ocular disorder;
KW   wound healing; chemotaxis.
XX
OS   Homo sapiens.
XX
PN   WO200056754-A1.
XX
PD   28-SEP-2000.
XX
PF   16-MAR-2000; 2000WO-US06792.
XX
PR   19-MAR-1999;   99US-0125362.
PR   10-DEC-1999;   99US-0169980.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen GA,  Ruben SM,  Komatsoulis G;
XX
DR   WPI; 2000-579483/54.
DR   N-PSDB; AAC74260.
XX
PT   Isolated nucleic acid molecule encoding a human secreted protein is
PT   used in preventing, treating or ameliorating a medical condition  -
XX
PS   Claim 11; Page 386-387; 434pp; English.
XX
CC   The polynucleotide sequences given in AAC74223-C74279 encode the human
CC   secreted proteins represented in AAB39179-B39226. Sequences
CC   AAB39227-B39308 are alternative proteins encoded by the genes, and also
CC   protein sequences with which they share homology. The proteins have
CC   activities based on the tissues and cells in which they are expressed.
CC   Examples of activities include: immunosuppressive; antiarthritic;
CC   antirheumatic; antiproliferative; cytostatic; cardiant; vasotropic;
CC   cerebroprotective; nootropic; neuroprotective; antibacterial; virucide;
CC   fungicide; and opthalmalogical. The human secreted proteins,
CC   polynucleotides, antagonists and agonists of the invention may be useful
CC   in the treatment, prevention, and/or diagnosis of various disease,
CC   disorders and conditions such as autoimmune diseases e.g. rheumatoid
CC   arthritis, hyperproliferative disorders e.g. neoplasms of the breast or
CC   liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular
CC   disorders e.g. cerebral ischaemia, angiogenesis, nervous system disorders
CC   e.g. Alzheimer's disease, infections caused by bacteria, viruses and
CC   fungi and ocular disorders e.g. corneal infection. The polypeptides can
CC   also be used to aid wound healing and epithelial cell proliferation, to
CC   regenerate tissues, maintain organs before transplantation, in
CC   chemotaxis and as a food additive or preservative e.g. to increase
CC   storage capabilities. Sequences AAC74214-C74222 and AAB39178 are used
CC   during the isolation and characterisation of the genes of the invention.
XX
SQ   Sequence   236 AA;

  Query Match             46.4%;  Score 123;  DB 21;  Length 236;
  Best Local Similarity   100.0%;  Pred. No. 1.2e-114;
  Matches  123;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWS 123
               |||
Db        121 LWS 123


RESULT 18
AAU21256
ID   AAU21256 standard; Protein; 175 AA.
XX
AC   AAU21256;
XX
DT   17-DEC-2001  (first entry)
XX
DE   Human novel foetal antigen, SEQ ID NO 1500.
XX
KW   Human; foetal tissue antigen; antiinflammatory; neuroprotective;
KW   immunomodulator; cardiovascular; cytostatic; nephrothropic;
KW   cardiovascular; autoimmune disease; rheumatoid arthritis;
KW   hyperproliferative disorder; breast neoplasm; cancer;
KW   cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW   cerebral ischaemia; angiogenesis; nervous system disorder;
KW   Alzheimer's disease; infection; ocular disorder; corneal infection;
KW   wound healing; epithelial cell proliferation; food additive.
XX
OS   Homo sapiens.
XX
PN   WO200155312-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01321.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
```

PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488782/53.
DR N-PSDB; AAS34076.
XX
PT New polynucleotides and polypeptides for diagnosing, treating,
PT preventing or prognosing e.g. diseases or disorders of the nervous,
PT musculoskeletal, excretory, gastrointestinal, reproductive, and
PT respiratory systems -
XX
PS Claim 11; SEQ ID No 1500; 642pp; English.
XX
CC The invention relates to novel nucleic acids encoding novel human foetal
CC antigens. The nucleic acids and proteins are used to prevent, treat (e.g.
CC by gene therapy) or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They
CC are also used in diagnosing a pathological condition or susceptibility
CC to a pathological condition. The antibodies to the antigens can also
CC be used in alleviating symptoms associated with the disorders and in
CC diagnostic immunoassays e.g. radioimmunoassays or enzyme linked
CC immunosorbent assays (ELISA). Disorders which are diagnosed or treated
CC include autoimmune diseases e.g. rheumatoid arthritis,
CC hyperproliferative disorders e.g. neoplasms of the breast or liver,
CC cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders
CC e.g. cerebral ischaemia, angiogenesis, nervous system disorders e.g.
CC Alzheimer's disease, infections caused by bacteria, viruses and fungi
CC and ocular disorders e.g. corneal infection. The polypeptides can also
CC be used to aid wound healing and epithelial cell proliferation, to
CC prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. Numerous

```
CC   examples of diseases and disorders treated by the nucleic acids and
CC   proteins are given in the specification. The present sequence

  Query Match             44.9%;  Score 119;  DB 22;  Length 175;
  Best Local Similarity   100.0%;  Pred. No. 9.1e-111;
  Matches  119;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         24 EITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITYSLCGTKNIKVAKKVVKTHEPASF 83
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         54 EITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITYSLCGTKNIKVAKKVVKTHEPASF 113

Qy         84 NLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWELWSKPVSELRANFTLQDRGAGP 142
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        114 NLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWELWSKPVSELRANFTLQDRGAGP 172


RESULT 19
AAW11113
ID   AAW11113 standard; peptide; 13 AA.
XX
AC   AAW11113;
XX
DT   25-JUN-1997  (first entry)
XX
DE   Src SH3 domain-binding peptide used in signal transduction modulation.
XX
KW   Src; SH3; Src homology region 3; binding affinity; oncogenic protein;
KW   protein tyrosine kinase; signal transduction; RNA processing;
KW   trafficking; translation.
XX
OS   Synthetic.
XX
PN   WO9603649-A1.
XX
PD   08-FEB-1996.
XX
PF   24-JUL-1995;   95WO-US09382.
XX
PR   07-JUN-1995;   95US-0483555.
PR   22-JUL-1994;   94US-0278865.
XX
PA   (UYNC-) UNIV NORTH CAROLINA.
XX
PI   Der CJ,  Kay BK,  Quilliam LA,  Sparks AB,  Thorn JM;
XX
DR   WPI; 1996-117151/12.
XX
PT   Peptide with binding affinity for Src homology region 3 (SH3)
PT   domains of proteins - useful for e.g. modulating signal transduction
PT   pathways at the cellular level, esp. protein tyrosine
PT   kinase-mediated
XX
PS   Claim 38; Page 87; 116pp; English.
XX
CC   AAW11098-W11124 are peptides that bind to the Src SH3 domain. The SH3
CC   binding peptides are useful in modulating signal transduction pathways
CC   at the cellular level (especially protein tyrosine kinase-mediated),
CC   modulating oncogenic protein activity, or providing compounds for the
CC   development of drugs with the ability to modulate broad classes, as
CC   well as specific classes, of proteins involved in signal transduction
CC   and also for regulating the processing, trafficking or translation of
CC   RNA. Conjugates of the peptides with detectable labels or imaging agents
CC   are useful for imaging cells, tissues and organs in which Src or
CC   Src-related proteins are expressed.
XX
SQ   Sequence   13 AA;

  Query Match             3.0%;  Score 8;  DB 17;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 1.5;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         52 PQPPPPIT 59
              ||||||||
Db          5 PQPPPPIT 12


RESULT 20
AAW25511
ID   AAW25511 standard; peptide; 31 AA.
XX
AC   AAW25511;
XX
DT   27-MAR-1998  (first entry)
XX
DE   Random peptide recombinant clone R8C.YES3.9.
XX
KW   Cortactin; SH3 domain; binding peptide; Src homology region 3;
KW   tyrosine kinase; immune response; lymphokine; interleukin 1; Nck;
KW   Abl; PLCgamma; p53bp2; Crk; Yes; Grb2.
XX
OS   Synthetic.
OS   Unidentified.
XX
PN   WO9730074-A1.
XX
PD   21-AUG-1997.
XX
PF   14-FEB-1997;   97WO-US02298.
XX
PR   16-FEB-1996;   96US-0602999.
XX
PA   (CYTO-) CYTOGEN CORP.
PA   (UYNC-) UNIV NORTH CAROLINA.
XX
PI   Der CJ,  Fowlkes DM,  Kay BK,  Quilliam LA,  Rider JE;
PI   Sparks AB,  Thorn JM;
XX
DR   WPI; 1997-424972/39.
XX
PT   Src homology region 3 binding peptide - used to activate Src
PT   tyrosine kinase(s) and to stimulate immune response by increasing
PT   production of certain lymphokine(s), e.g. interleukin-1
XX
PS   Disclosure; Fig 5; 131pp; English.
XX
CC   The present sequence represents a random peptide recombinant isolated by
CC   the method of the present invention. SH3 (Src homology region 3) binding
CC   peptides are selected from: (a) peptides which bind the SH3 domain of
CC   Cortactin; (b) peptides which bind the middle SH3 domain of Nck; (c)
CC   peptides which bind the SH3 domain of Abl; (d) peptides which bind the
CC   SH3 domain of Src; (e) peptides which bind the SH3 domain of PLC gamma;
CC   (f) peptides which bind the SH3 domain of p53bp2; (g) peptides which
CC   bind the amino-terminal SH3 domain of Crk; (h) peptides which bind the
CC   SH3 domain of Yes; and (i) peptides which bind the amino-terminal SH3
CC   domain of Grb2. The purified binding peptides can be used in the method
CC   to identify inhibitors of their binding to their respective SH3 domains,
CC   which could be used to modulate the pharmacological activity of proteins
CC   or polypeptide containing the SH3 domain. The peptides can also be used
CC   to activate Src or Src-related protein tyrosine kinases, to stimulate
CC   the immune response by increasing the production of certain lymphokines,
CC   e.g. tumour necrosis factor-alpha and interleukin-1, or to deliver a
CC   conjugated molecule to certain cellular compartments containing Src or
CC   Src related proteins.
XX
SQ   Sequence   31 AA;

  Query Match             3.0%;  Score 8;  DB 18;  Length 31;
  Best Local Similarity   100.0%;  Pred. No. 3.1;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         52 PQPPPPIT 59
              ||||||||
Db         19 PQPPPPIT 26


RESULT 21
```

```
AAW72021
ID   AAW72021 standard; Protein; 273 AA.
XX
AC   AAW72021;
XX
DT   07-DEC-1998  (first entry)
XX
DE   HSV-2 strain SB5 Contig ID 102 ORF#7 protein.
XX
KW   HSV-2 strain SB5; immunological response induction; therapy;
KW   antiviral identification; viral protein inhibitor.
XX
OS   Herpes simplex virus type 2.
XX
PN   WO9820016-A1.
XX
PD   14-MAY-1998.
XX
PF   31-OCT-1997;   97WO-US20016.
XX
PR   09-JUN-1997;   97US-0049018.
PR   04-NOV-1996;   96US-0030279.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Chan JY,  Dabrowski-Amaral CE,  Delvecchio AM,  Dillon SB;
PI   Esser KM,  Leary JJ;
XX
DR   WPI; 1998-286847/25.
DR   N-PSDB; AAV62132.
XX
PT   Herpes simplex virus type-2 sequences - useful in, e.g. prevention
PT   and treatment of infection or inducing immunological response in
PT   mammal
XX
PS   Claim 10; Page 47; 748pp; English.
XX
CC   This sequence represents a Herpes simplex virus type-2 (HSV-2) protein
CC   sequence of the invention. This sequence was isolated from a HSV-2 strain
CC   SB5 (deposited as ATCC VR-2546) DNA fragment designated Contig ID 102.
CC   The proteins can be used for the treatment or prevention of disease, to
CC   induce an immunological response in a mammal or to identify inhibitors,
CC   activators or novel antivirals. Antagonists of the proteins can be used
CC   to inhibit a viral polypeptide. The DNA sequence or a vector containing
CC   it can also be used to induce an immunological response in a mammal.
XX
SQ   Sequence   273 AA;

  Query Match             3.0%;  Score 8;  DB 19;  Length 273;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          9 LAVLAASS 16
              ||||||||
Db        182 LAVLAASS 189


RESULT 22
AAW72230
ID   AAW72230 standard; Protein; 466 AA.
XX
AC   AAW72230;
XX
DT   13-JAN-1999  (first entry)
XX
DE   HSV-2 strain SB5 Contig ID 15 ORF#41c protein.
XX
KW   HSV-2 strain SB5; immunological response induction; therapy;
KW   antiviral identification; viral protein inhibitor.
XX
OS   Herpes simplex virus type 2.
XX
PN   WO9820016-A1.
XX
PD   14-MAY-1998.
XX
PF   31-OCT-1997;   97WO-US20016.
XX
PR   09-JUN-1997;   97US-0049018.
PR   04-NOV-1996;   96US-0030279.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Chan JY,  Dabrowski-Amaral CE,  Delvecchio AM,  Dillon SB;
PI   Esser KM,  Leary JJ;
XX
DR   WPI; 1998-286847/25.
DR   N-PSDB; AAV62176.
XX
PT   Herpes simplex virus type-2 sequences - useful in, e.g. prevention
PT   and treatment of infection or inducing immunological response in
PT   mammal
XX
PS   Claim 10; Page 145; 748pp; English.
XX
CC   This sequence represents a Herpes simplex virus type-2 (HSV-2) protein
CC   sequence of the invention. This sequence was isolated from a HSV-2 strain
CC   SB5 (deposited as ATCC VR-2546) DNA fragment designated Contig ID 15.
CC   The proteins can be used for the treatment or prevention of disease, to
CC   induce an immunological response in a mammal or to identify inhibitors,
CC   activators or novel antivirals. Antagonists of the proteins can be used
CC   to inhibit a viral polypeptide. The DNA sequence or a vector containing
CC   it can also be used to induce an immunological response in a mammal.
XX
SQ   Sequence   466 AA;

  Query Match             3.0%;  Score 8;  DB 19;  Length 466;
  Best Local Similarity   100.0%;  Pred. No. 34;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          9 LAVLAASS 16
              ||||||||
Db        375 LAVLAASS 382


RESULT 23
AAW72229
ID   AAW72229 standard; Protein; 523 AA.
XX
AC   AAW72229;
XX
DT   13-JAN-1999  (first entry)
XX
DE   HSV-2 strain SB5 Contig ID 15 ORF#41b protein.
XX
KW   HSV-2 strain SB5; immunological response induction; therapy;
KW   antiviral identification; viral protein inhibitor.
XX
OS   Herpes simplex virus type 2.
XX
PN   WO9820016-A1.
XX
PD   14-MAY-1998.
XX
PF   31-OCT-1997;   97WO-US20016.
XX
PR   09-JUN-1997;   97US-0049018.
PR   04-NOV-1996;   96US-0030279.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Chan JY,  Dabrowski-Amaral CE,  Delvecchio AM,  Dillon SB;
PI   Esser KM,  Leary JJ;
XX
DR   WPI; 1998-286847/25.
DR   N-PSDB; AAV62176.
```

XX
PT Herpes simplex virus type-2 sequences - useful in, e.g. prevention
PT and treatment of infection or inducing immunological response in
PT mammal
XX
PS Claim 10; Page 144; 748pp; English.
XX
CC This sequence represents a Herpes simplex virus type-2 (HSV-2) protein
CC sequence of the invention. This sequence was isolated from a HSV-2 strain
CC SB5 (deposited as ATCC VR-2546) DNA fragment designated Contig ID 15.
CC The proteins can be used for the treatment or prevention of disease, to
CC induce an immunological response in a mammal or to identify inhibitors,
CC activators or novel antivirals. Antagonists of the proteins can be used
CC to inhibit a viral polypeptide. The DNA sequence or a vector containing
CC it can also be used to induce an immunological response in a mammal.
XX
SQ Sequence 523 AA;

Query Match 3.0%; Score 8; DB 19; Length 523;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 LAVLAASS 16
||||||||
Db 432 LAVLAASS 439

RESULT 24
AAW72228
ID AAW72228 standard; Protein; 610 AA.
XX
AC AAW72228;
XX
DT 13-JAN-1999 (first entry)
XX
DE HSV-2 strain SB5 Contig ID 15 ORF#41a protein.
XX
KW HSV-2 strain SB5; immunological response induction; therapy;
KW antiviral identification; viral protein inhibitor.
XX
OS Herpes simplex virus type 2.
XX
PN WO9820016-A1.
XX
PD 14-MAY-1998.
XX
PF 31-OCT-1997; 97WO-US20016.
XX
PR 09-JUN-1997; 97US-0049018.
PR 04-NOV-1996; 96US-0030279.
XX
PA (SMIK) SMITHKLINE BEECHAM CORP.
XX
PI Chan JY, Dabrowski-Amaral CE, Delvecchio AM, Dillon SB;
PI Esser KM, Leary JJ;
XX
DR WPI; 1998-286847/25.
DR N-PSDB; AAV62176.
XX
PT Herpes simplex virus type-2 sequences - useful in, e.g. prevention
PT and treatment of infection or inducing immunological response in
PT mammal
XX
PS Claim 10; Page 143-144; 748pp; English.
XX
CC This sequence represents a Herpes simplex virus type-2 (HSV-2) protein
CC sequence of the invention. This sequence was isolated from a HSV-2 strain
CC SB5 (deposited as ATCC VR-2546) DNA fragment designated Contig ID 15.
CC The proteins can be used for the treatment or prevention of disease, to
CC induce an immunological response in a mammal or to identify inhibitors,
CC activators or novel antivirals. Antagonists of the proteins can be used
CC to inhibit a viral polypeptide. The DNA sequence or a vector containing
CC it can also be used to induce an immunological response in a mammal.
XX
SQ Sequence 610 AA;

Query Match 3.0%; Score 8; DB 19; Length 610;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 LAVLAASS 16
||||||||
Db 519 LAVLAASS 526

RESULT 25
AAW72097
ID AAW72097 standard; Protein; 649 AA.
XX
AC AAW72097;
XX
DT 18-DEC-1998 (first entry)
XX
DE HSV-2 strain SB5 Contig ID 10 ORF#3 protein.
XX
KW HSV-2 strain SB5; immunological response induction; therapy;
KW antiviral identification; viral protein inhibitor.
XX
OS Herpes simplex virus type 2.
XX
PN WO9820016-A1.
XX
PD 14-MAY-1998.
XX
PF 31-OCT-1997; 97WO-US20016.
XX
PR 09-JUN-1997; 97US-0049018.
PR 04-NOV-1996; 96US-0030279.
XX
PA (SMIK) SMITHKLINE BEECHAM CORP.
XX
PI Chan JY, Dabrowski-Amaral CE, Delvecchio AM, Dillon SB;
PI Esser KM, Leary JJ;
XX
DR WPI; 1998-286847/25.
DR N-PSDB; AAV62154.
XX
PT Herpes simplex virus type-2 sequences - useful in, e.g. prevention
PT and treatment of infection or inducing immunological response in
PT mammal
XX
PS Claim 10; Page 79-80; 748pp; English.
XX
CC This sequence represents a Herpes simplex virus type-2 (HSV-2) protein
CC sequence of the invention. This sequence was isolated from a HSV-2 strain
CC SB5 (deposited as ATCC VR-2546) DNA fragment designated Contig ID 10.
CC The proteins can be used for the treatment or prevention of disease, to
CC induce an immunological response in a mammal or to identify inhibitors,
CC activators or novel antivirals. Antagonists of the proteins can be used
CC to inhibit a viral polypeptide. The DNA sequence or a vector containing
CC it can also be used to induce an immunological response in a mammal.
XX
SQ Sequence 649 AA;

Query Match 3.0%; Score 8; DB 19; Length 649;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 LAVLAASS 16
||||||||
Db 558 LAVLAASS 565

RESULT 26
AAG74210
ID AAG74210 standard; Protein; 68 AA.

XX
AC AAG74210;
XX
DT 03-SEP-2001 (first entry)
XX
DE Human colon cancer antigen protein SEQ ID NO:4974.
XX
KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW colorectal carcinoma.
XX
OS Homo sapiens.
XX
PN WO200122920-A2.
XX
PD 05-APR-2001.
XX
PF 28-SEP-2000; 2000WO-US26524.
XX
PR 29-SEP-1999; 99US-0157137.
PR 03-NOV-1999; 99US-0163280.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Ruben SM, Barash SC, Birse CE, Rosen CA;
XX
DR WPI; 2001-235357/24.
DR N-PSDB; AAH33641.
XX
PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides,
PT useful for preventing, diagnosing and/or treating colorectal cancers -
XX
PS Claim 11; Page 6726; 9803pp; English.
XX
CC AAH32943 to AAH37195 and AAG73514 to AAG77788 represent human colon
CC cancer-associated nucleic acid molecules (N) and proteins (P), where
CC the proteins are collectively known as colon cancer antigens. The colon
CC cancer antigens have cytostatic activity and can be used in gene
CC therapy and vaccine production. N and P may be used in the prevention,
CC diagnosis and treatment of diseases associated with inappropriate P
CC expression. For example, N and P may be used to treat disorders
CC associated with decreased expression by rectifying mutations or deletions
CC in a patient's genome that affect the activity of P by expressing
CC inactive proteins or to supplement the patients own production of P.
CC Additionally, N may be used to produce the colon cancer-associated Ps,
CC by inserting the nucleic acids into a host cell and culturing the cell
CC to express the proteins. N and P can be used in the prevention, diagnosis
CC and treatment of colorectal carcinomas and cancers. AAH37196 to AAH37204
CC and AAB77789 represent sequences used in the exemplification of the
CC present invention.
CC N.B. Pages 666 to 682 and page 7053 of the sequence listing were
CC missing at time of publication, meaning no sequences are present for
CC SEQ ID NO:1027 to 1052, 7921 and 7922.
XX
SQ Sequence 68 AA;

Query Match 2.6%; Score 7; DB 22; Length 68;
Best Local Similarity 100.0%; Pred. No. 62;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 181 NFSFLPS 187
|||||||
Db 11 NFSFLPS 17

RESULT 27
ABB53619
ID ABB53619 standard; Protein; 72 AA.
XX
AC ABB53619;
XX
DT 16-MAY-2002 (first entry)
XX
DE Lactococcus lactis protein ydbC.
XX
KW Biosynthesis; biodegradation; lactic bacterium; yogurt; cheese.
XX
OS Lactococcus lactis IL1403.
XX
PN FR2807446-A1.
XX
PD 12-OCT-2001.
XX
PF 11-APR-2000; 2000FR-0004630.
XX
PR 11-APR-2000; 2000FR-0004630.
XX
PA (INRG) INRA INST NAT RECH AGRONOMIQUE.
XX
PI Bolotine A, Sorokine A, Renault P, Ehrlich SD;
XX
DR WPI; 2002-043418/06.
XX
PT New nucleotide sequence useful in the identification or Lactococcus
PT lactis and related species -
XX
PS Claim 6; SEQ ID No 321; 2504pp; French.
XX
CC The present invention is related to a Lactococcus lactis nucleotide
CC sequence (ABA90521) and related proteins (ABB53300-ABB55621). The
CC nucleic acid sequence is useful in the detection and/or amplification of
CC nucleic acid sequence, particularly to identify Lactococcus lactis or
CC related species. The proteins of the invention are useful for the
CC biosynthesis or biodegradation of a composition of interest. The
CC invention helps research in lactic bacteria, particularly useful in the
CC production of yogurt and cheese.
CC Note: The sequence data for this patent is based on equivalent patent
CC WO200177334 (published 18-OCT-2001) which is available in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 72 AA;

Query Match 2.6%; Score 7; DB 23; Length 72;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 242 LSEEEFG 248
|||||||
Db 57 LSEEEFG 63

RESULT 28
AAM85245
ID AAM85245 standard; Protein; 89 AA.
XX
AC AAM85245;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:12838.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.

PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK58026.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Claim 11; SEQ ID NO 12838; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)

```
CC   amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (I) by expressing inactive proteins or to
CC   supplement the patients own production of (I). Additionally, (I)
CC   polynucleotides may be used to produce the secreted (I), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express the
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention.
XX
SQ   Sequence   89 AA;

  Query Match             2.6%;  Score 7;  DB 22;  Length 89;
  Best Local Similarity   100.0%;  Pred. No. 79;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        100 CRASSTS 106
              |||||||
Db         53 CRASSTS 59


RESULT 29
ABJ01104
ID   ABJ01104 standard; Protein; 104 AA.
XX
AC   ABJ01104;
XX
DT   28-NOV-2002  (first entry)
XX
DE   Ovary cell-specific amino acid sequence 50.
XX
KW   Ovary cell; neoplastic ovary cell; ovary specific nucleic acid;
KW   ovary specific protein; ovarian cancer; breast cancer; vaccine;
KW   gene therapy.
XX
OS   Homo sapiens.
XX
PN   WO200238606-A2.
XX
PD   16-MAY-2002.
XX
PF   07-NOV-2001; 2001WO-US46459.
XX
PR   08-NOV-2000; 2000US-246640P.
XX
PA   (DIAD-) DIADEXUS INC.
XX
PI   Sun Y,  Recipon H,  Salceda S,  Liu C;
XX
DR   WPI; 2002-519297/55.
XX
PT   Polypeptide and polynucleotides present in normal and neoplastic ovary
PT   cells, useful for identifying, monitoring, staging, diagnosing,
PT   preventing and treating ovarian cancer, and non-cancerous disease
PT   states in the ovary -
XX
PS   Claim 11; Page 223; 247pp; English.
XX
CC   The invention comprises amino acid and DNA sequences which are present in
CC   normal and neoplastic ovary cells. The DNA and protein sequences of the
CC   invention are useful for determining the presence of an ovary specific
CC   nucleic acid or an ovary specific protein in a sample. The DNA and
CC   protein sequences of the invention are useful for diagnosing and
CC   monitoring the presence and metastasis of ovarian cancer and breast
CC   cancer. Amino acids ABJ01055 - ABJ01155 represent the ovary cell
CC   specific protein sequences of the invention.
XX
SQ   Sequence   104 AA;

  Query Match             2.6%;  Score 7;  DB 23;  Length 104;
  Best Local Similarity   100.0%;  Pred. No. 91;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          9 LAVLAAS 15
              |||||||
Db         77 LAVLAAS 83


RESULT 30
AAU31945
ID   AAU31945 standard; Protein; 110 AA.
XX
AC   AAU31945;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Novel human secreted protein #2436.
XX
KW   Human; vaccination; gene therapy; nutritional supplement;
KW   stem cell proliferation; haematopoiesis; nerve tissue regeneration;
KW   immune suppression; immune stimulation; anti-inflammatory; leukaemia.
XX
OS   Homo sapiens.
XX
PN   WO200179449-A2.
XX
PD   25-OCT-2001.
XX
PF   16-APR-2001; 2001WO-US08656.
XX
PR   18-APR-2000; 2000US-0552929.
PR   26-JAN-2001; 2001US-0770160.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Drmanac RT;
XX
DR   WPI; 2001-611725/70.
XX
PT   Nucleic acids encoding a range of human polypeptides, useful in genetic
PT   vaccination, testing and therapy -
XX
PS   Claim 20; Page 530; 765pp; English.
XX
CC   The invention relates to novel human secreted polypeptides. The
CC   polypeptides and antibodies to the polypeptides are useful for
CC   determining the presence of or predisposition to a disease associated
CC   with altered levels of polypeptide. The polypeptides are also useful for
CC   identifying agents (agonists and antagonists) that bind to them. Cells
CC   expressing the proteins are useful for identifying a therapeutic agent
CC   for use in treatment of a pathology related to aberrant expression or
CC   physiological interactions of the polypeptide. Vectors comprising
CC   the nucleic acids encoding the polypeptides and cells genetically
CC   engineered to express them are also useful for producing the proteins.
CC   The proteins are useful in genetic vaccination, testing and
CC   therapy, and can be used as nutritional supplements. They may be used to
CC   increase stem cell proliferation; to regulate haematopoiesis; and in
CC   bone, cartilage, tendon  and/or nerve tissue growth or regeneration;
CC   immune suppression and/or stimulation; as anti-inflammatory agents; and
CC   in treatment of leukaemias. AAU29510-AAU33304 represent the amino acid
CC   sequences of novel human secreted proteins of the invention.
XX
SQ   Sequence   110 AA;

  Query Match             2.6%;  Score 7;  DB 22;  Length 110;
  Best Local Similarity   100.0%;  Pred. No. 95;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        179 PANFSFL 185
```

```
Db          46 PANFSFL 52
```

RESULT 31
AAU55856
ID AAU55856 standard; Protein; 117 AA.
XX
AC AAU55856;
XX
DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #16752.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US12865.
XX
PR 21-APR-2000; 2000US-199047P.
PR 02-JUN-2000; 2000US-208841P.
PR 07-JUL-2000; 2000US-216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59572.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris -
XX
PS Example 1; SEQ ID No 17051; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA).
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 117 AA;

```
  Query Match             2.6%;  Score 7;  DB 22;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        149 QASSGSP 155
```

```
Db          32 QASSGSP 38
```

RESULT 32
AAB95436
ID AAB95436 standard; Protein; 117 AA.
XX
AC AAB95436;
XX
DT 26-JUN-2001 (first entry)
XX
DE Human protein sequence SEQ ID NO:17866.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS Homo sapiens.
XX
PN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-0116126.
XX
PR 29-JUL-1999; 99JP-0248036.
PR 27-AUG-1999; 99JP-0300253.
PR 11-JAN-2000; 2000JP-0118776.
PR 02-MAY-2000; 2000JP-0183767.
PR 09-JUN-2000; 2000JP-0241899.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
DR WPI; 2001-318749/34.
XX
PT Primer sets for synthesizing polynucleotides, particularly the 5602
PT full-length cDNAs defined in the specification, and for the detection
PT and/or diagnosis of the abnormality of the proteins encoded by the
PT full-length cDNAs -
XX
PS Claim 8; SEQ ID 17866; 2537pp + CD ROM; English.
XX
CC The present invention describes primer sets for synthesising 5602
CC full-length cDNAs defined in the specification. Where a primer set
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC to the complementary strand of a polynucleotide which comprises one of
CC the 5602 nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and
CC in gene therapy. The primers are useful for synthesising polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to
CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.
XX
SQ Sequence 117 AA;

```
  Query Match             2.6%;  Score 7;  DB 22;  Length 117;
  Best Local Similarity   100.0%;  Pred. No. 1e+02;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy        170 LQQRPCH 176
              |||||||
Db         21 LQQRPCH 27
```

RESULT 33
AAY12386
ID AAY12386 standard; Protein; 125 AA.
XX
AC AAY12386;
XX
DT 17-JUN-1999 (first entry)
XX
DE Human 5' EST secreted protein SEQ ID NO:417.
XX
KW Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS Homo sapiens.
XX
PN WO9906548-A2.
XX
PD 11-FEB-1999.
XX
PF 31-JUL-1998; 98WO-IB01222.
XX
PR 01-AUG-1997; 97US-0905135.
XX
PA (GEST) GENSET.
XX
PI Duclert A, Dumas Milne Edwards J, Lacroix B;
XX
DR WPI; 1999-153778/13.
DR N-PSDB; AAX41219.
XX
PT New nucleic acids encoding human secreted proteins - obtained from
PT cDNA libraries prepared from e.g. liver, ovary, brain, prostate,
PT kidney, lung, umbilical cord, placenta and colon tissue
XX
PS Claim 27; Page 736; 824pp; English.
XX
CC AAX41094 to AAX41347 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins, and encode the proteins given in AAY12261 to
CC AAY12514, respectively. The proteins given represent the signal peptide
CC and an N-terminal fragment of a secreted protein. The nucleic acid
CC sequences can be used for producing secreted human gene products. They
CC can also be used to develop products for diagnosis and therapy. The
CC proteins obtained may have cytokine activity, cell
CC proliferation/differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/ chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptide can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ Sequence 125 AA;

```
  Query Match              2.6%;  Score 7;  DB 20;  Length 125;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         53 QPPPPIT 59
              |||||||
Db         71 QPPPPIT 77
```

RESULT 34
AAG24134
ID AAG24134 standard; Protein; 129 AA.
XX
AC AAG24134;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 27692.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.

PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 2.6%; Score 7; DB 21; Length 129;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 91 SSPDLLT 97
|||||||
Db 41 SSPDLLT 47

RESULT 35
AAG24133
ID AAG24133 standard; Protein; 133 AA.
XX
AC AAG24133;
XX

DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 27691.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.

PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 2.6%; Score 7; DB 21; Length 133;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 91 SSPDLLT 97
|||||||
Db 45 SSPDLLT 51

RESULT 36
ABP01270
ID ABP01270 standard; Protein; 140 AA.
XX
AC ABP01270;
XX
DT 25-JUN-2002 (first entry)
XX
DE Human ORFX protein sequence SEQ ID NO:2522.
XX
KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;
KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;
KW degenerative disorder; osteoarthritis; neurodegenerative disorder;
KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;
KW hypertension; hypothyroidism; cholesterol ester storage disease;
KW immune deficiency; immune disorder; infectious disease;
KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;
KW myasthenia gravis.
XX
OS Homo sapiens.
XX
PN WO200192523-A2.
XX
PD 06-DEC-2001.
XX
PF 29-MAY-2001; 2001WO-US10836.
XX
PR 30-MAY-2000; 2000US-206132P.
PR 29-AUG-2000; 2000US-228716P.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach MD;
XX
DR WPI; 2002-106308/14.
DR N-PSDB; ABN17022.
XX
PT Novel human polypeptides and polynucleotides useful for diagnosing,
PT preventing and treating cardiovascular disease, neurodegenerative,
PT hyperproliferative disorders and autoimmune disorders -
XX
PS Disclosure; SEQ ID 2522; 1037pp; English.
XX
CC The present invention describes substantially purified human proteins
CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1
CC in the specification). ABN15762 to ABN27252 encode the human ORFX
CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for
CC treating or preventing a pathology associated with an ORFX-associated
CC disorder in humans, and in the manufacture of a medicament for treating a
CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide
CC sequences can be used in gene therapy. ORFX sequences can be used in the
CC treatment of cancer, hyperproliferative disorders, cirrhosis of liver,
CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,
CC osteoarthritis, neurodegenerative disorders, disorders related to organ
CC transplantation, cardiovascular diseases, diabetes mellitus, systemic
CC lupus erythematosus, hypertension, hypothyroidism, cholesterol ester
CC storage disease, various immune deficiencies and disorders, infectious
CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid
CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host
CC disease and autoimmune inflammatory eye disease. ORFX proteins are also
CC useful for treating burns, incisions, ulcers, for treating osteoporosis,
CC bone degenerative disorders, or periodontal disease, and for gut
CC protection or regeneration and treatment of lung or liver fibrosis,
CC reperfusion injury in various tissues and conditions resulting from
CC systemic cytokine damage.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 140 AA;

Query Match 2.6%; Score 7; DB 23; Length 140;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 AVLAASS 16
|||||||
Db 38 AVLAASS 44

RESULT 37
AAU59496
ID AAU59496 standard; Protein; 141 AA.
XX
AC AAU59496;
XX

DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #20392.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US12865.
XX
PR 21-APR-2000; 2000US-199047P.
PR 02-JUN-2000; 2000US-208841P.
PR 07-JUL-2000; 2000US-216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59602.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris -
XX
PS Example 1; SEQ ID No 20691; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA).
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 141 AA;

Query Match 2.6%; Score 7; DB 22; Length 141;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 100 CRASSTS 106
|||||||
Db 122 CRASSTS 128

RESULT 38
AAB63549
ID AAB63549 standard; Protein; 141 AA.
XX
AC AAB63549;
XX
DT 26-MAR-2001 (first entry)
XX
DE Human gastric cancer associated antigen protein sequence SEQ ID NO:911.
XX
KW Human; breast cancer; gastric cancer; prostate cancer; diagnosis;
KW cancer associated antigen; cytostatic; cancer vaccine.
XX
OS Homo sapiens.
XX
PN WO200073801-A2.
XX
PD 07-DEC-2000.
XX
PF 26-MAY-2000; 2000WO-US14749.
XX
PR 28-MAY-1999; 99US-0136526.
PR 10-SEP-1999; 99US-0153454.
XX
PA (LUDW-) LUDWIG INST CANCER RES.
XX
PI Obata Y;
XX
DR WPI; 2001-025274/03.
XX
PT Nucleic acids encoding breast, gastric and prostate cancer associated
PT antigen precursors, useful for diagnosing and treating a condition
PT characterized by expression of an abnormal amount of a protein, e.g.
PT cancer -
XX
PS Example 1; Page 610; 799pp; English.
XX
CC AAF22422 to AAF22626, AAF22627 to AAF22773 and AAF22774 to AAF23014
CC represent nucleotide sequences encoding human breast, gastric and
CC prostate cancer associated antigen precursors (CAAP) respectively.
CC AAB63232 to AAB63467, AAB63468 to AAB63721 and AAB63722 to AAB63970
CC represent human breast, gastric and prostate CAAP protein sequence
CC respectively. CAAPs have cytostatic activity and can be used in the
CC production of cancer vaccines. The human CAAP proteins, peptides, nucleic
CC acids or anti-CAAP antibodies are useful for diagnosing and treating a
CC condition characterised by expression of an abnormal amount of a protein,
CC e.g. cancer.
XX
SQ Sequence 141 AA;

Query Match 2.6%; Score 7; DB 22; Length 141;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 12 LAASSFS 18
|||||||
Db 45 LAASSFS 51

RESULT 39
AAU49867
ID AAU49867 standard; Protein; 149 AA.
XX
AC AAU49867;
XX
DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #10763.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.

XX
PF 20-APR-2001; 2001WO-US12865.
XX
PR 21-APR-2000; 2000US-199047P.
PR 02-JUN-2000; 2000US-208841P.
PR 07-JUL-2000; 2000US-216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59545.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris -
XX
PS Claim 6; SEQ ID No 11062; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA).
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 149 AA;

Query Match 2.6%; Score 7; DB 22; Length 149;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 AVLAASS 16
|||||||
Db 8 AVLAASS 14

RESULT 40
AAY35951
ID AAY35951 standard; Protein; 151 AA.
XX
AC AAY35951;
XX
DT 13-SEP-1999 (first entry)
XX
DE Extended human secreted protein sequence, SEQ ID NO. 200.
XX
KW Secreted protein; human; cytokine; cellular proliferation; cell movement;
KW cellular differentiation; immune system regulator; anti-inflammatory;
KW haematopoiesis regulator; tissue growth regulator; tumour inhibitor;
KW reproductive hormone regulator; chemotaxis; chemokinesis; gene therapy;
KW genetic disease.
XX
OS Homo sapiens.
XX
PN WO9931236-A2.
XX
PD 24-JUN-1999.
XX
PF 17-DEC-1998; 98WO-IB02122.
XX
PR 10-AUG-1998; 98US-0096116.
PR 17-DEC-1997; 97US-0069957.
PR 09-FEB-1998; 98US-0074121.
PR 13-APR-1998; 98US-0081563.
XX
PA (GEST) GENSET.
XX
PI Bougueleret L, Duclert A, Dumas Milne Edwards J;
XX
DR WPI; 1999-385906/32.
DR N-PSDB; AAX97635.
XX
PT New isolated human secreted proteins
XX
PS Claim 9; Page 229-230; 516pp; English.
XX
CC This sequence is encoded by an extended human secreted protein coding
CC sequence of the invention. The secreted proteins can be used in treating
CC or controlling a variety of human conditions. The secreted proteins may
CC act as cytokines or may affect cellular proliferation or differentiation
CC or may act as immune system regulators, haematopoiesis regulators, tissue
CC growth regulators, regulators of reproductive hormones or cell movement
CC or have chemotactic/chemokinetic, receptor/ligand, anti-inflammatory or
CC tumour inhibition activity. The DNAs can be used in forensic procedures
CC to identify individuals or in diagnostic procedures to identify
CC individuals having genetic diseases resulting from abnormal expression of
CC the genes corresponding to the extended cDNAs. They are also useful for
CC constructing a high resolution map of the human chromosomes. They can
CC also be used for gene therapy to control or treat genetic diseases.
XX
SQ Sequence 151 AA;

Query Match 2.6%; Score 7; DB 20; Length 151;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 53 QPPPPIT 59
|||||||
Db 71 QPPPPIT 77

RESULT 41
AAY36094
ID AAY36094 standard; Protein; 151 AA.
XX
AC AAY36094;
XX
DT 13-SEP-1999 (first entry)
XX
DE Extended human secreted protein sequence, SEQ ID NO. 479.
XX
KW Secreted protein; human; cytokine; cellular proliferation; cell movement;
KW cellular differentiation; immune system regulator; anti-inflammatory;
KW haematopoiesis regulator; tissue growth regulator; tumour inhibitor;
KW reproductive hormone regulator; chemotaxis; chemokinesis; gene therapy;
KW genetic disease.
XX
OS Homo sapiens.
XX
PN WO9931236-A2.
XX
PD 24-JUN-1999.
XX
PF 17-DEC-1998; 98WO-IB02122.
XX
PR 10-AUG-1998; 98US-0096116.
PR 17-DEC-1997; 97US-0069957.
PR 09-FEB-1998; 98US-0074121.
PR 13-APR-1998; 98US-0081563.

XX
PA (GEST) GENSET.
XX
PI Bougueleret L, Duclert A, Dumas Milne Edwards J;
XX
DR WPI; 1999-385906/32.
DR N-PSDB; AAX97778.
XX
PT New isolated human secreted proteins
XX
PS Claim 9; Page 414; 516pp; English.
XX
CC This sequence is encoded by an extended human secreted protein coding
CC sequence of the invention. The secreted proteins can be used in treating
CC or controlling a variety of human conditions. The secreted proteins may
CC act as cytokines or may affect cellular proliferation or differentiation
CC or may act as immune system regulators, haematopoiesis regulators, tissue
CC growth regulators, regulators of reproductive hormones or cell movement
CC or have chemotactic/chemokinetic, receptor/ligand, anti-inflammatory or
CC tumour inhibition activity. The DNAs can be used in forensic procedures
CC to identify individuals or in diagnostic procedures to identify
CC individuals having genetic diseases resulting from abnormal expression of
CC the genes corresponding to the extended cDNAs. They are also useful for
CC constructing a high resolution map of the human chromosomes. They can
CC also be used for gene therapy to control or treat genetic diseases.
XX
SQ Sequence 151 AA;

Query Match 2.6%; Score 7; DB 20; Length 151;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 53 QPPPPIT 59
|||||||
Db 71 QPPPPIT 77

RESULT 42
ABG19542
ID ABG19542 standard; Protein; 172 AA.
XX
AC ABG19542;
XX
DT 13-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #19533.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS83729.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 49901; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 172 AA;

Query Match 2.6%; Score 7; DB 22; Length 172;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 51 APQPPPP 57
|||||||
Db 97 APQPPPP 103

RESULT 43
AAY76035
ID AAY76035 standard; Protein; 199 AA.
XX
AC AAY76035;
XX
DT 27-MAR-2000 (first entry)
XX
DE Murine skin cell protein, SEQ ID NO:290.
XX
KW Skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;
KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;
KW secreted; transmembrane; inflammation; cancer; neurological disease;
KW angiogenesis; tumour vascularisation; growth disorder;
KW developmental disorder; skin wound; hair follicle disorder;
KW anti-inflammatory; cytostatic; neuroprotective; vulnery.
XX
OS Mus sp.
XX
PN WO9955865-A1.
XX
PD 04-NOV-1999.
XX
PF 29-APR-1999; 99WO-NZ00051.
XX
PR 29-APR-1998; 98US-0069726.
PR 09-NOV-1998; 98US-0188930.
XX
PA (GENE-) GENESIS RES & DEV CORP LTD.
XX
PI Strachan L, Sleeman M, Watson JD, Onrust R, Kumble A, Murison JG;
XX
DR WPI; 2000-072177/06.
DR N-PSDB; AAZ61740.
XX
PT Novel polynucleotides useful for the treatment of various conditions
PT including wounds and cancer -
XX

PS Claim 4; Page 172; 235pp; English.
XX
CC The invention relates to novel nucleic acid sequences derived from rat
CC dermal papilla, human keratinocytes and neonatal foreskin fibroblasts,
CC and mouse embryonic skin, keratinocyte stem cells and transit amplifying
CC cells. Polypeptides of the invention may be used to treat inflammation,
CC cancer and neurological diseases. The proteins may be used to stimulate
CC the growth and motility of keratinocytes, to inhibit the growth of
CC cancer cells, to modulate angiogenesis and tumour vascularisation, to
CC modulate skin inflammation, to modulate epithelial cell growth and to
CC inhibit binding of HIV-1 to leukocytes. The invention may also be used
CC to treat growth and developmental defects, skin wounds and hair follicle
CC disorders. Sequences AAY75942-Y76123 represent polypeptides encoded
CC by cDNA sequences derived from several mouse, rat or human skin cell
CC types. Sequences AAY75942-Y75947, AAY76020-Y76021, AAY76094-Y76104 and
CC AAY76119 are proteins with an N-terminal signal sequence, indicating
CC that they are secreted. Sequences AAY75986-Y75989, AAY76061-Y76071,
CC AAY76106-Y76109 and AAY76121-Y76122 are proteins with one or more
CC putative transmembrane domains.
XX
SQ Sequence 199 AA;

Query Match 2.6%; Score 7; DB 21; Length 199;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 138 RGAGPRV 144
|||||||
Db 38 RGAGPRV 44

RESULT 44
AAB55974
ID AAB55974 standard; Protein; 199 AA.
XX
AC AAB55974;
XX
DT 08-MAR-2001 (first entry)
XX
DE Skin cell protein, SEQ ID NO: 290.
XX
KW Mouse; skin cell; cytostatic; antiinflammatory; anti-HIV;
KW nootropic; neuroprotective; vulnerary; immunomodulatory; vaccine;
KW keratinocyte growth stimulation; cancer; angiogenesis inhibition;
KW inflammation; neurological disease.
XX
OS Mus sp.
XX
PN WO200069884-A2.
XX
PD 23-NOV-2000.
XX
PF 15-MAY-2000; 2000WO-NZ00075.
XX
PR 14-MAY-1999; 99US-0312283.
XX
PA (GENE-) GENESIS RES & DEV CORP LTD.
XX
PI Watson JD, Strachan L, Onrust R, Sleeman M, Kumble KD, Murison JG;
XX
DR WPI; 2001-007495/01.
DR N-PSDB; AAC99673.
XX
PT New isolated polynucleotide used in the identification of genetic
PT disorders and encoding polypeptides used for treating inflammatory
PT disease, cancer and neurological diseases -
XX
PS Claim 4; Page 236; 352pp; English.
XX
CC The present sequence is a polypeptide which is expressed in
CC mammalian skin cells. The polypeptide is useful for stimulating
CC keratinocyte growth and motility, inhibiting the growth of cancer cells,
CC modulating angiogenesis, inhibiting angiogenesis and vascularisation of
CC tumours, modulating skin inflammation, stimulating the growth of
CC epithelial cells, inhibiting the binding of human immunodeficiency virus
CC (HIV)-1 to leukocytes, and treating inflammmatory disease, cancer and
CC neurological diseases. The polynucleotide can be used as a marker, in
CC the identification of genetic disorders, and for the design of
CC oligonucleotides for examining expression patterns.
XX
SQ Sequence 199 AA;

Query Match 2.6%; Score 7; DB 22; Length 199;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 138 RGAGPRV 144
|||||||
Db 38 RGAGPRV 44

RESULT 45
ABB72174
ID ABB72174 standard; Protein; 199 AA.
XX
AC ABB72174;
XX
DT 04-APR-2002 (first entry)
XX
DE Murine protein isolated from skin cells SEQ ID NO: 290.
XX
KW Human; rat; mouse; skin cell; skin wound; cancer; growth defect;
KW developmental defect; inflammatory disease; dermatological; vulnerary;
KW immunomodulator; anti-inflammatory; cytostatic; neuroprotective.
XX
OS Mus sp.
XX
PN WO200190357-A1.
XX
PD 29-NOV-2001.
XX
PF 24-MAY-2001; 2001WO-NZ00099.
XX
PR 24-MAY-2000; 2000US-206650P.
PR 25-JUL-2000; 2000US-221232P.
XX
PA (GENE-) GENESIS RES & DEV CORP LTD.
XX
PI Watson JD, Strachan L, Sleeman M, Onrust R, Murison JG, Kumble KD;
XX
DR WPI; 2002-122020/16.
XX
PT New polynucleotides and polypeptides encoded by the polynucleotides
PT isolated from skin cells, useful for treating skin wounds, cancers,
PT growth and developmental defects, inflammatory diseases, or for
PT modulating immune responses -
XX
PS Example 2; Page 192-193; 466pp; English.
XX
CC The present invention provides the protein and coding sequences of cDNAs
CC isolated from human, murine and rat skin cell libraries. The sequences
CC can be used in the development of therapeutic agents useful in the
CC treatment of skin diseases, including skin wounds, cancer, growth
CC defects, developmental defects and inflammatory diseases. The proteins
CC have important roles in the induction of hair growth, cell proliferation
CC and cell-cell interaction, in maintaining tissue integrity, in wound
CC healing and in modulating immune responses. The present sequence is a
CC polypeptide of the invention.
XX
SQ Sequence 199 AA;

Query Match 2.6%; Score 7; DB 23; Length 199;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 138 RGAGPRV 144

```
                ||||||
Db         38 RGAGPRV 44
```

RESULT 46
AAO16499
ID AAO16499 standard; Protein; 200 AA.
XX
AC AAO16499;
XX
DT 01-MAY-2003 (first entry)
XX
DE Argiope trifasciata aciniform fibronin 1 protein #1.
XX
KW Spider silk; spider silk protein; fabric; suture; medical covering;
KW high-tech clothing; rope; reinforced plastic.
XX
OS Argiope trifasciata.
XX
PN WO200299082-A2.
XX
PD 12-DEC-2002.
XX
PF 06-JUN-2002; 2002WO-US18256.
XX
PR 06-JUN-2001; 2001US-296184P.
XX
PA (UYWY-) UNIV WYOMING.
XX
PI Roth DA, Lewis RV;
XX
DR WPI; 2003-140616/13.
XX
PT Expressing spider silk protein in a higher plant, by contacting a plant
PT cell with silk protein encoding a gene linked to a gene that confers
PT resistance to selection agent, and selecting cells that survive when
PT incubated with the agent -
XX
PS Disclosure; Fig 17; 114pp; English.
XX
CC The invention comprises a method for expressing spider silk in a higher
CC plant (e.g. arabidopsis, tobacco, tubers, sunflower, canola, alfalfa,
CC soybean, maize, sorghum, wheat, cotton, small grains and rice). The
CC method is useful for expressing spider silk in a higher plant. The silk
CC produced is useful in the production of fabrics, sutures, medical
CC coverings, high-tech clothing, rope, reinforced plastics, and other
CC applications in which various combinations of strength and elasticity are
CC required. The present amino acid sequence represents a spider silk-
CC related protein.
XX
SQ Sequence 200 AA;

```
  Query Match              2.6%;  Score 7;  DB 24;  Length 200;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        102 ASSTSGA 108
              |||||||
Db        117 ASSTSGA 123
```

RESULT 47
AAU36248
ID AAU36248 standard; Protein; 202 AA.
XX
AC AAU36248;
XX
DT 14-FEB-2002 (first entry)
XX
DE Pseudomonas aeruginosa cellular proliferation protein #238.
XX
KW Antisense; prokaryotic cellular proliferation protein;
KW antibiotic; antibacterial; drug design.
XX
OS Pseudomonas aeruginosa.
XX
PN WO200170955-A2.
XX
PD 27-SEP-2001.
XX
PF 21-MAR-2001; 2001WO-US09180.
XX
PR 21-MAR-2000; 2000US-191078P.
PR 23-MAY-2000; 2000US-206848P.
PR 26-MAY-2000; 2000US-207727P.
PR 23-OCT-2000; 2000US-242578P.
PR 27-NOV-2000; 2000US-253625P.
PR 22-DEC-2000; 2000US-257931P.
PR 16-FEB-2001; 2001US-269308P.
XX
PA (ELIT-) ELITRA PHARM INC.
XX
PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;
PI Yamamoto RT, Xu HH;
XX
DR WPI; 2001-611495/70.
DR N-PSDB; AAS54107.
XX
PT New polynucleotides for the identification and development of
PT antibiotics, comprise sequences of antisense nucleic acids -
XX
PS Example 3; Seq ID No 11841; 511pp; English.
XX
CC The invention relates to antisense inhibitors of genes essential to
CC prokaryotic cellular proliferation, their use in identifying the
CC genes, their use in the discovery of novel antibiotics, the essential
CC genes themselves and the encoded proteins. The prokaryotes used are
CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella
CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The
CC invention is also useful for the identification of potential new targets
CC for antibiotic development. The antisense nucleic acids can also be used
CC to identify proteins used in proliferation, to express these proteins,
CC and to obtain antibodies capable of binding to the expressed proteins.
CC The proteins can be used to screen compounds in rational drug discovery
CC programmes. The antisense nucleic acid sequence is also useful to screen
CC for homologous nucleic acids which are required for cell proliferation in
CC a wide variety of organisms. The present sequence represents an
CC essential prokaryotic cellular proliferation protein.
CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 202 AA;

```
  Query Match              2.6%;  Score 7;  DB 22;  Length 202;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        109 HVDSARL 115
              |||||||
Db        172 HVDSARL 178
```

RESULT 48
AAU30601
ID AAU30601 standard; Protein; 220 AA.
XX
AC AAU30601;
XX
DT 18-DEC-2001 (first entry)
XX
DE Novel human secreted protein #1092.
XX
KW Human; vaccination; gene therapy; nutritional supplement;
KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;

KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
XX
OS Homo sapiens.
XX
PN WO200179449-A2.
XX
PD 25-OCT-2001.
XX
PF 16-APR-2001; 2001WO-US08656.
XX
PR 18-APR-2000; 2000US-0552929.
PR 26-JAN-2001; 2001US-0770160.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-611725/70.
XX
PT Nucleic acids encoding a range of human polypeptides, useful in genetic
PT vaccination, testing and therapy -
XX
PS Claim 20; Page 316; 765pp; English.
XX
CC The invention relates to novel human secreted polypeptides. The
CC polypeptides and antibodies to the polypeptides are useful for
CC determining the presence of or predisposition to a disease associated
CC with altered levels of polypeptide. The polypeptides are also useful for
CC identifying agents (agonists and antagonists) that bind to them. Cells
CC expressing the proteins are useful for identifying a therapeutic agent
CC for use in treatment of a pathology related to aberrant expression or
CC physiological interactions of the polypeptide. Vectors comprising
CC the nucleic acids encoding the polypeptides and cells genetically
CC engineered to express them are also useful for producing the proteins.
CC The proteins are useful in genetic vaccination, testing and
CC therapy, and can be used as nutritional supplements. They may be used to
CC increase stem cell proliferation; to regulate haematopoiesis; and in
CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
CC immune suppression and/or stimulation; as anti-inflammatory agents; and
CC in treatment of leukaemias. AAU29510-AAU33304 represent the amino acid
CC sequences of novel human secreted proteins of the invention.
XX
SQ Sequence 220 AA;

Query Match 2.6%; Score 7; DB 22; Length 220;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 51 APQPPPP 57
|||||||
Db 147 APQPPPP 153

RESULT 49
AAE07065
ID AAE07065 standard; Protein; 230 AA.
XX
AC AAE07065;
XX
DT 16-OCT-2001 (first entry)
XX
DE Human gene 15 encoded secreted protein HFXDI56, SEQ ID NO:82.
XX
KW Human secreted protein; proliferative disorder; cancer; tumour;
KW foetal abnormality; developmental abnormality; haematopoietic disorder;
KW immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW inflammation; allergy; neurological disorder; Alzheimer's disease;
KW Parkinson's disease; cognitive disorder; schizophrenia; asthma;
KW skin disorder; psoriasis; sepsis; diabetes; atherosclerosis;
KW cardiovascular disorder; angiogenic disorder; kidney disorder;
KW gastrointestinal disorder; pregnancy-related disorder;
KW endocrine disorder; infection; wound healing; vulnerary;
KW cell culture; chemotaxis; food additive; gene therapy;
KW binding partner identification.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..30
FT /label= Signal_peptide
FT Protein 31..230
FT /label= Mature_human_secreted_protein
FT Misc-difference 63
FT /label= Unknown
FT /note= "Encoded by YTT"
FT Misc-difference 66
FT /label= Unknown
FT /note= "Encoded by TYT"
XX
PN WO200154708-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01434.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 18-AUG-2000; 2000US-0226279.
PR 05-DEC-2000; 2000US-0251988.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Komatsoulis GA, Baker KP, Birse CE, Soppet DR, Olsen HS;
PI Moore PA, Wei P, Ebner R, Duan DR, Shi Y, Choi GH, Fiscella M;
PI Ni J, Ruben SM, Barash SC;
XX
DR WPI; 2001-488743/53.
DR N-PSDB; AAD13359.
XX
PT New isolated nucleic acids and polypeptides, useful for diagnosing,
PT treating and/or preventing human diseases and disorders -
XX
PS Claim 11; Page 502; 558pp; English.
XX
CC AAD13345-AAD13401 represent cDNAs corresponding to 22 human secreted
CC protein genes, and AAE07051-AAE07105 represent the proteins they encode.
CC AAE07106-AAE07129 represent human secreted protein fragments or variants.
CC The genes and their secreted proteins are useful for preventing,
CC treating or ameliorating medical conditions, e.g., by protein or gene
CC therapy. Pathological conditions can be diagnosed by determining the
CC amount of the new protein in a sample or by determining the presence of
CC mutations in the new genes. Specific uses are described for each of the
CC 22 genes, based on the tissues in which they are most highly expressed,
CC and include developing products for the diagnosis or treatment of
CC proliferative disorders, cancer, tumours, foetal and developmental
CC abnormalities, haematopoietic disorders, diseases of the immune system,
CC AIDS, autoimmune diseases (e.g., rheumatoid arthritis), inflammation,
CC allergies, neurological disorders (e.g., Alzheimer's disease,
CC Parkinson's disease), cognitive disorders, schizophrenia, asthma,
CC skin disorders (e.g., psoriasis), sepsis, diabetes, atherosclerosis,
CC cardiovascular disorders, angiogenic disorders, kidney disorders,
CC gastrointestinal disorders, pregnancy-related disorders, endocrine
CC disorders, and infections. The proteins can also be used to aid wound
CC healing and epithelial cell proliferation, to prevent skin aging due to
CC sunburn, to maintain organs before transplantation, for supporting cell
CC culture of primary tissues, to regenerate tissues, to identify their
CC cognate ligands or binding partners, and in chemotaxis, and can be used
CC as a food additive or preservative to modify storage properties.
CC Antibodies specific for a protein of the invention can be used in
CC alleviating symptoms associated with the disorders mentioned above, and
CC in diagnostic immunoassays e.g., radioimmunoassay or enzyme linked
CC immunosorbent assay (ELISA). The present sequence represents a human
CC secreted protein of the invention.
XX
SQ Sequence 230 AA;

Query Match 2.6%; Score 7; DB 22; Length 230;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        174 PCHRQPA 180
              |||||||
Db         18 PCHRQPA 24
```

RESULT 50
ABG65063
ID ABG65063 standard; Protein; 230 AA.
XX
AC ABG65063;
XX
DT 27-AUG-2002 (first entry)
XX
DE Human albumin fusion protein #1738.
XX
KW Albumin fusion protein; therapeutic protein X; human albumin; HA;
KW human serum albumin; HSA; cancer; reproductive disorder;
KW digestive disorder; immune disorder; endocrine disorder;
KW haematopoietic disorder; neural disorder; connective disorder;
KW cytostatic; antiinfertility; antiinflammatory; antiulcer;
KW immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;
KW neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;
KW osteopathic; antiarthritic.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200177137-A1.
XX
PD 18-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US11988.
XX
PR 12-APR-2000; 2000US-229358P.
PR 25-APR-2000; 2000US-199384P.
PR 21-DEC-2000; 2000US-256931P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Haseltine WA;
XX
DR WPI; 2002-010886/01.
XX
PT New fusion protein for treating disease e.g. diabetes comprises an
PT albumin fused to a therapeutic protein -
XX
PS Claim 1; Page 1720-1721; 2102pp; English.
XX
CC The present invention relates to albumin fusion proteins comprising a
CC therapeutic protein X and human albumin (HA, also known as human serum
CC albumin, HSA). The proteins are useful for treating a disease or
CC disorder that may be modulated by therapeutic protein X. The albumin
CC extends the shelf-life of protein X, and may increase its biological
CC in vitro/in vivo activity. The protein is useful for treating and
CC diagnosing disorders such as cancer, reproductive disorders, digestive
CC disorders (e.g. Crohn's disease, ulcerative colitis), immune disorders
CC (e.g. acquired immunodeficiency syndrome, AIDS), endocrine disorders
CC (e.g. diabetes), haematopoietic disorders, neural disorders
CC (e.g. Alzheimer's, Parkinson's, Creutzfeldt-Jacob disease,
CC encephalomyelitis, meningitis, schizophrenia), and connective disorders
CC (e.g. osteoporosis, arthritis). ABG63326-ABG65518 represent albumin
CC fusion proteins of the invention.
XX
SQ Sequence 230 AA;

Query Match 2.6%; Score 7; DB 23; Length 230;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        174 PCHRQPA 180
              |||||||
Db         18 PCHRQPA 24
```

Search completed: February 5, 2004, 16:36:07
Job time : 60 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 5, 2004, 16:35:19 ; Search time 21 Seconds
(without alignments)
533.923 Million cell updates/sec

Title: US-09-990-726-223
Perfect score: 265
Sequence: 1 MGLPGLFCLAVLAASSFSKA.....EFGGFRIGNGEVRGRKAAAM 265

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 328717 seqs, 42310858 residues

Word size : 6

Total number of hits satisfying chosen parameters: 896

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 150 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	265	100.0	265	4	US-09-996-243-223	Sequence 223, App
2	8	3.0	13	3	US-08-602-999A-94	Sequence 94, Appl
3	8	3.0	13	4	US-08-278-865-94	Sequence 94, Appl
4	8	3.0	13	4	US-09-500-124-94	Sequence 94, Appl
5	8	3.0	31	3	US-08-602-999A-61	Sequence 61, Appl
6	8	3.0	31	4	US-08-278-865-61	Sequence 61, Appl
7	8	3.0	31	4	US-09-500-124-61	Sequence 61, Appl
8	7	2.6	199	3	US-09-188-930-290	Sequence 290, App
9	7	2.6	199	4	US-09-312-283C-290	Sequence 290, App
10	7	2.6	257	4	US-09-252-991A-32918	Sequence 32918, A
11	7	2.6	306	4	US-09-252-991A-30319	Sequence 30319, A
12	7	2.6	313	4	US-09-252-991A-20727	Sequence 20727, A
13	7	2.6	341	4	US-09-252-991A-21757	Sequence 21757, A
14	7	2.6	346	4	US-08-894-139-2	Sequence 2, Appli
15	7	2.6	362	4	US-09-252-991A-18068	Sequence 18068, A
16	7	2.6	367	4	US-09-252-991A-17216	Sequence 17216, A
17	7	2.6	371	4	US-09-252-991A-30926	Sequence 30926, A
18	7	2.6	480	1	US-07-882-292-2	Sequence 2, Appli
19	7	2.6	480	2	US-08-331-644-2	Sequence 2, Appli
20	7	2.6	480	5	PCT-US93-04102-2	Sequence 2, Appli
21	7	2.6	635	4	US-09-252-991A-18485	Sequence 18485, A
22	7	2.6	673	4	US-09-252-991A-28287	Sequence 28287, A
23	7	2.6	903	4	US-09-228-986-78	Sequence 78, Appl
24	6	2.3	8	1	US-08-209-261B-10	Sequence 10, Appl
25	6	2.3	8	2	US-08-769-745-22	Sequence 22, Appl
26	6	2.3	15	3	US-08-602-999A-382	Sequence 382, App
27	6	2.3	15	3	US-08-602-999A-415	Sequence 415, App
28	6	2.3	15	4	US-09-500-124-382	Sequence 382, App
29	6	2.3	15	4	US-09-500-124-415	Sequence 415, App
30	6	2.3	16	6	5196511-24	Patent No. 5196511
31	6	2.3	23	1	US-08-231-730A-18	Sequence 18, Appl
32	6	2.3	23	1	US-08-231-730A-24	Sequence 24, Appl
33	6	2.3	23	1	US-08-427-001C-18	Sequence 18, Appl
34	6	2.3	23	1	US-08-427-001C-24	Sequence 24, Appl
35	6	2.3	23	1	US-08-457-798-18	Sequence 18, Appl
36	6	2.3	23	1	US-08-457-798-24	Sequence 24, Appl
37	6	2.3	23	1	US-08-457-171-18	Sequence 18, Appl
38	6	2.3	23	1	US-08-457-171-24	Sequence 24, Appl
39	6	2.3	23	2	US-08-505-486-18	Sequence 18, Appl
40	6	2.3	23	2	US-08-505-486-24	Sequence 24, Appl
41	6	2.3	23	3	US-08-689-489C-18	Sequence 18, Appl
42	6	2.3	23	3	US-08-689-489C-24	Sequence 24, Appl
43	6	2.3	23	3	US-08-801-028-18	Sequence 18, Appl
44	6	2.3	23	3	US-08-801-028-24	Sequence 24, Appl
45	6	2.3	23	3	US-09-340-154-18	Sequence 18, Appl
46	6	2.3	23	3	US-09-340-154-24	Sequence 24, Appl
47	6	2.3	23	3	US-09-232-802A-18	Sequence 18, Appl
48	6	2.3	23	3	US-09-232-802A-24	Sequence 24, Appl
49	6	2.3	23	4	US-09-482-611B-18	Sequence 18, Appl
50	6	2.3	23	4	US-09-482-611B-24	Sequence 24, Appl
51	6	2.3	23	4	US-09-019-922A-18	Sequence 18, Appl
52	6	2.3	23	4	US-09-019-922A-24	Sequence 24, Appl
53	6	2.3	23	5	PCT-US94-06176-18	Sequence 18, Appl
54	6	2.3	23	5	PCT-US94-06176-24	Sequence 24, Appl
55	6	2.3	23	5	PCT-US94-12550-18	Sequence 18, Appl
56	6	2.3	23	5	PCT-US94-12550-24	Sequence 24, Appl
57	6	2.3	23	5	PCT-US95-04335-18	Sequence 18, Appl
58	6	2.3	23	5	PCT-US95-04335-24	Sequence 24, Appl
59	6	2.3	23	5	PCT-US95-04718-18	Sequence 18, Appl
60	6	2.3	23	5	PCT-US95-04718-24	Sequence 24, Appl
61	6	2.3	23	5	PCT-US95-09338-18	Sequence 18, Appl
62	6	2.3	23	5	PCT-US95-09338-24	Sequence 24, Appl
63	6	2.3	23	5	PCT-US95-09339-18	Sequence 18, Appl
64	6	2.3	23	5	PCT-US95-09339-24	Sequence 24, Appl
65	6	2.3	25	1	US-08-427-001C-39	Sequence 39, Appl
66	6	2.3	25	2	US-08-505-486-39	Sequence 39, Appl
67	6	2.3	25	3	US-08-801-028-39	Sequence 39, Appl
68	6	2.3	25	3	US-09-340-154-39	Sequence 39, Appl
69	6	2.3	25	4	US-09-344-587-4	Sequence 4, Appli
70	6	2.3	25	4	US-09-482-611B-39	Sequence 39, Appl
71	6	2.3	25	4	US-09-019-922A-39	Sequence 39, Appl
72	6	2.3	25	5	PCT-US94-12550-39	Sequence 39, Appl
73	6	2.3	25	5	PCT-US95-09338-39	Sequence 39, Appl
74	6	2.3	25	5	PCT-US95-09339-39	Sequence 39, Appl
75	6	2.3	26	1	US-07-776-272-25	Sequence 25, Appl
76	6	2.3	27	1	US-08-231-730A-15	Sequence 15, Appl
77	6	2.3	27	1	US-08-231-730A-21	Sequence 21, Appl
78	6	2.3	27	1	US-08-231-730A-27	Sequence 27, Appl
79	6	2.3	27	1	US-08-427-001C-15	Sequence 15, Appl
80	6	2.3	27	1	US-08-427-001C-21	Sequence 21, Appl
81	6	2.3	27	1	US-08-427-001C-27	Sequence 27, Appl
82	6	2.3	27	1	US-08-427-001C-41	Sequence 41, Appl
83	6	2.3	27	1	US-08-427-001C-43	Sequence 43, Appl
84	6	2.3	27	1	US-08-457-798-15	Sequence 15, Appl
85	6	2.3	27	1	US-08-457-798-21	Sequence 21, Appl
86	6	2.3	27	1	US-08-457-798-27	Sequence 27, Appl
87	6	2.3	27	1	US-08-519-180-6	Sequence 6, Appli
88	6	2.3	27	1	US-08-457-171-15	Sequence 15, Appl
89	6	2.3	27	1	US-08-457-171-21	Sequence 21, Appl
90	6	2.3	27	1	US-08-457-171-27	Sequence 27, Appl
91	6	2.3	27	2	US-08-505-486-15	Sequence 15, Appl
92	6	2.3	27	2	US-08-505-486-21	Sequence 21, Appl
93	6	2.3	27	2	US-08-505-486-27	Sequence 27, Appl
94	6	2.3	27	2	US-08-505-486-41	Sequence 41, Appl
95	6	2.3	27	2	US-08-505-486-43	Sequence 43, Appl
96	6	2.3	27	2	US-08-818-253-36	Sequence 36, Appl
97	6	2.3	27	3	US-08-689-489C-15	Sequence 15, Appl
98	6	2.3	27	3	US-08-689-489C-21	Sequence 21, Appl
99	6	2.3	27	3	US-08-689-489C-27	Sequence 27, Appl
100	6	2.3	27	3	US-08-801-028-15	Sequence 15, Appl

101	6	2.3	27	3	US-08-801-028-21	Sequence 21, Appl
102	6	2.3	27	3	US-08-801-028-27	Sequence 27, Appl
103	6	2.3	27	3	US-08-801-028-41	Sequence 41, Appl
104	6	2.3	27	3	US-08-801-028-43	Sequence 43, Appl
105	6	2.3	27	3	US-09-340-154-15	Sequence 15, Appl
106	6	2.3	27	3	US-09-340-154-21	Sequence 21, Appl
107	6	2.3	27	3	US-09-340-154-27	Sequence 27, Appl
108	6	2.3	27	3	US-09-340-154-41	Sequence 41, Appl
109	6	2.3	27	3	US-09-340-154-43	Sequence 43, Appl
110	6	2.3	27	3	US-09-232-802A-15	Sequence 15, Appl
111	6	2.3	27	3	US-09-232-802A-21	Sequence 21, Appl
112	6	2.3	27	3	US-09-232-802A-27	Sequence 27, Appl
113	6	2.3	27	3	US-08-818-252-36	Sequence 36, Appl
114	6	2.3	27	4	US-09-260-846-18	Sequence 18, Appl
115	6	2.3	27	4	US-08-842-322-30	Sequence 30, Appl
116	6	2.3	27	4	US-09-482-611B-15	Sequence 15, Appl
117	6	2.3	27	4	US-09-482-611B-21	Sequence 21, Appl
118	6	2.3	27	4	US-09-482-611B-27	Sequence 27, Appl
119	6	2.3	27	4	US-09-482-611B-41	Sequence 41, Appl
120	6	2.3	27	4	US-09-482-611B-43	Sequence 43, Appl
121	6	2.3	27	4	US-09-316-919-52	Sequence 52, Appl
122	6	2.3	27	4	US-09-019-922A-15	Sequence 15, Appl
123	6	2.3	27	4	US-09-019-922A-21	Sequence 21, Appl
124	6	2.3	27	4	US-09-019-922A-27	Sequence 27, Appl
125	6	2.3	27	4	US-09-019-922A-41	Sequence 41, Appl
126	6	2.3	27	4	US-09-019-922A-43	Sequence 43, Appl
127	6	2.3	27	5	PCT-US94-06176-15	Sequence 15, Appl
128	6	2.3	27	5	PCT-US94-06176-21	Sequence 21, Appl
129	6	2.3	27	5	PCT-US94-06176-27	Sequence 27, Appl
130	6	2.3	27	5	PCT-US94-12550-15	Sequence 15, Appl
131	6	2.3	27	5	PCT-US94-12550-21	Sequence 21, Appl
132	6	2.3	27	5	PCT-US94-12550-27	Sequence 27, Appl
133	6	2.3	27	5	PCT-US94-12550-41	Sequence 41, Appl
134	6	2.3	27	5	PCT-US94-12550-43	Sequence 43, Appl
135	6	2.3	27	5	PCT-US95-04335-15	Sequence 15, Appl
136	6	2.3	27	5	PCT-US95-04335-21	Sequence 21, Appl
137	6	2.3	27	5	PCT-US95-04335-27	Sequence 27, Appl
138	6	2.3	27	5	PCT-US95-04718-15	Sequence 15, Appl
139	6	2.3	27	5	PCT-US95-04718-21	Sequence 21, Appl
140	6	2.3	27	5	PCT-US95-04718-27	Sequence 27, Appl
141	6	2.3	27	5	PCT-US95-09338-15	Sequence 15, Appl
142	6	2.3	27	5	PCT-US95-09338-21	Sequence 21, Appl
143	6	2.3	27	5	PCT-US95-09338-27	Sequence 27, Appl
144	6	2.3	27	5	PCT-US95-09338-41	Sequence 41, Appl
145	6	2.3	27	5	PCT-US95-09338-43	Sequence 43, Appl
146	6	2.3	27	5	PCT-US95-09339-15	Sequence 15, Appl
147	6	2.3	27	5	PCT-US95-09339-21	Sequence 21, Appl
148	6	2.3	27	5	PCT-US95-09339-27	Sequence 27, Appl
149	6	2.3	27	5	PCT-US95-09339-41	Sequence 41, Appl
150	6	2.3	27	5	PCT-US95-09339-43	Sequence 43, Appl

ALIGNMENTS

RESULT 1
US-09-996-243-223
; Sequence 223, Application US/09996243
; Patent No. 6478825
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi,Avi J.
; APPLICANT: Baker,Kevin P.
; APPLICANT: Botstein,David
; APPLICANT: Desnoyers,Luc
; APPLICANT: Eaton,Dan L.
; APPLICANT: Ferrara,Napoleone
; APPLICANT: Fong,Sherman
; APPLICANT: Gerber,Hanspeter
; APPLICANT: Gerritsen,Mary E.
; APPLICANT: Goddard,Audrey
; APPLICANT: Godowski,Paul J.
; APPLICANT: Grimaldi,J.Christopher
; APPLICANT: Gurney,Austin L.
; APPLICANT: Kljavin,Ivar J.
; APPLICANT: Napier,Mary A.
; APPLICANT: Pan,James
; APPLICANT: Paoni,Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2730P1C13
; CURRENT APPLICATION NUMBER: US/09/996,243
; CURRENT FILING DATE: 2001-11-14
; PRIOR APPLICATION NUMBER: 60/049787
; PRIOR FILING DATE: 1997-06-16
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/065186
; PRIOR FILING DATE: 1997-11-12
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066770
; PRIOR FILING DATE: 1997-11-24
; PRIOR APPLICATION NUMBER: 60/075945
; PRIOR FILING DATE: 1998-02-25
; PRIOR APPLICATION NUMBER: 60/078910
; PRIOR FILING DATE: 1998-03-20
; PRIOR APPLICATION NUMBER: 60/083322
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/087106
; PRIOR FILING DATE: 1998-05-28
; PRIOR APPLICATION NUMBER: 60/087607
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087609
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087759
; PRIOR FILING DATE: 1998-06-02
; PRIOR APPLICATION NUMBER: 60/087827
; PRIOR FILING DATE: 1998-06-03
; PRIOR APPLICATION NUMBER: 60/088021
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088025
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738

; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090535
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 100.0%; Score 265; DB 4; Length 265;
Best Local Similarity 100.0%; Pred. No. 2.6e-255;
Matches 265; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGLPGLFCLAVLAASSFSKAREEEITPVVSIAYKVLEVFPKGRWVLITCCAPQPPPPITY 60

Qy         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 SLCGTKNIKVAKKVVKTHEPASFNLNVTLKSSPDLLTYFCRASSTSGAHVDSARLQMHWE 120

Qy        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 LWSKPVSELRANFTLQDRGAGPRVEMICQASSGSPPITNSLIGKDGQVHLQQRPCHRQPA 180

Qy        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 NFSFLPSQTSDWFWCQAANNANVQHSALTVVPPGGDQKMEDWQGPLESPILALPLYRSTR 240

Qy        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
              |||||||||||||||||||||||||
Db        241 RLSEEEFGGFRIGNGEVRGRKAAAM 265
```

RESULT 2
US-08-602-999A-94
; Sequence 94, Application US/08602999A
; Patent No. 6184205
; GENERAL INFORMATION:
; APPLICANT: SPARKS, Andrew B.
; APPLICANT: KAY, Brian K.
; APPLICANT: THORN, Judith M.
; APPLICANT: QUILLIAM, Lawrence A.

```
;    APPLICANT:  DER, Channing J.
;    APPLICANT:  FOWLKES, Dana M.
;    APPLICANT:  RIDER, James E.
;    TITLE OF INVENTION:  SH3 BINDING PEPTIDES AND METHODS OF
;    TITLE OF INVENTION:  ISOLATING AND USING SAME
;    NUMBER OF SEQUENCES:  467
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/602,999A
;      FILING DATE:  16-FEB-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  1101-202
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  94:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  peptide
US-08-602-999A-94

  Query Match             3.0%;  Score 8;  DB 3;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 0.38;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         52 PQPPPPIT 59
              ||||||||
Db          5 PQPPPPIT 12


RESULT 3
US-08-278-865-94
; Sequence 94, Application US/08278865
; Patent No. 6303574
;  GENERAL INFORMATION:
;    APPLICANT:  KAY, BRIAN K.
;    APPLICANT:  SPARKS, ANDREW B.
;    APPLICANT:  THORN, JUDITH M.
;    APPLICANT:  QUILLIAM, LAWRENCE A.
;    APPLICANT:  DER, CHANNING J.
;    TITLE OF INVENTION:  Src SH3 BINDING PEPTIDES AND METHODS OF
;    TITLE OF INVENTION:  ISOLATING AND USING SAME
;    NUMBER OF SEQUENCES:  106
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT,
;      ADDRESSEE:  P.C.
;      STREET:  1755 S. Jefferson Davis Highway, Suite 400
;      CITY:  Arlington
;      STATE:  Virginia
;      COUNTRY:  U.S.A.
;      ZIP:  22202
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/278,865
;      FILING DATE:
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Villacorta, Gilberto M.
;      REGISTRATION NUMBER:  34,038
;      REFERENCE/DOCKET NUMBER:  4980-007-0
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (703) 413-3000
;      TELEFAX:  (703) 413-2220
;      TELEX:  248855 OPAT UR
;  INFORMATION FOR SEQ ID NO:  94:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  13 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  peptide
US-08-278-865-94

  Query Match             3.0%;  Score 8;  DB 4;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 0.38;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         52 PQPPPPIT 59
              ||||||||
Db          5 PQPPPPIT 12


RESULT 4
US-09-500-124-94
; Sequence 94, Application US/09500124
; Patent No. 6432920
;  GENERAL INFORMATION:
;    APPLICANT:  SPARKS, Andrew B.
;    APPLICANT:  KAY, Brian K.
;    APPLICANT:  THORN, Judith M.
;    APPLICANT:  QUILLIAM, Lawrence A.
;    APPLICANT:  DER, Channing J.
;    APPLICANT:  FOWLKES, Dana M.
;    APPLICANT:  RIDER, James E.
;    TITLE OF INVENTION:  SH3 BINDING PEPTIDES AND METHODS OF
;    TITLE OF INVENTION:  ISOLATING AND USING SAME
;    NUMBER OF SEQUENCES:  467
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/500,124
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/602,999
;      FILING DATE:  16-FEB-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  1101-202
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  94:
;    SEQUENCE CHARACTERISTICS:
```

; LENGTH: 13 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-09-500-124-94

Query Match 3.0%; Score 8; DB 4; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.38;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 52 PQPPPPIT 59
||||||||
Db 5 PQPPPPIT 12

RESULT 5
US-08-602-999A-61
; Sequence 61, Application US/08602999A
; Patent No. 6184205
; GENERAL INFORMATION:
; APPLICANT: SPARKS, Andrew B.
; APPLICANT: KAY, Brian K.
; APPLICANT: THORN, Judith M.
; APPLICANT: QUILLIAM, Lawrence A.
; APPLICANT: DER, Channing J.
; APPLICANT: FOWLKES, Dana M.
; APPLICANT: RIDER, James E.
; TITLE OF INVENTION: SH3 BINDING PEPTIDES AND METHODS OF
; TITLE OF INVENTION: ISOLATING AND USING SAME
; NUMBER OF SEQUENCES: 467
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/602,999A
; FILING DATE: 16-FEB-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Misrock, S. Leslie
; REGISTRATION NUMBER: 18,872
; REFERENCE/DOCKET NUMBER: 1101-202
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 869-9741/8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-602-999A-61

Query Match 3.0%; Score 8; DB 3; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.83;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 52 PQPPPPIT 59
||||||||
Db 19 PQPPPPIT 26

RESULT 6
US-08-278-865-61
; Sequence 61, Application US/08278865
; Patent No. 6303574
; GENERAL INFORMATION:
; APPLICANT: KAY, BRIAN K.
; APPLICANT: SPARKS, ANDREW B.
; APPLICANT: THORN, JUDITH M.
; APPLICANT: QUILLIAM, LAWRENCE A.
; APPLICANT: DER, CHANNING J.
; TITLE OF INVENTION: Src SH3 BINDING PEPTIDES AND METHODS OF
; TITLE OF INVENTION: ISOLATING AND USING SAME
; NUMBER OF SEQUENCES: 106
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. Jefferson Davis Highway, Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/278,865
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Villacorta, Gilberto M.
; REGISTRATION NUMBER: 34,038
; REFERENCE/DOCKET NUMBER: 4980-007-0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 413-3000
; TELEFAX: (703) 413-2220
; TELEX: 248855 OPAT UR
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-278-865-61

Query Match 3.0%; Score 8; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.83;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 52 PQPPPPIT 59
||||||||
Db 19 PQPPPPIT 26

RESULT 7
US-09-500-124-61
; Sequence 61, Application US/09500124
; Patent No. 6432920
; GENERAL INFORMATION:
; APPLICANT: SPARKS, Andrew B.
; APPLICANT: KAY, Brian K.
; APPLICANT: THORN, Judith M.
; APPLICANT: QUILLIAM, Lawrence A.
; APPLICANT: DER, Channing J.
; APPLICANT: FOWLKES, Dana M.
; APPLICANT: RIDER, James E.
; TITLE OF INVENTION: SH3 BINDING PEPTIDES AND METHODS OF
; TITLE OF INVENTION: ISOLATING AND USING SAME
; NUMBER OF SEQUENCES: 467
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York

; COUNTRY: U.S.A.
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/500,124
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/602,999
; FILING DATE: 16-FEB-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Misrock, S. Leslie
; REGISTRATION NUMBER: 18,872
; REFERENCE/DOCKET NUMBER: 1101-202
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 869-9741/8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 61:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-09-500-124-61

Query Match 3.0%; Score 8; DB 4; Length 31;
Best Local Similarity 100.0%; Pred. No. 0.83;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 52 PQPPPPIT 59
||||||||
Db 19 PQPPPPIT 26

RESULT 8
US-09-188-930-290
; Sequence 290, Application US/09188930A
; Patent No. 6150502
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Strachan, Lorna
; APPLICANT: Sleeman, Matthew
; APPLICANT: Onrust, Rene
; APPLICANT: Murison, James Greg
; TITLE OF INVENTION: Compositions Isolated From Skin Cells
; TITLE OF INVENTION: and Methods For Their Use
; FILE REFERENCE: 11000.1011c1
; CURRENT APPLICATION NUMBER: US/09/188,930A
; CURRENT FILING DATE: 1998-11-09
; NUMBER OF SEQ ID NOS: 348
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 290
; LENGTH: 199
; TYPE: PRT
; ORGANISM: Mouse
US-09-188-930-290

Query Match 2.6%; Score 7; DB 3; Length 199;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 138 RGAGPRV 144
|||||||
Db 38 RGAGPRV 44

RESULT 9
US-09-312-283C-290
; Sequence 290, Application US/09312283C
; Patent No. 6573095
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Strachan, Lorna
; APPLICANT: Sleeman, Matthew
; APPLICANT: Onrust, Rene
; APPLICANT: Murison, James G.
; APPLICANT: Kumble, Krishanand D.
; TITLE OF INVENTION: Compositions Isolated from Skin Cells
; TITLE OF INVENTION: and Methods for Their Use
; FILE REFERENCE: 11000.1011c2
; CURRENT APPLICATION NUMBER: US/09/312,283C
; CURRENT FILING DATE: 1999-05-14
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 290
; LENGTH: 199
; TYPE: PRT
; ORGANISM: Mouse
US-09-312-283C-290

Query Match 2.6%; Score 7; DB 4; Length 199;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 138 RGAGPRV 144
|||||||
Db 38 RGAGPRV 44

RESULT 10
US-09-252-991A-32918
; Sequence 32918, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 32918
; LENGTH: 257
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-32918

Query Match 2.6%; Score 7; DB 4; Length 257;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 138 RGAGPRV 144
|||||||
Db 174 RGAGPRV 180

RESULT 11
US-09-252-991A-30319
; Sequence 30319, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18

; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 30319
; LENGTH: 306
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-30319

Query Match 2.6%; Score 7; DB 4; Length 306;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 237 RSTRRLS 243
|||||||
Db 281 RSTRRLS 287

RESULT 12
US-09-252-991A-20727
; Sequence 20727, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 20727
; LENGTH: 313
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-20727

Query Match 2.6%; Score 7; DB 4; Length 313;
Best Local Similarity 100.0%; Pred. No. 66;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 235 LYRSTRR 241
|||||||
Db 60 LYRSTRR 66

RESULT 13
US-09-252-991A-21757
; Sequence 21757, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 21757
; LENGTH: 341
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-21757

Query Match 2.6%; Score 7; DB 4; Length 341;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 237 RSTRRLS 243
|||||||
Db 86 RSTRRLS 92

RESULT 14
US-08-894-139-2
; Sequence 2, Application US/08894139
; Patent No. 6448376
; GENERAL INFORMATION:
; APPLICANT: LA THANGUE, NICHOLAS B.
; APPLICANT: BERNARDS, RENE
; APPLICANT: HIJMANS, ELEANORE M.
; TITLE OF INVENTION: TRANSCRIPTION FACTOR E2F-5
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/894,139
; FILING DATE: 13-AUG-1997
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 620-22
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 346 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-894-139-2

Query Match 2.6%; Score 7; DB 4; Length 346;
Best Local Similarity 100.0%; Pred. No. 73;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 51 APQPPPP 57
|||||||
Db 32 APQPPPP 38

RESULT 15
US-09-252-991A-18068
; Sequence 18068, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190

```
;  PRIOR FILING DATE:  1998-07-27
;  NUMBER OF SEQ ID NOS:  33142
; SEQ ID NO 18068
;   LENGTH: 362
;   TYPE: PRT
;   ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-18068

  Query Match             2.6%;  Score 7;  DB 4;  Length 362;
  Best Local Similarity   100.0%;  Pred. No. 76;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          9 LAVLAAS 15
              |||||||
Db        269 LAVLAAS 275


RESULT 16
US-09-252-991A-17216
; Sequence 17216, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
;  APPLICANT:  Marc J. Rubenfield et al.
;  TITLE OF INVENTION:  NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
;  TITLE OF INVENTION:  AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE:  107196.136
;  CURRENT APPLICATION NUMBER: US/09/252,991A
;  CURRENT FILING DATE:  1999-02-18
;  PRIOR APPLICATION NUMBER:  US 60/074,788
;  PRIOR FILING DATE:  1998-02-18
;  PRIOR APPLICATION NUMBER:  US 60/094,190
;  PRIOR FILING DATE:  1998-07-27
;  NUMBER OF SEQ ID NOS:  33142
; SEQ ID NO 17216
;   LENGTH: 367
;   TYPE: PRT
;   ORGANISM: Pseudomonas aeruginosa
;   FEATURE:
;   NAME/KEY: UNSURE
;   LOCATION: (194)
;   OTHER INFORMATION: Identity of amino acid at the above locations are unknown.
US-09-252-991A-17216

  Query Match             2.6%;  Score 7;  DB 4;  Length 367;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          9 LAVLAAS 15
              |||||||
Db        153 LAVLAAS 159


RESULT 17
US-09-252-991A-30926
; Sequence 30926, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
;  APPLICANT:  Marc J. Rubenfield et al.
;  TITLE OF INVENTION:  NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
;  TITLE OF INVENTION:  AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE:  107196.136
;  CURRENT APPLICATION NUMBER: US/09/252,991A
;  CURRENT FILING DATE:  1999-02-18
;  PRIOR APPLICATION NUMBER:  US 60/074,788
;  PRIOR FILING DATE:  1998-02-18
;  PRIOR APPLICATION NUMBER:  US 60/094,190
;  PRIOR FILING DATE:  1998-07-27
;  NUMBER OF SEQ ID NOS:  33142
; SEQ ID NO 30926
;   LENGTH: 371
;   TYPE: PRT
;   ORGANISM: Pseudomonas aeruginosa
;   FEATURE:
;   NAME/KEY: UNSURE
;   LOCATION: (259)
;   OTHER INFORMATION: Identity of amino acid at the above locations are unknown.
US-09-252-991A-30926

  Query Match             2.6%;  Score 7;  DB 4;  Length 371;
  Best Local Similarity   100.0%;  Pred. No. 77;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        100 CRASSTS 106
              |||||||
Db        329 CRASSTS 335


RESULT 18
US-07-882-292-2
; Sequence 2, Application US/07882292
; Patent No. 5324638
;  GENERAL INFORMATION:
;    APPLICANT:  Tao, Wufan
;    APPLICANT:  Lai, Eseng
;    TITLE OF INVENTION:  BRAIN TRANSCRIPTION FACTOR, NUCLEIC ACIDS
;    TITLE OF INVENTION:  ENCODING SAME AND USES THEREOF
;    NUMBER OF SEQUENCES:  2
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  John P. White
;      STREET:  c/o Cooper and Dunham, 30 Rockefeller
;      STREET:  Plaza
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10112
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.24
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/882,292
;      FILING DATE:  19920513
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  41472
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;      TELEX:  422523 COOP UI
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  480 amino acids
;      TYPE:  AMINO ACID
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
US-07-882-292-2

  Query Match             2.6%;  Score 7;  DB 1;  Length 480;
  Best Local Similarity   100.0%;  Pred. No. 98;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 APQPPPP 57
              |||||||
Db         61 APQPPPP 67


RESULT 19
US-08-331-644-2
; Sequence 2, Application US/08331644
; Patent No. 5976872
;  GENERAL INFORMATION:
;    APPLICANT:  Tao, Wufan
;    APPLICANT:  Lai, Eseng
```

```
;    TITLE OF INVENTION:  BRAIN TRANSCRIPTION FACTOR, NUCLEIC
;    TITLE OF INVENTION:  ACIDS ENCODING SAME AND USES THEREOF
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Cooper & Dunham
;      STREET:  1185 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10036
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/331,644
;      FILING DATE:
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/882,292
;      FILING DATE:  13-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  41472-A-PCT-US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-278-0400
;      TELEFAX:  212-391-0525
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  480 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
US-08-331-644-2

  Query Match              2.6%;  Score 7;  DB 2;  Length 480;
  Best Local Similarity   100.0%;  Pred. No. 98;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 APQPPPP 57
               |||||||
Db         61 APQPPPP 67


RESULT 20
PCT-US93-04102-2
; Sequence 2, Application PC/TUS9304102
;  GENERAL INFORMATION:
;    APPLICANT:  Tao, Wufan
;    APPLICANT:  Lai, Eseng
;    TITLE OF INVENTION:  BRAIN TRANSCRIPTION FACTOR, NUCLEIC
;    TITLE OF INVENTION:  ACIDS ENCODING SAME AND USES THEREOF
;    NUMBER OF SEQUENCES:  4
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  John P. White
;      STREET:  c/o Cooper and Dunham, 30 Rockefeller Plaza
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  USA
;      ZIP:  10112
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US93/04102
;      FILING DATE:  19930430
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/882,292
;      FILING DATE:  13-MAY-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  White, John P.
;      REGISTRATION NUMBER:  28,678
;      REFERENCE/DOCKET NUMBER:  41472A-PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  212-977-9550
;      TELEFAX:  212-664-0525
;      TELEX:  422523 COOP UI
;  INFORMATION FOR SEQ ID NO:  2:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  480 amino acids
;      TYPE:  AMINO ACID
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  protein
PCT-US93-04102-2

  Query Match              2.6%;  Score 7;  DB 5;  Length 480;
  Best Local Similarity   100.0%;  Pred. No. 98;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         51 APQPPPP 57
               |||||||
Db         61 APQPPPP 67


RESULT 21
US-09-252-991A-18485
; Sequence 18485, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
;  APPLICANT:  Marc J. Rubenfield et al.
;  TITLE OF INVENTION:  NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
;  TITLE OF INVENTION:  AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE:  107196.136
;  CURRENT APPLICATION NUMBER: US/09/252,991A
;  CURRENT FILING DATE:  1999-02-18
;  PRIOR APPLICATION NUMBER:  US 60/074,788
;  PRIOR FILING DATE:  1998-02-18
;  PRIOR APPLICATION NUMBER:  US 60/094,190
;  PRIOR FILING DATE:  1998-07-27
;  NUMBER OF SEQ ID NOS:  33142
; SEQ ID NO 18485
;   LENGTH: 635
;   TYPE: PRT
;   ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-18485

  Query Match              2.6%;  Score 7;  DB 4;  Length 635;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        247 FGGFRIG 253
              |||||||
Db        467 FGGFRIG 473


RESULT 22
US-09-252-991A-28287
; Sequence 28287, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
;  APPLICANT:  Marc J. Rubenfield et al.
;  TITLE OF INVENTION:  NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
;  TITLE OF INVENTION:  AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE:  107196.136
;  CURRENT APPLICATION NUMBER: US/09/252,991A
;  CURRENT FILING DATE:  1999-02-18
;  PRIOR APPLICATION NUMBER:  US 60/074,788
;  PRIOR FILING DATE:  1998-02-18
;  PRIOR APPLICATION NUMBER:  US 60/094,190
;  PRIOR FILING DATE:  1998-07-27
;  NUMBER OF SEQ ID NOS:  33142
```

; SEQ ID NO 28287
; LENGTH: 673
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-28287

Query Match 2.6%; Score 7; DB 4; Length 673;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 174 PCHRQPA 180
|||||||
Db 127 PCHRQPA 133

RESULT 23
US-09-228-986-78
; Sequence 78, Application US/09228986
; Patent No. 6359198
; GENERAL INFORMATION:
; APPLICANT: Strabala, Timothy
; APPLICANT: Nieuwenhuizen, Niels
; TITLE OF INVENTION: Compositions Isolated from Plant Cells
; TITLE OF INVENTION: and Their Use in the Modification of Plant Cell Signalling
; FILE REFERENCE: 11000/1020
; CURRENT APPLICATION NUMBER: US/09/228,986
; CURRENT FILING DATE: 1999-01-12
; NUMBER OF SEQ ID NOS: 130
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 78
; LENGTH: 903
; TYPE: PRT
; ORGANISM: Eucalyptus grandis
US-09-228-986-78

Query Match 2.6%; Score 7; DB 4; Length 903;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 85 LNVTLKS 91
|||||||
Db 323 LNVTLKS 329

RESULT 24
US-08-209-261B-10
; Sequence 10, Application US/08209261B
; Patent No. 5789152
; GENERAL INFORMATION:
; APPLICANT: Black, Christopher
; APPLICANT: Tosi, Pierre-Francois
; APPLICANT: Atkin, Andrew
; APPLICANT: Lazarte, Jaime E.
; APPLICANT: Nicolau, Yves Claude
; TITLE OF INVENTION: Diagnostic Device and Method
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jones & Askew
; STREET: 191 Peachtree Street, Ste. 3700
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30303-1769
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/209,261B
; FILING DATE: 16-MAR-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Stults, Larry W.
; REGISTRATION NUMBER: 34,025
; REFERENCE/DOCKET NUMBER: 05213-0061
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404) 818-3700
; TELEFAX: (404) 818-3799
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 8 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-209-261B-10

Query Match 2.3%; Score 6; DB 1; Length 8;
Best Local Similarity 100.0%; Pred. No. 2.5e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 64 GTKNIK 69
||||||
Db 3 GTKNIK 8

RESULT 25
US-08-769-745-22
; Sequence 22, Application US/08769745
; Patent No. 5955259
; GENERAL INFORMATION:
; APPLICANT: Holmes, Todd C.
; APPLICANT: Levitan, Irwin B.
; APPLICANT: Brandeis University
; TITLE OF INVENTION: Mechanism for the Regulation of Ion
; TITLE OF INVENTION: Channel Activity
; FILE REFERENCE: BRU96-02
; CURRENT APPLICATION NUMBER: US/08/769,745
; CURRENT FILING DATE: 1996-12-19
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 22
; LENGTH: 8
; TYPE: PRT
; ORGANISM: Rat
US-08-769-745-22

Query Match 2.3%; Score 6; DB 2; Length 8;
Best Local Similarity 100.0%; Pred. No. 2.5e+05;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 54 PPPPIT 59
||||||
Db 1 PPPPIT 6

RESULT 26
US-08-602-999A-382
; Sequence 382, Application US/08602999A
; Patent No. 6184205
; GENERAL INFORMATION:
; APPLICANT: SPARKS, Andrew B.
; APPLICANT: KAY, Brian K.
; APPLICANT: THORN, Judith M.
; APPLICANT: QUILLIAM, Lawrence A.
; APPLICANT: DER, Channing J.
; APPLICANT: FOWLKES, Dana M.
; APPLICANT: RIDER, James E.
; TITLE OF INVENTION: SH3 BINDING PEPTIDES AND METHODS OF
; TITLE OF INVENTION: ISOLATING AND USING SAME
; NUMBER OF SEQUENCES: 467
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York

```
;       COUNTRY:  U.S.A.
;       ZIP:  10036-2711
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/602,999A
;       FILING DATE:  16-FEB-1996
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Misrock, S. Leslie
;       REGISTRATION NUMBER:  18,872
;       REFERENCE/DOCKET NUMBER:  1101-202
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (212) 790-9090
;       TELEFAX:  (212) 869-9741/8864
;       TELEX:  66141 PENNIE
;   INFORMATION FOR SEQ ID NO:  382:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  15 amino acids
;       TYPE:  amino acid
;       TOPOLOGY:  unknown
;     MOLECULE TYPE:  peptide
US-08-602-999A-382

  Query Match             2.3%;  Score 6;  DB 3;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         52 PQPPPP 57
               ||||||
Db          3 PQPPPP 8


RESULT 27
US-08-602-999A-415
; Sequence 415, Application US/08602999A
; Patent No. 6184205
;  GENERAL INFORMATION:
;    APPLICANT:  SPARKS, Andrew B.
;    APPLICANT:  KAY, Brian K.
;    APPLICANT:  THORN, Judith M.
;    APPLICANT:  QUILLIAM, Lawrence A.
;    APPLICANT:  DER, Channing J.
;    APPLICANT:  FOWLKES, Dana M.
;    APPLICANT:  RIDER, James E.
;    TITLE OF INVENTION:  SH3 BINDING PEPTIDES AND METHODS OF
;    TITLE OF INVENTION:  ISOLATING AND USING SAME
;    NUMBER OF SEQUENCES:  467
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/602,999A
;      FILING DATE:  16-FEB-1996
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  1101-202
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  415:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  peptide
US-08-602-999A-415

  Query Match             2.3%;  Score 6;  DB 3;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         52 PQPPPP 57
               ||||||
Db          3 PQPPPP 8


RESULT 28
US-09-500-124-382
; Sequence 382, Application US/09500124
; Patent No. 6432920
;  GENERAL INFORMATION:
;    APPLICANT:  SPARKS, Andrew B.
;    APPLICANT:  KAY, Brian K.
;    APPLICANT:  THORN, Judith M.
;    APPLICANT:  QUILLIAM, Lawrence A.
;    APPLICANT:  DER, Channing J.
;    APPLICANT:  FOWLKES, Dana M.
;    APPLICANT:  RIDER, James E.
;    TITLE OF INVENTION:  SH3 BINDING PEPTIDES AND METHODS OF
;    TITLE OF INVENTION:  ISOLATING AND USING SAME
;    NUMBER OF SEQUENCES:  467
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/500,124
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/602,999
;      FILING DATE:  16-FEB-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  1101-202
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  382:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  peptide
US-09-500-124-382

  Query Match             2.3%;  Score 6;  DB 4;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          52 PQPPPP 57
               ||||||
Db           3 PQPPPP 8


RESULT 29
US-09-500-124-415
; Sequence 415, Application US/09500124
; Patent No. 6432920
;  GENERAL INFORMATION:
;    APPLICANT:  SPARKS, Andrew B.
;    APPLICANT:  KAY, Brian K.
;    APPLICANT:  THORN, Judith M.
;    APPLICANT:  QUILLIAM, Lawrence A.
;    APPLICANT:  DER, Channing J.
;    APPLICANT:  FOWLKES, Dana M.
;    APPLICANT:  RIDER, James E.
;    TITLE OF INVENTION:  SH3 BINDING PEPTIDES AND METHODS OF
;    TITLE OF INVENTION:  ISOLATING AND USING SAME
;    NUMBER OF SEQUENCES:  467
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Pennie & Edmonds
;      STREET:  1155 Avenue of the Americas
;      CITY:  New York
;      STATE:  New York
;      COUNTRY:  U.S.A.
;      ZIP:  10036-2711
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/500,124
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/602,999
;      FILING DATE:  16-FEB-1996
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Misrock, S. Leslie
;      REGISTRATION NUMBER:  18,872
;      REFERENCE/DOCKET NUMBER:  1101-202
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (212) 790-9090
;      TELEFAX:  (212) 869-9741/8864
;      TELEX:  66141 PENNIE
;  INFORMATION FOR SEQ ID NO:  415:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  unknown
;    MOLECULE TYPE:  peptide
US-09-500-124-415

  Query Match              2.3%;  Score 6;  DB 4;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 42;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          52 PQPPPP 57
               ||||||
Db           3 PQPPPP 8


RESULT 30
5196511-24
;Patent No. 5196511
;    APPLICANT: PLOW, EDWARD F.;D'SOUZA, STANLEY E.
;GINSBERG,MARK H.
;    TITLE OF INVENTION: PEPTIDES AND ANTIBODIES THAT INHIBIT
;INTEGRIN-LIGAND BINDING
;    NUMBER OF SEQUENCES: 31
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER: US/07/444,777
;      FILING DATE: 01-DEC-1989
;SEQ ID NO:24:
;      LENGTH: 16
5196511-24

  Query Match              2.3%;  Score 6;  DB 6;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 44;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          15 SSFSKA 20
               ||||||
Db           9 SSFSKA 14


RESULT 31
US-08-231-730A-18
; Sequence 18, Application US/08231730A
; Patent No. 5561107
;  GENERAL INFORMATION:
;    APPLICANT:  JAYNES, JESSE M.
;    APPLICANT:  JULIAN, GORDON R.
;    TITLE OF INVENTION:  METHOD OF ENHANCING WOUND HEALING BY STIMULATING FIBROBLAST A
;    NUMBER OF SEQUENCES:  46
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  STEVEN J. HULTQUIST
;      ADDRESSEE:  INTELLECTUAL PROPERTY/TECHNOLOGY LAW
;      STREET:  200 PARK DRIVE, SUITE 210
;      STREET:  P.O. BOX 14329
;      CITY:  RESEARCH TRIANGLE PARK
;      STATE:  NORTH CAROLINA
;      COUNTRY:  USA
;      ZIP:  27709
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.4 MB STORAGE
;      COMPUTER:  APPLE MACINTOSH
;      OPERATING SYSTEM:  MACINTOSH
;      SOFTWARE:  M.S. WORD 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/231,730A
;      FILING DATE:  04-20-94
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/225,476
;      FILING DATE:  04-08-94
;      APPLICATION NUMBER:  08/039,620
;      FILING DATE:  06-04-93
;      APPLICATION NUMBER:  08/148,491
;      FILING DATE:  11-08-93
;      APPLICATION NUMBER:  08/148,889
;      FILING DATE:  11-08-93
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  HULTQUIST, STEVEN J.
;      REGISTRATION NUMBER:  28021
;      REFERENCE/DOCKET NUMBER:  4013-106
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919)990-9531
;      TELEFAX:  (919)990-9532
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23
;      TYPE:  AMINO ACID
;      TOPOLOGY:  LINEAR
;    MOLECULE TYPE:
;      DESCRIPTION:  PEPTIDE
;    HYPOTHETICAL:  NO
;    FRAGMENT TYPE:  COMPLETE PEPTIDE
;    ORIGINAL SOURCE:  SYNTHETIC
;    IMMEDIATE SOURCE:  SYNTHETIC
;    PUBLICATION INFORMATION:  NOT PREVIOUSLY PUBLISHED
US-08-231-730A-18

  Query Match              2.3%;  Score 6;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 61;
```

Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          69 KVAKKV 74
               ||||||
Db           4 KVAKKV 9
```

RESULT 32
US-08-231-730A-24
; Sequence 24, Application US/08231730A
; Patent No. 5561107
; GENERAL INFORMATION:
; APPLICANT: JAYNES, JESSE M.
; APPLICANT: JULIAN, GORDON R.
; TITLE OF INVENTION: METHOD OF ENHANCING WOUND HEALING BY STIMULATING FIBROBLAST AN
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STEVEN J. HULTQUIST
; ADDRESSEE: INTELLECTUAL PROPERTY/TECHNOLOGY LAW
; STREET: 200 PARK DRIVE, SUITE 210
; STREET: P.O. BOX 14329
; CITY: RESEARCH TRIANGLE PARK
; STATE: NORTH CAROLINA
; COUNTRY: USA
; ZIP: 27709
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
; COMPUTER: APPLE MACINTOSH
; OPERATING SYSTEM: MACINTOSH
; SOFTWARE: M.S. WORD 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/231,730A
; FILING DATE: 04-20-94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/225,476
; FILING DATE: 04-08-94
; APPLICATION NUMBER: 08/039,620
; FILING DATE: 06-04-93
; APPLICATION NUMBER: 08/148,491
; FILING DATE: 11-08-93
; APPLICATION NUMBER: 08/148,889
; FILING DATE: 11-08-93
; ATTORNEY/AGENT INFORMATION:
; NAME: HULTQUIST, STEVEN J.
; REGISTRATION NUMBER: 28021
; REFERENCE/DOCKET NUMBER: 4013-106
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919)990-9531
; TELEFAX: (919)990-9532
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23
; TYPE: AMINO ACID
; TOPOLOGY: LINEAR
; MOLECULE TYPE:
; DESCRIPTION: PEPTIDE
; HYPOTHETICAL: NO
; FRAGMENT TYPE: COMPLETE PEPTIDE
; ORIGINAL SOURCE: SYNTHETIC
; IMMEDIATE SOURCE: SYNTHETIC
; PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
US-08-231-730A-24

Query Match 2.3%; Score 6; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          69 KVAKKV 74
               ||||||
Db           7 KVAKKV 12
```

RESULT 33

US-08-427-001C-18
; Sequence 18, Application US/08427001C
; Patent No. 5717064
; GENERAL INFORMATION:
; APPLICANT: JULIAN, GORDON R.
; TITLE OF INVENTION: METHYLATED LYSINE-RICH LYTIC PEPTIDES,
; TITLE OF INVENTION: AND METHOD OF MAKING THE SAME BY REDUCTIVE ALKYLATION
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROTHWELL, FIGG, ERNST & KURZ
; STREET: 555 Thirteenth Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
; COMPUTER: IBM COMPATIBLE
; OPERATING SYSTEM: DOS
; SOFTWARE: WordPerfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/427,001C
; FILING DATE: 24-APR-95
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: U.S.08/148,889
; FILING DATE: 08-NOV-93
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: WALKER, BARBARA W.
; REGISTRATION NUMBER: 35,400
; REFERENCE/DOCKET NUMBER: 2093-105A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)783-6040
; TELEFAX: (202)783-6031
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23
; TYPE: AMINO ACID
; TOPOLOGY: LINEAR
; MOLECULE TYPE: PEPTIDE
US-08-427-001C-18

Query Match 2.3%; Score 6; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          69 KVAKKV 74
               ||||||
Db           4 KVAKKV 9
```

RESULT 34
US-08-427-001C-24
; Sequence 24, Application US/08427001C
; Patent No. 5717064
; GENERAL INFORMATION:
; APPLICANT: JULIAN, GORDON R.
; TITLE OF INVENTION: METHYLATED LYSINE-RICH LYTIC PEPTIDES,
; TITLE OF INVENTION: AND METHOD OF MAKING THE SAME BY REDUCTIVE ALKYLATION
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROTHWELL, FIGG, ERNST & KURZ
; STREET: 555 Thirteenth Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
; COMPUTER: IBM COMPATIBLE
; OPERATING SYSTEM: DOS
; SOFTWARE: WordPerfect

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/427,001C
;      FILING DATE:  24-APR-95
;      CLASSIFICATION:  530
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  U.S.08/148,889
;      FILING DATE:  08-NOV-93
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  WALKER, BARBARA W.
;      REGISTRATION NUMBER:  35,400
;      REFERENCE/DOCKET NUMBER:  2093-105A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202)783-6040
;      TELEFAX:  (202)783-6031
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23
;      TYPE:  AMINO ACID
;      TOPOLOGY:  LINEAR
;    MOLECULE TYPE:  PEPTIDE
US-08-427-001C-24

  Query Match             2.3%;  Score 6;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 61;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         69 KVAKKV 74
              ||||||
Db          7 KVAKKV 12


RESULT 35
US-08-457-798-18
; Sequence 18, Application US/08457798
; Patent No. 5744445
;  GENERAL INFORMATION:
;    APPLICANT:  JAYNES, JESSE M.
;    APPLICANT:  JULIAN, GORDON R.
;    TITLE OF INVENTION:  METHOD OF TREATING PULMONARY DISEASE
;    TITLE OF INVENTION:  STATES WITH NON-NATURALLY OCCURRING
;    TITLE OF INVENTION:  AMPHIPATHIC PEPTIDES
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  JESSE M. JAYNES,
;      ADDRESSEE:  DEMETER BIOTECHNOLOGIES, LTD.
;      STREET:  150 FAYETTEVILLE ST. MALL, SUITE 2700
;      CITY:  RALEIGH
;      STATE:  NORTH CAROLINA
;      COUNTRY:  USA
;      ZIP:  27601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.4 MB STORAGE
;      COMPUTER:  APPLE MACINTOSH
;      OPERATING SYSTEM:  MACINTOSH
;      SOFTWARE:  M.S. WORD 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/457,798
;      FILING DATE:
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/039,620A
;      FILING DATE:  19930604
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  HULTQUIST, STEVEN J.
;      REGISTRATION NUMBER:  28021
;      REFERENCE/DOCKET NUMBER:  4013-103
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919)990-9531
;      TELEFAX:  (919)990-9532
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23
;      TYPE:  AMINO ACID
;      TOPOLOGY:  LINEAR
;    MOLECULE TYPE:
;      DESCRIPTION:  PEPTIDE
;    HYPOTHETICAL:  NO
;    FRAGMENT TYPE:  COMPLETE PEPTIDE
;    ORIGINAL SOURCE:  SYNTHETIC
;    IMMEDIATE SOURCE:  SYNTHETIC
;    PUBLICATION INFORMATION:  NOT PREVIOUSLY PUBLISHED
US-08-457-798-18

  Query Match             2.3%;  Score 6;  DB 1;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 61;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         69 KVAKKV 74
              ||||||
Db          4 KVAKKV 9


RESULT 36
US-08-457-798-24
; Sequence 24, Application US/08457798
; Patent No. 5744445
;  GENERAL INFORMATION:
;    APPLICANT:  JAYNES, JESSE M.
;    APPLICANT:  JULIAN, GORDON R.
;    TITLE OF INVENTION:  METHOD OF TREATING PULMONARY DISEASE
;    TITLE OF INVENTION:  STATES WITH NON-NATURALLY OCCURRING
;    TITLE OF INVENTION:  AMPHIPATHIC PEPTIDES
;    NUMBER OF SEQUENCES:  38
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  JESSE M. JAYNES,
;      ADDRESSEE:  DEMETER BIOTECHNOLOGIES, LTD.
;      STREET:  150 FAYETTEVILLE ST. MALL, SUITE 2700
;      CITY:  RALEIGH
;      STATE:  NORTH CAROLINA
;      COUNTRY:  USA
;      ZIP:  27601
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.4 MB STORAGE
;      COMPUTER:  APPLE MACINTOSH
;      OPERATING SYSTEM:  MACINTOSH
;      SOFTWARE:  M.S. WORD 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/457,798
;      FILING DATE:
;      CLASSIFICATION:  514
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/039,620A
;      FILING DATE:  19930604
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  HULTQUIST, STEVEN J.
;      REGISTRATION NUMBER:  28021
;      REFERENCE/DOCKET NUMBER:  4013-103
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919)990-9531
;      TELEFAX:  (919)990-9532
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23
;      TYPE:  AMINO ACID
;      TOPOLOGY:  LINEAR
;    MOLECULE TYPE:
;      DESCRIPTION:  PEPTIDE
;    HYPOTHETICAL:  NO
;    FRAGMENT TYPE:  COMPLETE PEPTIDE
;    ORIGINAL SOURCE:  SYNTHETIC
;    IMMEDIATE SOURCE:  SYNTHETIC
;    PUBLICATION INFORMATION:  NOT PREVIOUSLY PUBLISHED
US-08-457-798-24

  Query Match             2.3%;  Score 6;  DB 1;  Length 23;
```

Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          69 KVAKKV 74
               ||||||
Db           7 KVAKKV 12
```

```
RESULT 37
US-08-457-171-18
; Sequence 18, Application US/08457171
; Patent No. 5773413
;  GENERAL INFORMATION:
;    APPLICANT:  JAYNES, JESSE M.
;    APPLICANT:  JULIAN, GORDON R.
;    TITLE OF INVENTION:  METHOD OF COMBATTING MAMMALIAN NEOPLASIA, AND LYTIC PEPTIDES T
;    NUMBER OF SEQUENCES:  40
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  STEVEN J. HULTQUIST
;      ADDRESSEE:  INTELLECTUAL PROPERTY/TECHNOLOGY LAW
;      STREET:  200 PARK DRIVE, SUITE 210
;      STREET:  P.O. BOX 14329
;      CITY:  RESEARCH TRIANGLE PARK
;      STATE:  NORTH CAROLINA
;      COUNTRY:  USA
;      ZIP:  27709
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.4 MB STORAGE
;      COMPUTER:  APPLE MACINTOSH
;      OPERATING SYSTEM:  MACINTOSH
;      SOFTWARE:  M.S. WORD 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/457,171
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/225,476A
;      FILING DATE:  04-08-94
;      APPLICATION NUMBER:  08/039,620
;      FILING DATE:  06-04-93
;      APPLICATION NUMBER:  08/148,491
;      FILING DATE:  11-08-93
;      APPLICATION NUMBER:  08/148,889
;      FILING DATE:  11-08-93
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  HULTQUIST, STEVEN J.
;      REGISTRATION NUMBER:  28021
;      REFERENCE/DOCKET NUMBER:  4013-106
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919)990-9531
;      TELEFAX:  (919)990-9532
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23
;      TYPE:  AMINO ACID
;      TOPOLOGY:  LINEAR
;    MOLECULE TYPE:
;      DESCRIPTION:  PEPTIDE
;    HYPOTHETICAL:  NO
;    FRAGMENT TYPE:  COMPLETE PEPTIDE
;    ORIGINAL SOURCE:  SYNTHETIC
;    IMMEDIATE SOURCE:  SYNTHETIC
;    PUBLICATION INFORMATION:  NOT PREVIOUSLY PUBLISHED
US-08-457-171-18
```

Query Match 2.3%; Score 6; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          69 KVAKKV 74
               ||||||
Db           4 KVAKKV 9
```

```
RESULT 38
US-08-457-171-24
; Sequence 24, Application US/08457171
; Patent No. 5773413
;  GENERAL INFORMATION:
;    APPLICANT:  JAYNES, JESSE M.
;    APPLICANT:  JULIAN, GORDON R.
;    TITLE OF INVENTION:  METHOD OF COMBATTING MAMMALIAN NEOPLASIA, AND LYTIC PEPTIDES T
;    NUMBER OF SEQUENCES:  40
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  STEVEN J. HULTQUIST
;      ADDRESSEE:  INTELLECTUAL PROPERTY/TECHNOLOGY LAW
;      STREET:  200 PARK DRIVE, SUITE 210
;      STREET:  P.O. BOX 14329
;      CITY:  RESEARCH TRIANGLE PARK
;      STATE:  NORTH CAROLINA
;      COUNTRY:  USA
;      ZIP:  27709
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.4 MB STORAGE
;      COMPUTER:  APPLE MACINTOSH
;      OPERATING SYSTEM:  MACINTOSH
;      SOFTWARE:  M.S. WORD 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/457,171
;      FILING DATE:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/225,476A
;      FILING DATE:  04-08-94
;      APPLICATION NUMBER:  08/039,620
;      FILING DATE:  06-04-93
;      APPLICATION NUMBER:  08/148,491
;      FILING DATE:  11-08-93
;      APPLICATION NUMBER:  08/148,889
;      FILING DATE:  11-08-93
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  HULTQUIST, STEVEN J.
;      REGISTRATION NUMBER:  28021
;      REFERENCE/DOCKET NUMBER:  4013-106
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919)990-9531
;      TELEFAX:  (919)990-9532
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23
;      TYPE:  AMINO ACID
;      TOPOLOGY:  LINEAR
;    MOLECULE TYPE:
;      DESCRIPTION:  PEPTIDE
;    HYPOTHETICAL:  NO
;    FRAGMENT TYPE:  COMPLETE PEPTIDE
;    ORIGINAL SOURCE:  SYNTHETIC
;    IMMEDIATE SOURCE:  SYNTHETIC
;    PUBLICATION INFORMATION:  NOT PREVIOUSLY PUBLISHED
US-08-457-171-24
```

Query Match 2.3%; Score 6; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          69 KVAKKV 74
               ||||||
Db           7 KVAKKV 12
```

```
RESULT 39
US-08-505-486-18
; Sequence 18, Application US/08505486
; Patent No. 5955573
;  GENERAL INFORMATION:
;    APPLICANT:  Jesse M. Jaynes
;    TITLE OF INVENTION:  UBIQUTIN-LYTIC PEPTIDE FUSION GENE
;    TITLE OF INVENTION:  CONSTRUCTS, PROTEIN PRODUCTS DERIVING THEREFROM, AND
```

; TITLE OF INVENTION: METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROTHWELL, FIGG, ERNST & KURZ
; STREET: 555 Thirteenth Street N.W.
; CITY: Washington
; STATE: D. C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
; COMPUTER: IBM COMPATIBLE
; OPERATING SYSTEM: DOS
; SOFTWARE: WordPerfect 5.1+
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/505,486
; FILING DATE: 21-JUL-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: U.S. 08/279,472
; FILING DATE: 22-JUL-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: WALKER, BARBARA W.
; REGISTRATION NUMBER: 35,400
; REFERENCE/DOCKET NUMBER: 2093-117A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)783-6040
; TELEFAX: (202)783-6031
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23
; TYPE: AMINO ACID
; TOPOLOGY: LINEAR
; MOLECULE TYPE:
; DESCRIPTION: PEPTIDE
; HYPOTHETICAL: NO
; FRAGMENT TYPE: COMPLETE PEPTIDE
; ORIGINAL SOURCE: SYNTHETIC
; IMMEDIATE SOURCE: SYNTHETIC
; PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
US-08-505-486-18

Query Match 2.3%; Score 6; DB 2; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 69 KVAKKV 74
||||||
Db 4 KVAKKV 9

RESULT 40
US-08-505-486-24
; Sequence 24, Application US/08505486
; Patent No. 5955573
; GENERAL INFORMATION:
; APPLICANT: Jesse M. Jaynes
; TITLE OF INVENTION: UBIQUTIN-LYTIC PEPTIDE FUSION GENE
; TITLE OF INVENTION: CONSTRUCTS, PROTEIN PRODUCTS DERIVING THEREFROM, AND
; TITLE OF INVENTION: METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROTHWELL, FIGG, ERNST & KURZ
; STREET: 555 Thirteenth Street N.W.
; CITY: Washington
; STATE: D. C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
; COMPUTER: IBM COMPATIBLE
; OPERATING SYSTEM: DOS
; SOFTWARE: WordPerfect 5.1+
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/505,486
; FILING DATE: 21-JUL-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: U.S. 08/279,472
; FILING DATE: 22-JUL-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: WALKER, BARBARA W.
; REGISTRATION NUMBER: 35,400
; REFERENCE/DOCKET NUMBER: 2093-117A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)783-6040
; TELEFAX: (202)783-6031
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23
; TYPE: AMINO ACID
; TOPOLOGY: LINEAR
; MOLECULE TYPE:
; DESCRIPTION: PEPTIDE
; HYPOTHETICAL: NO
; FRAGMENT TYPE: COMPLETE PEPTIDE
; ORIGINAL SOURCE: SYNTHETIC
; IMMEDIATE SOURCE: SYNTHETIC
; PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
US-08-505-486-24

Query Match 2.3%; Score 6; DB 2; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 69 KVAKKV 74
||||||
Db 7 KVAKKV 12

RESULT 41
US-08-689-489C-18
; Sequence 18, Application US/08689489C
; Patent No. 6001805
; GENERAL INFORMATION:
; APPLICANT: Jesse M. Jaynes, Gordon R. Julian
; TITLE OF INVENTION: Method of Enhancing Wound Healing By
; TITLE OF INVENTION: Stimulating Fibro-blast and Keratinocyte Growth In
; TITLE OF INVENTION: Vivo, Utilizing Amphipathic Peptides
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rothwell, Figg, Ernst & Kurz
; STREET: 555 13TH STREET
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/689,489C
; FILING DATE: August 12, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/231,730
; FILING DATE: April 20, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/225,476
; FILING DATE: April 8, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/039,620
; FILING DATE: June 4, 1993

```
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/148,889
;      FILING DATE:  No. 6001805ember 8, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/148,491
;      FILING DATE:  No. 6001805ember, 8, 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mark I. Bowditch
;      REGISTRATION NUMBER:  40,315
;      REFERENCE/DOCKET NUMBER:  2093-120
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-783-6040
;      TELEFAX:  202-783-6031
;  INFORMATION FOR SEQ ID NO:  18:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    HYPOTHETICAL:  NO
;    FRAGMENT TYPE:  linear
US-08-689-489C-18

  Query Match             2.3%;  Score 6;  DB 3;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 61;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          69 KVAKKV 74
               ||||||
Db           4 KVAKKV 9


RESULT 42
US-08-689-489C-24
; Sequence 24, Application US/08689489C
; Patent No. 6001805
;  GENERAL INFORMATION:
;    APPLICANT:  Jesse M. Jaynes, Gordon R. Julian
;    TITLE OF INVENTION:  Method of Enhancing Wound Healing By
;    TITLE OF INVENTION:  Stimulating Fibro-blast and Keratinocyte Growth In
;    TITLE OF INVENTION:  Vivo, Utilizing Amphipathic Peptides
;    NUMBER OF SEQUENCES:  46
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Rothwell, Figg, Ernst & Kurz
;      STREET:  555 13TH STREET
;      CITY:  Washington
;      STATE:  DC
;      COUNTRY:  USA
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/689,489C
;      FILING DATE:  August 12, 1996
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/231,730
;      FILING DATE:  April 20, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/225,476
;      FILING DATE:  April 8, 1994
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/039,620
;      FILING DATE:  June 4, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/148,889
;      FILING DATE:  No. 6001805ember 8, 1993
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/148,491
;      FILING DATE:  No. 6001805ember, 8, 1993
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Mark I. Bowditch
;      REGISTRATION NUMBER:  40,315
;      REFERENCE/DOCKET NUMBER:  2093-120
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  202-783-6040
;      TELEFAX:  202-783-6031
;  INFORMATION FOR SEQ ID NO:  24:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  23 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    HYPOTHETICAL:  NO
US-08-689-489C-24

  Query Match             2.3%;  Score 6;  DB 3;  Length 23;
  Best Local Similarity   100.0%;  Pred. No. 61;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          69 KVAKKV 74
               ||||||
Db           7 KVAKKV 12


RESULT 43
US-08-801-028-18
; Sequence 18, Application US/08801028
; Patent No. 6018102
;  GENERAL INFORMATION:
;    APPLICANT:  JOAN GARBARINO
;    APPLICANT:  JESSE M. JAYNES
;    APPLICANT:  WILLIAM BELKNAP
;    TITLE OF INVENTION:  UBIQUITIN-LYTIC PEPTIDE FUSION GENE CONSTRUCTS, PROTEIN PRODUC
;    NUMBER OF SEQUENCES:  98
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  STEVEN J. HULTQUIST
;      ADDRESSEE:  INTELLECTUAL PROPERTY/TECHNOLOGY LAW
;      STREET:  200 PARK DRIVE, SUITE 210
;      STREET:  P.O. BOX 14329
;      CITY:  RESEARCH TRIANGLE PARK
;      STATE:  NORTH CAROLINA
;      COUNTRY:  USA
;      ZIP:  27709
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  DISKETTE, 3.5 INCH, 1.4 MB STORAGE
;      COMPUTER:  APPLE MACINTOSH
;      OPERATING SYSTEM:  MACINTOSH
;      SOFTWARE:  M.S. WORD 5.0
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/801,028
;      FILING DATE:  19-FEB-1997
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/279,472
;      FILING DATE:  JULY 22, 1994
;      APPLICATION NUMBER:  08/225,476
;      FILING DATE:  04-20-94
;      APPLICATION NUMBER:  08/225,476
;      FILING DATE:  04-08-94
;      APPLICATION NUMBER:  08/039,620
;      FILING DATE:  06-04-93
;      APPLICATION NUMBER:  08/148,491
;      FILING DATE:  11-08-93
;      APPLICATION NUMBER:  08/148,889
;      FILING DATE:  11-08-93
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  WASSERMAN, FRAN S.
;      REGISTRATION NUMBER:  34,273
;      REFERENCE/DOCKET NUMBER:  4013-104
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (919)990-9531
;      TELEFAX:  (919)990-9532
```

; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23
; TYPE: AMINO ACID
; TOPOLOGY: LINEAR
; MOLECULE TYPE:
; DESCRIPTION: PEPTIDE
; HYPOTHETICAL: NO
; FRAGMENT TYPE: COMPLETE PEPTIDE
; ORIGINAL SOURCE: SYNTHETIC
; IMMEDIATE SOURCE: SYNTHETIC
; PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
US-08-801-028-18

Query Match 2.3%; Score 6; DB 3; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 69 KVAKKV 74
||||||
Db 4 KVAKKV 9

RESULT 44
US-08-801-028-24
; Sequence 24, Application US/08801028
; Patent No. 6018102
; GENERAL INFORMATION:
; APPLICANT: JOAN GARBARINO
; APPLICANT: JESSE M. JAYNES
; APPLICANT: WILLIAM BELKNAP
; TITLE OF INVENTION: UBIQUITIN-LYTIC PEPTIDE FUSION GENE CONSTRUCTS, PROTEIN PRODUC
; NUMBER OF SEQUENCES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STEVEN J. HULTQUIST
; ADDRESSEE: INTELLECTUAL PROPERTY/TECHNOLOGY LAW
; STREET: 200 PARK DRIVE, SUITE 210
; STREET: P.O. BOX 14329
; CITY: RESEARCH TRIANGLE PARK
; STATE: NORTH CAROLINA
; COUNTRY: USA
; ZIP: 27709
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
; COMPUTER: APPLE MACINTOSH
; OPERATING SYSTEM: MACINTOSH
; SOFTWARE: M.S. WORD 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/801,028
; FILING DATE: 19-FEB-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/279,472
; FILING DATE: JULY 22, 1994
; APPLICATION NUMBER: 08/225,476
; FILING DATE: 04-20-94
; APPLICATION NUMBER: 08/225,476
; FILING DATE: 04-08-94
; APPLICATION NUMBER: 08/039,620
; FILING DATE: 06-04-93
; APPLICATION NUMBER: 08/148,491
; FILING DATE: 11-08-93
; APPLICATION NUMBER: 08/148,889
; FILING DATE: 11-08-93
; ATTORNEY/AGENT INFORMATION:
; NAME: WASSERMAN, FRAN S.
; REGISTRATION NUMBER: 34,273
; REFERENCE/DOCKET NUMBER: 4013-104
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (919)990-9531
; TELEFAX: (919)990-9532
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23
; TYPE: AMINO ACID
; TOPOLOGY: LINEAR
; MOLECULE TYPE:
; DESCRIPTION: PEPTIDE
; HYPOTHETICAL: NO
; FRAGMENT TYPE: COMPLETE PEPTIDE
; ORIGINAL SOURCE: SYNTHETIC
; IMMEDIATE SOURCE: SYNTHETIC
; PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
US-08-801-028-24

Query Match 2.3%; Score 6; DB 3; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 69 KVAKKV 74
||||||
Db 7 KVAKKV 12

RESULT 45
US-09-340-154-18
; Sequence 18, Application US/09340154
; Patent No. 6084156
; GENERAL INFORMATION:
; APPLICANT: Jesse M. Jaynes
; TITLE OF INVENTION: UBIQUTIN-LYTIC PEPTIDE FUSION GENE
; TITLE OF INVENTION: CONSTRUCTS, PROTEIN PRODUCTS DERIVING THEREFROM, AND
; TITLE OF INVENTION: METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROTHWELL, FIGG, ERNST & KURZ
; STREET: 555 Thirteenth Street N.W.
; CITY: Washington
; STATE: D. C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
; COMPUTER: IBM COMPATIBLE
; OPERATING SYSTEM: DOS
; SOFTWARE: WordPerfect 5.1+
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/340,154
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/505,486
; FILING DATE: 21-JUL-1995
; APPLICATION NUMBER: U.S. 08/279,472
; FILING DATE: 22-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: WALKER, BARBARA W.
; REGISTRATION NUMBER: 35,400
; REFERENCE/DOCKET NUMBER: 2093-117A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)783-6040
; TELEFAX: (202)783-6031
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23
; TYPE: AMINO ACID
; TOPOLOGY: LINEAR
; MOLECULE TYPE:
; DESCRIPTION: PEPTIDE
; HYPOTHETICAL: NO
; FRAGMENT TYPE: COMPLETE PEPTIDE
; ORIGINAL SOURCE: SYNTHETIC
; IMMEDIATE SOURCE: SYNTHETIC
; PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
US-09-340-154-18

Query Match 2.3%; Score 6; DB 3; Length 23;

Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          69 KVAKKV 74
               ||||||
Db           4 KVAKKV 9
```

RESULT 46
US-09-340-154-24
; Sequence 24, Application US/09340154
; Patent No. 6084156
; GENERAL INFORMATION:
; APPLICANT: Jesse M. Jaynes
; TITLE OF INVENTION: UBIQUTIN-LYTIC PEPTIDE FUSION GENE
; TITLE OF INVENTION: CONSTRUCTS, PROTEIN PRODUCTS DERIVING THEREFROM, AND
; TITLE OF INVENTION: METHODS OF MAKING AND USING SAME
; NUMBER OF SEQUENCES: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ROTHWELL, FIGG, ERNST & KURZ
; STREET: 555 Thirteenth Street N.W.
; CITY: Washington
; STATE: D. C.
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.4 MB STORAGE
; COMPUTER: IBM COMPATIBLE
; OPERATING SYSTEM: DOS
; SOFTWARE: WordPerfect 5.1+
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/340,154
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/505,486
; FILING DATE: 21-JUL-1995
; APPLICATION NUMBER: U.S. 08/279,472
; FILING DATE: 22-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: WALKER, BARBARA W.
; REGISTRATION NUMBER: 35,400
; REFERENCE/DOCKET NUMBER: 2093-117A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)783-6040
; TELEFAX: (202)783-6031
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23
; TYPE: AMINO ACID
; TOPOLOGY: LINEAR
; MOLECULE TYPE:
; DESCRIPTION: PEPTIDE
; HYPOTHETICAL: NO
; FRAGMENT TYPE: COMPLETE PEPTIDE
; ORIGINAL SOURCE: SYNTHETIC
; IMMEDIATE SOURCE: SYNTHETIC
; PUBLICATION INFORMATION: NOT PREVIOUSLY PUBLISHED
US-09-340-154-24

Query Match 2.3%; Score 6; DB 3; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          69 KVAKKV 74
               ||||||
Db           7 KVAKKV 12
```

RESULT 47
US-09-232-802A-18
; Sequence 18, Application US/09232802A
; Patent No. 6191110
; GENERAL INFORMATION:
; APPLICANT: Jesse M. Jaynes, Gordon R. Julian
; TITLE OF INVENTION: Method of Enhancing Wound Healing By
; Stimulating Fibro-blast and Keratinocyte Growth In
; Vivo, Utilizing Amphipathic Peptides
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rothwell, Figg, Ernst & Manbeck
; STREET: 555 13TH STREET
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/232,802A
; FILING DATE: 19-Jan-1999
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/689,489
; FILING DATE: August 12, 1996
; APPLICATION NUMBER: US 08/231,730
; FILING DATE: April 20, 1994
; APPLICATION NUMBER: US 08/225,476
; FILING DATE: April 8, 1994
; APPLICATION NUMBER: US 08/039,620
; FILING DATE: June 4, 1993
; APPLICATION NUMBER: 08/148,889
; FILING DATE: No. 6191110ember 8, 1993
; APPLICATION NUMBER: 08/148,491
; FILING DATE: No. 6191110ember, 8, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Mark I. Bowditch
; REGISTRATION NUMBER: 40,315
; REFERENCE/DOCKET NUMBER: 2093-142
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-783-6040
; TELEFAX: 202-783-6031
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; FRAGMENT TYPE: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-232-802A-18

Query Match 2.3%; Score 6; DB 3; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          69 KVAKKV 74
               ||||||
Db           4 KVAKKV 9
```

RESULT 48
US-09-232-802A-24
; Sequence 24, Application US/09232802A
; Patent No. 6191110
; GENERAL INFORMATION:
; APPLICANT: Jesse M. Jaynes, Gordon R. Julian
; TITLE OF INVENTION: Method of Enhancing Wound Healing By
; Stimulating Fibro-blast and Keratinocyte Growth In
; Vivo, Utilizing Amphipathic Peptides
; NUMBER OF SEQUENCES: 46
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Rothwell, Figg, Ernst & Manbeck
; STREET: 555 13TH STREET
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/232,802A
; FILING DATE: 19-Jan-1999
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/689,489
; FILING DATE: August 12, 1996
; APPLICATION NUMBER: US 08/231,730
; FILING DATE: April 20, 1994
; APPLICATION NUMBER: US 08/225,476
; FILING DATE: April 8, 1994
; APPLICATION NUMBER: US 08/039,620
; FILING DATE: June 4, 1993
; APPLICATION NUMBER: 08/148,889
; FILING DATE: No. 6191110ember 8, 1993
; APPLICATION NUMBER: 08/148,491
; FILING DATE: No. 6191110ember, 8, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Mark I. Bowditch
; REGISTRATION NUMBER: 40,315
; REFERENCE/DOCKET NUMBER: 2093-142
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-783-6040
; TELEFAX: 202-783-6031
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 24:
US-09-232-802A-24

Query Match 2.3%; Score 6; DB 3; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 69 KVAKKV 74
||||||
Db 7 KVAKKV 12

RESULT 49
US-09-482-611B-18
; Sequence 18, Application US/09482611B
; Patent No. 6448391
; GENERAL INFORMATION:
; APPLICANT: Garbarino, Joan
; APPLICANT: Belknap, William
; TITLE OF INVENTION: Ubiquitin-Lytic Peptide Fusion Gene Constructs, Protein Products
; TITLE OF INVENTION: Therefrom, and Methods of Making and Using Same
; FILE REFERENCE: 2093-149
; CURRENT APPLICATION NUMBER: US/09/482,611B
; CURRENT FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 08/801,028
; PRIOR FILING DATE: 1997-02-19
; PRIOR APPLICATION NUMBER: US 08/279,472
; PRIOR FILING DATE: 1994-07-22
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
; LENGTH: 23
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Lytic Peptide
US-09-482-611B-18

Query Match 2.3%; Score 6; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 69 KVAKKV 74
||||||
Db 4 KVAKKV 9

RESULT 50
US-09-482-611B-24
; Sequence 24, Application US/09482611B
; Patent No. 6448391
; GENERAL INFORMATION:
; APPLICANT: Garbarino, Joan
; APPLICANT: Belknap, William
; TITLE OF INVENTION: Ubiquitin-Lytic Peptide Fusion Gene Constructs, Protein Products
; TITLE OF INVENTION: Therefrom, and Methods of Making and Using Same
; FILE REFERENCE: 2093-149
; CURRENT APPLICATION NUMBER: US/09/482,611B
; CURRENT FILING DATE: 2000-01-14
; PRIOR APPLICATION NUMBER: US 08/801,028
; PRIOR FILING DATE: 1997-02-19
; PRIOR APPLICATION NUMBER: US 08/279,472
; PRIOR FILING DATE: 1994-07-22
; NUMBER OF SEQ ID NOS: 102
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 23
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Lytic Peptide
US-09-482-611B-24

Query Match 2.3%; Score 6; DB 4; Length 23;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 69 KVAKKV 74
||||||
Db 7 KVAKKV 12

Search completed: February 5, 2004, 16:38:22
Job time : 22 secs

```
  Best Local Similarity   92.0%;  Pred. No. 3.3e-43;
  Matches  439;  Conservative    0;  Mismatches   29;  Indels    9;  Gaps    4;

Qy         12 GGAACTAGGAGGTTCTCACTGCCCGAGCAGAGGCCCTACACCCACCGAGGCATGGGGCTC 71
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          4 GAAACTAGGAGGTTCTCACTGCCCGAGCAGAGGCCCTACACCCACCGAGGCATGGGGCTC 63

Qy         72 CCTGGGCTGTTCTGCTTGGCCGTGCTGGCTGCCAGCAGCTTCTCCAAGGCACGGGAGGAA 131
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         64 CCTGGGCTGTTCTGCTTGGCCGTGCTGGCTGCCAGCAGCTTCTCCAAGGCACGGGAGGAA 123

Qy        132 GAAATTACCCCTGTGGTCTCCATTGCCTACAAAGTCCTGGAAGTTTTCCCCAAAGGCCGC 191
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        124 GAAATTACCCCTGTGGTCTCCATTGCCTACAAAGTCCTGGAAGTTTTCCCCAAAGGCCGC 183

Qy        192 TGGGTGCTCATAACCTGCTGTGCACCCCAGCCACCACCGCCCATCACCTATTCCCTCTGT 251
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        184 TGGGTGCTCATAACCTGCTGTGCACCCCAGCCACCACCGCCCATCACCTATTCCCTCTGT 243

Qy        252 GGAACCAAGAACATCAAGGTGGCCAAGAAGGTGGTGAAGACCCACGAGCCGGCCTCCTTC 311
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        244 GGAACCAAGAACATCAAGGTGGCCAAGAAGGTGGTGAAGACCCACGAGCCGGCCTCCTTC 303

Qy        312 AACCTCAACGTCACACTCAAGTCCAGTCCAGACGTGCT----CACCTACTTCTGCCGGGC 367
              |||||||||||||||||||||||||||||||||||||    |  |  |  | ||
Db        304 AACCTCAACGTCACACTCAAGTCCAGTCCAGACCTGCTTCACCTNATTTCTTGCCGGGCG 363

Qy        368 GTCCTCCACCTCAGGTGCCCATGT-GGACAGTGCCAGGCT---ACAGATGCACTGGGAGC 423
              ||||||||||||||||||||||| |||||||||||||  |   |  |     ||||||
Db        364 TTCCTCCACCTCAGGTGCCCATGTGGGACAGTGCCAGGGTTACAGATGGCATTGGGGAGC 423

Qy        424 TGTGGTCCAAGCCAGTG-TCTGAGCTGCGGGCCAACTTCACTCTGCAGGACAGAGGG 479
              |||||||||||||||| | |||| |||||||||| |||| | ||||||||||||||
Db        424 TGTGGTCCAAGCCAGTGTTTTGAGGTGCGGGCCAATTTCATTTTGCAGGACAGAGGG 480


RESULT 5
H58326
LOCUS       H58326                   418 bp    mRNA    linear   EST 05-OCT-1995
DEFINITION  yr25c07.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone
            IMAGE:206316 5', mRNA sequence.
ACCESSION   H58326
VERSION     H58326.1  GI:1011158
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 418)
  AUTHORS   Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M., Holman
            ,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M., Parsons,J.,
            Rifkin,L., Rohlfing,T., Soares,M., Tan,F., Trevaskis,E., Waterston
            ,R., Williamson,A., Wohldmann,P. and Wilson,R.
  TITLE     The WashU-Merck EST Project
  JOURNAL   Unpublished
COMMENT     Contact: Wilson RK
            Washington University School of Medicine
            4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
            Tel: 314 286 1800
            Fax: 314 286 1810
            Email: est@watson.wustl.edu
            Insert Size: 912
            High quality sequence stops: 251
            Source: IMAGE Consortium, LLNL
            This clone is available royalty-free through LLNL ; contact the
            IMAGE Consortium (info@image.llnl.gov) for further information.
            Insert Length: 912    Std Error: 0.00
            Seq primer: M13RP1
            High quality sequence stop: 251.
FEATURES             Location/Qualifiers
     source          1. .418
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="GDB:3775447"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:206316"
                     /sex="male"
                     /dev_stage="20 week-post conception fetus"
                     /lab_host="DH10B (ampicillin resistant)"
                     /clone_lib="Soares fetal liver spleen 1NFLS"
                     /note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia)
                     with a modified polylinker; Site_1: Pac I; Site_2: Eco RI;
                     1st strand cDNA was primed with a Pac I - oligo(dT) primer
                     [5' AACTGGAAGAATTAATTAAAGATCTTTTTTTTTTTTTTTTTT 3'],
                     double-stranded cDNA was ligated to Eco RI adaptors
                     (Pharmacia), digested with Pac I and cloned into the Pac I
                     and Eco RI sites of the modified pT7T3 vector.  Library
                     went through one round of normalization. Library
                     constructed by Bento Soares and M.Fatima Bonaldo."
BASE COUNT       89 a    130 c    119 g     76 t      4 others
ORIGIN

  Query Match            35.7%;  Score 354;  DB 14;  Length 418;
  Best Local Similarity  96.1%;  Pred. No. 1.7e-40;
  Matches  393;  Conservative    0;  Mismatches   13;  Indels    3;  Gaps    3;

Qy        279 AAGGTGGTGAAGACCCACGAGCCGGCCTCCTTCAACCTCAACGTCACACTCAAGTCCAGT 338
              | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          3 AGGTGGGTGAAGACCCACGAGCCGGCCTCCTTCAACCTCAACGTCACACTCAAGTCCAGT 62

Qy        339 CCAGACCTGCTCACCTACTTCTGCCGGGCGTCCTCCACCTCAGGTGCCCATGTGGACAGT 398
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         63 CCAGACCTGCTCACCTACTTCTGCCGGGCGTCCTCCACCTCAGGTGCCCATGTGGACAGT 122

Qy        399 GCCAGGCTACAGATGCACTGGGAGCTGTGGTCCAAGCCAGTGTCTGAGCTGCGGGCCAAC 458
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        123 GCCAGGCTACAGATGCACTGGGAGCTGTGGTCCAAGCCAGTGTCTGAGCTGCGGGCCAAC 182

Qy        459 TTCACTCTGCAGGACAGAGGGGCAGGCCCCAGGGTGGAGATGATCTGCCAGGCGTCCTCG 518
              ||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||
Db        183 TTCACTCTGCAGGACAGAGGGGCAGG-CCCAGGGTGGAGATGATCTGCCAGGCGTCCTCG 241

Qy        519 GGCAGCCCACCTATCACCAACAGCCTGATCGGGAAGGATGGGCAGGTCCACCTGCAGCAG 578
              |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||
Db        242 GGCAGCCCACCTATCACCAACAGCCTGATCGGGAAGGATGGGCAGGTCCACCTNCAGCAG 301

Qy        579 AGACCATGCCACAGGCAGCCTGCCAACTTCTCCTTCC-TGCCGAGCCAGACATCGGACTG 637
              |||||||||||||| |||||||||| ||||||| |||||||||||||||||||||||||
Db        302 AGACCATGCCACAGGAGGCCTGCCAACTTGTCCTTCCTTGCCGAGCCAGACATCGGACTG 361

Qy        638 G-TTCTGGTGCCAGGCTGCAAACAACGCCAATGTCCAGCACAGCGCCCT 685
              | || |||||||||| |||||||||| |||||||||| |||| | |||
Db        362 GTTTTTGGTGCCAGGGTGCAAACAACGTCAATGTCCAGNACAGGGNCCT 410


RESULT 6
H74302
LOCUS       H74302                   582 bp    mRNA    linear   EST 31-OCT-1995
DEFINITION  yu56c11.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone
            IMAGE:230132 5', mRNA sequence.
ACCESSION   H74302
VERSION     H74302.1  GI:1047713
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 582)
  AUTHORS   Hillier,L., Lennon,G., Becker,M., Bonaldo,M.F., Chiapelli,B.,
            Chissoe,S., Dietrich,N., DuBuque,T., Favello,A., Gish,W., Hawkins
            ,M., Hultman,M., Kucaba,T., Lacy,M., Le,M., Le,N., Mardis,E., Moore
            ,B., Morris,M., Parsons,J., Prange,C., Rifkin,L., Rohlfing,T.,
            Schellenberg,K., Soares,M.B., Tan,F., Thierry-Meg,J., Trevaskis,E.,
            Underwood,K., Wohldmann,P., Waterston,R., Wilson,R. and Marra,M.
  TITLE     Generation and analysis of 280,000 human expressed sequence tags
  JOURNAL   Genome Res. 6 (9), 807-828 (1996)
```

```
Db        221 CCAAGCACGGCAGAGGACTGCAGGCCATCAGCGTGCACTGTTCGTATTTGGAGTTCATGC 162

Qy        939 AAAATGAGTGTGTTTTAGCTGCTCTTGCCACAAAAAAAAAAAAAAAAAAAAAAA 992
              |||||||||||||||||||||||||||||| ||||||||||||||||||||||||
Db        161 AAAATGAGTGTGTTTTAGCTGCTCTTGCCCCAAAAAAAAAAAAAAAAAAAAAAA 108
```

RESULT 10
H73374/c
LOCUS H73374 296 bp mRNA linear EST 31-OCT-1995
DEFINITION yu48f10.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:229387 3', mRNA sequence.
ACCESSION H73374
VERSION H73374.1 GI:1047624
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 296)
AUTHORS Hillier,L., Lennon,G., Becker,M., Bonaldo,M.F., Chiapelli,B., Chissoe,S., Dietrich,N., DuBuque,T., Favello,A., Gish,W., Hawkins,M., Hultman,M., Kucaba,T., Lacy,M., Le,M., Le,N., Mardis,E., Moore,B., Morris,M., Parsons,J., Prange,C., Rifkin,L., Rohlfing,T., Schellenberg,K., Soares,M.B., Tan,F., Thierry-Meg,J., Trevaskis,E., Underwood,K., Wohldmann,P., Waterston,R., Wilson,R. and Marra,M.
TITLE Generation and analysis of 280,000 human expressed sequence tags
JOURNAL Genome Res. 6 (9), 807-828 (1996)
MEDLINE 97044478
PUBMED 8889549
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 1102
High quality sequence stops: 182
Source: IMAGE Consortium, LLNL
This clone is available royalty-free through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Insert Length: 1102 Std Error: 0.00
Seq primer: Promega -21m13
High quality sequence stop: 182.
FEATURES Location/Qualifiers
source 1. .296
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:3780483"
/db_xref="taxon:9606"
/clone="IMAGE:229387"
/sex="male"
/dev_stage="20 week-post conception fetus"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares fetal liver spleen 1NFLS"
/note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia) with a modified polylinker; Site_1: Pac I; Site_2: Eco RI; 1st strand cDNA was primed with a Pac I - oligo(dT) primer [5' AACTGGAAGAATTAATTAAAGATCTTTTTTTTTTTTTTTTT 3'], double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Pac I and cloned into the Pac I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization. Library constructed by Bento Soares and M.Fatima Bonaldo."
BASE COUNT 52 a 93 c 72 g 72 t 7 others
ORIGIN

Query Match 28.6%; Score 284.2; DB 14; Length 296;
Best Local Similarity 96.6%; Pred. No. 1.2e-30;
Matches 286; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

```
Qy        658 ACAACGCCAATGTCCAGCACAGCGCCCTCACAGTGGTGCCCCCAGGTGGTGACCAGAAGA 717
              | |  ||||| ||||| |||||||||||| |||||||||||||||||| |||||||||
```

```
Db        296 AAANGCCCAATNTCCAGNACAGCGCCCTCANAGTGGTGCCCCCAGGTGGTNACCAGAAGA 237

Qy        718 TGGAGGACTGGCAGGGTCCCCTGGAGAGCCCCATCCTTGCCTTGCCGCTCTACAGGAGCA 777
              |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||
Db        236 TGGAGGACTGGCAGGGTCCCCTGGAGANCCCCATCCTTGCCTTGCCGCTCTACAGGAGCA 177

Qy        778 CCCGCCGTCTGAGTGAAGAGGAGTTTGGGGGGTTCAGGATAGGGAATGGGGAGGTCAGAG 837
              |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||
Db        176 CCCGCCGTCTGAGTNAAGAGGAGTTTGGGGGGTTCAGGATAGGGAATGGGGAGGTCAGAG 117

Qy        838 GACGCAAAGCAGCAGCCATGTAGAATGAACCGTCCAGAGAGCCAAGCACGGCAGAGGACT 897
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        116 GACGCAAAGCAGCAGCCATGTAGAATGAACCGTCCAGAGAGCCAAGCACGGCAGAGGACT 57

Qy        898 GCAGGCCATCAGCGTGCACTGTTCGTATTTGGAGTTCATGCAAAATGAGTGTGTTT 953
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         56 GCAGGCCATCAGCGTGCACTGTTCGTATTTGGAGTTCATGCAAAATGAGTGTGTTT 1
```

RESULT 11
R02548/c
LOCUS R02548 379 bp mRNA linear EST 31-MAR-1995
DEFINITION ye80a07.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:124020 3', mRNA sequence.
ACCESSION R02548
VERSION R02548.1 GI:752284
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 379)
AUTHORS Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M., Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M., Parsons,J., Rifkin,L., Rohlfing,T., Soares,M., Tan,F., Trevaskis,E., Waterston,R., Williamson,A., Wohldmann,P. and Wilson,R.
TITLE The WashU-Merck EST Project
JOURNAL Unpublished
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
Insert Size: 846
High quality sequence stops: 309 Source: IMAGE Consortium, LLNL
This clone is available royalty-free through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Insert Length: 846 Std Error: 0.00
Seq primer: -21m13
High quality sequence stop: 309.
FEATURES Location/Qualifiers
source 1. .379
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:476565"
/db_xref="taxon:9606"
/clone="IMAGE:124020"
/sex="male"
/dev_stage="20 week-post conception fetus"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares fetal liver spleen 1NFLS"
/note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia) with a modified polylinker; Site_1: Pac I; Site_2: Eco RI; 1st strand cDNA was primed with a Pac I - oligo(dT) primer [5' AACTGGAAGAATTAATTAAAGATCTTTTTTTTTTTTTTTTT 3'], double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Pac I and cloned into the Pac I and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization. Library constructed by Bento Soares and M.Fatima Bonaldo."
BASE COUNT 71 a 121 c 103 g 83 t 1 others
ORIGIN

```
  Query Match             27.9%;  Score 277.2;  DB 14;  Length 379;
  Best Local Similarity   98.9%;  Pred. No. 1.1e-29;
  Matches  279;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy        693 GTGCCCCCAGGTGGTGACCAGAAGATGGAGGACTGGCAGGGTCCCCTGGAGAGCCCCATC 752
              |||  ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        282 GTGGGCCCAGGTGGTGACCAGAAGATGGAGGACTGGCAGGGTCCCCTGGAGAGCCCCATC 223

Qy        753 CTTGCCTTGCCGCTCTACAGGAGCACCCGCCGTCTGAGTGAAGAGGAGTTTGGGGGGTTC 812
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        222 CTTGCCTTGCCGCTCTACAGGAGCACCCGCCGTCTGAGTGAAGAGGAGTTTGGGGGGTTC 163

Qy        813 AGGATAGGGAATGGGGAGGTCAGAGGACGCAAAGCAGCAGCCATGTAGAATGAACCGTCC 872
              |||||||||||||||||||||||||||||||||||||||||||||||||||||| ||||
Db        162 AGGATAGGGAATGGGGAGGTCAGAGGACGCAAAGCAGCAGCCATGTAGAATGAACTGTCC 103

Qy        873 AGAGAGCCAAGCACGGCAGAGGACTGCAGGCCATCAGCGTGCACTGTTCGTATTTGGAGT 932
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        102 AGAGAGCCAAGCACGGCAGAGGACTGCAGGCCATCAGCGTGCACTGTTCGTATTTGGAGT 43

Qy        933 TCATGCAAAATGAGTGTGTTTTAGCTGCTCTTGCCACAAAAA 974
              |||||||||||||||||||||||||||||||||||||||||
Db         42 TCATGCAAAATGAGTGTGTTTTAGCTGCTCTTGCCACAAAAA 1


RESULT 12
AI438986/c
LOCUS       AI438986                450 bp    mRNA    linear   EST 18-MAR-1999
DEFINITION  tc84a08.x1 NCI_CGAP_CLL1 Homo sapiens cDNA clone IMAGE:2072822 3'
            similar to contains Alu repetitive element;contains element PTR5
            repetitive element ;, mRNA sequence.
ACCESSION   AI438986
VERSION     AI438986.1  GI:4301160
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1  (bases 1 to 450)
  AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
  TITLE     National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
            Tumor Gene Index
  JOURNAL   Unpublished
COMMENT     Contact: Robert Strausberg, Ph.D.
            Email: cgapbs-r@mail.nih.gov
            Tissue Procurement: Ash Alizadeh, John Byrd, M.D., Mike Grever,
            M.D., Louis M. Staudt, M.D., Ph.D.
             cDNA Library Preparation: M. Bento Soares, Ph.D.
             cDNA Library Arrayed by: Greg Lennon, Ph.D.
             DNA Sequencing by: Washington University Genome Sequencing Center
             Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html
            Insert Length: 1792    Std Error: 0.00
            Seq primer: -40UP from Gibco.
FEATURES             Location/Qualifiers
     source          1. .450
                     /organism="Homo sapiens"
                     /mol_type="mRNA"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:2072822"
                     /tissue_type="B-cell, chronic lymphotic leukemia"
                     /lab_host="DH10B"
                     /clone_lib="NCI_CGAP_CLL1"
                     /note="Vector: pT7T3D-Pac (Pharmacia) with a modified
                     polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
                     was primed with a Not I - oligo(dT) primer [5'
                     TGTTACCAATCTGAAGTGGGAGCGGCCGCATTGCTTTTTTTTTTTTTTTTTTTTTT
                     T 3']; double-stranded cDNA was ligated to Eco RI
                     adaptors (Pharmacia), digested with Not I and cloned into
                     the Not I and Eco RI sites of the modified pT7T3 vector.
                     Library is normalized, and was constructed by Bento
                                  Soares and M.Fatima Bonaldo."
BASE COUNT       85 a    144 c    109 g    112 t
ORIGIN

  Query Match             27.6%;  Score 274.2;  DB 9;  Length 450;
  Best Local Similarity   97.2%;  Pred. No. 2.6e-29;
  Matches  279;  Conservative    0;  Mismatches    8;  Indels    0;  Gaps    0;

Qy        688 CAGTGGTGCCCCCAGGTGGTGACCAGAAGATGGAGGACTGGCAGGGTCCCCTGGAGAGCC 747
              || || |    | ||||||||||||||||||||||||||||||||||||||||||||||
Db        287 CACTGCTTTGTCAAGGTGGTGACCAGAAGATGGAGGACTGGCAGGGTCCCCTGGAGAGCC 228

Qy        748 CCATCCTTGCCTTGCCGCTCTACAGGAGCACCCGCCGTCTGAGTGAAGAGGAGTTTGGGG 807
              ||||||||||||||||||||||||||||| |||||||||||||||||||||||||||||
Db        227 CCATCCTTGCCTTGCCGCTCTACAGGAGCGCCCGCCGTCTGAGTGAAGAGGAGTTTGGGG 168

Qy        808 GGTTCAGGATAGGGAATGGGGAGGTCAGAGGACGCAAAGCAGCAGCCATGTAGAATGAAC 867
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        167 GGTTCAGGATAGGGAATGGGGAGGTCAGAGGACGCAAAGCAGCAGCCATGTAGAATGAAC 108

Qy        868 CGTCCAGAGAGCCAAGCACGGCAGAGGACTGCAGGCCATCAGCGTGCACTGTTCGTATTT 927
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        107 CGTCCAGAGAGCCAAGCACGGCAGAGGACTGCAGGCCATCAGCGTGCACTGTTCGTATTT 48

Qy        928 GGAGTTCATGCAAAATGAGTGTGTTTTAGCTGCTCTTGCCACAAAAA 974
              |||||||||||||||||||||||||||||||||||||||||||||
Db         47 GGAGTTCATGCAAAATGAGTGTGTTTTAGCTGCTCTTGCCACAAAAA 1


RESULT 13
BY718164
LOCUS       BY718164                553 bp    mRNA    linear   EST 17-DEC-2002
DEFINITION  BY718164 RIKEN full-length enriched, 13 days embryo male testis Mus
            musculus cDNA clone 6030468B19 5', mRNA sequence.
ACCESSION   BY718164
VERSION     BY718164.1  GI:27131281
KEYWORDS    EST.
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (bases 1 to 553)
  AUTHORS   Okazaki,Y., Furuno,M., Kasukawa,T., Adachi,J., Bono,H., Kondo,S.,
            Nikaido,I., Osato,N., Saito,R., Suzuki,H., Yamanaka,I., Kiyosawa,H.
            , Yagi,K., Tomaru,Y., Hasegawa,Y., Nogami,A., Schonbach,C.,
            Gojobori,T., Baldarelli,R., Hill,D.P., Bult,C., Hume,D.A.,
            Quackenbush,J., Schriml,L.M., Kanapin,A., Matsuda,H., Batalov,S.,
            Beisel,K.W., Blake,J.A., Bradt,D., Brusic,V., Chothia,C., Corbani
            ,L.E., Cousins,S., Dalla,E., Dragani,T.A., Fletcher,C.F., Forrest
            ,A., Frazer,K.S., Gaasterland,T., Gariboldi,M., Gissi,C., Godzik,A.
            , Gough,J., Grimmond,S., Gustincich,S., Hirokawa,N., Jackson,I.J.,
            Jarvis,E.D., Kanai,A., Kawaji,H., Kawasawa,Y., Kedzierski,R.M.,
            King,B.L., Konagaya,A., Kurochkin,I.V., Lee,Y., Lenhard,B., Lyons
            ,P.A., Maglott,D.R., Maltais,L., Marchionni,L., McKenzie,L., Miki
            ,H., Nagashima,T., Numata,K., Okido,T., Pavan,W.J., Pertea,G.,
            Pesole,G., Petrovsky,N., Pillai,R., Pontius,J.U., Qi,D.,
            Ramachandran,S., Ravasi,T., Reed,J.C., Reed,D.J., Reid,J., Ring
            ,B.Z., Ringwald,M., Sandelin,A., Schneider,C., Semple,C.A., Setou
            ,M., Shimada,K., Sultana,R., Takenaka,Y., Taylor,M.S., Teasdale
            ,R.D., Tomita,M., Verardo,R., Wagner,L., Wahlestedt,C., Wang,Y.,
            Watanabe,Y., Wells,C., Wilming,L.G., Wynshaw-Boris,A., Yanagisawa
            ,M., Yang,I., Yang,L., Yuan,Z., Zavolan,M., Zhu,Y., Zimmer,A.,
            Carninci,P., Hayatsu,N., Hirozane-Kishikawa,T., Konno,H., Nakamura
            ,M., Sakazume,N., Sato,K., Shiraki,T., Waki,K., Kawai,J., Aizawa,K.
            , Arakawa,T., Fukuda,S., Hara,A., Hashizume,W., Imotani,K., Ishii
            ,Y., Itoh,M., Kagawa,I., Miyazaki,A., Sakai,K., Sasaki,D., Shibata
            ,K., Shinagawa,A., Yasunishi,A., Yoshino,M., Waterston,R., Lander
            ,E.S., Rogers,J., Birney,E. and Hayashizaki,Y.
  TITLE     Analysis of the mouse transcriptome based on functional annotation
            of 60,770 full-length cDNAs
  JOURNAL   Nature 420, 563-573 (2002)
  MEDLINE   22354683
   PUBMED   12466851
```